











































AFP        alpha feto‐protein 
AP        alkaline phosphatase 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 ammonium persulfate 
aa         amino acid 
BMP        bone 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protein 
bp 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serum 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CDK        cyclin dependent kinase 
cDNA        complementary DNA 
CKI        cyclin dependent kinase inhibitor 
cmc 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DTT 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ES        embryonic stem 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 fibroblast 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 Insulin / Transferrin 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Selenium 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 kilobase 
kDa         kiloDalton 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 Kip1 ubiquitylation‐promoting complex 
l         liter 
LB 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Bertani Medium 
LIF         leukemia inhibitory factor 
M         Mol per liter 
MALDI­TOF      Matrix 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Desorption/Ionisation 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MAPK        mitogen‐activated protein kinase  
MEF         murine embryonic fibroblast 
MEK        mitogen‐activated protein kinase kinase 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 2‐(N‐morpholino)ethanesulfonic 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mg         milligram 
min 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 nuclear 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density 
PAGE 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PBS 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buffered 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PCR        polymerase chain 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 Retinoblastoma protein 
PrE 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PTD        protein transduction 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RNA 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RT 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temperature resp. reverse transcription 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SA        senescence‐associated 
SSEA        stage‐specific 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antigen 
SDS         sodium dodecyl sulfate 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mother 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Stat3        signal transducer and 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transcription 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40 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buffered 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buffered 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TEMED 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TGFβ         transforming growth factor beta 
Tris        tris(hydroxymethyl)aminomethane  
TUJ1        neuron‐specific class III beta‐tubulin 
UV        ultraviolet 
V        volt 
rpm        rounds per 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Figure 1: Embryonic development from the morula stage to the late blastocyst 
(A) The 16-cell stage morula consists of central cells, which are surrounded by outer cells. (B) At E3.5 
the morula has developed into the blastocyst. (C) Parts of the inner cell mass (ICM) will give rise to the 
epiblast, whereas other cells of the ICM will form the primitive endoderm in the late blastocyst at E4.5. 
ICM: inner cell mass (adapted from Rossant and Tam, 2009). 




Figure 2: Schematic diagram of the embryonic development 
The morula gives rise to the ICM as well as to the trophectoderm (TE). The TE will form extra-
embryonic structures like giant cells, the ectoplacental cone and the extra-embryonic ectoderm. ICM 
splits up into primitive ectoderm comprising embryonic ectoderm, mesoderm and endoderm and 
primitive endoderm, which will form visceral extra-embryonic endoderm and parietal endoderm 




Figure 3: Expression patterns of Oct3/4, Cdx2 and Nanog during development 
(A) Homogenous expression of Oct3/4 is observed in 8-cell and 16-cell stage embryos. In the 
blastocyst Oct3/4 expression is limited to the inner cell mass (ICM) as it becomes down-regulated in 
the trophectoderm (TE) by Cdx2. (B) Cdx2 expression is randomly distributed within the 8-cell stage 
embryo but becomes restricted to outer cells in the 16-cell stage embryo already. The expression of 
Cdx2 within the blastocyst is found solely in the TE. (C) Similar to Cdx2, Nanog expression is 
incidentally spread within the 8-cell stage embryo but is distributed homogeneously throughout the 
16-cell stage embryo. Within the blastocyst Nanog expression displays a salt-and-pepper pattern, as it 
becomes down-regulated by Gata6 (adapted from Rossant and Tam, 2009).  1.1.2 Derivation and characteristics of ES cells ES cells are derived from the ICM of the developing blastocyst at stage day 3.5, which would give rise to the epiblast  in vivo. ES cells are characterized by two distinct properties, the first being self‐renewal (Suda et al., 1987), the second feature being pluripotency. The term self‐renewal is commonly referred to as the ability of cells to divide indefinitely thereby being able to maintain an  undifferentiated  state  as  well  as  genomic  stability.  This  remarkable  property  is  achieved through  symmetrical  cell  division  resulting  in  two  identical  daughter  cells  (Morrison  and Kimble, 2006). The ES cells’ ability to give rise to all three germ layers of a developing organism is  termed pluripotency.  In  contrast  to  totipotent  cells  i.e.  the  zygote  and  early blastomeres  (8 cells and less) that can give rise to every cell type of an organism, pluripotent cells are not able to form extra‐embryonic tissue, e.g.  trophectoderm or primitive endoderm. Besides the above‐
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mentioned cell types cells, which possess multi‐ or unipotency, such as hematopoietic stem cells or  hepatocytes,  exist  as  well.  Multipotent  cells  are  able  to  generate  multiple  cell  types  of  a certain lineage whereas unipotent cells are restricted to form one single cell type only. Pluripotency  can  be  analyzed  in  vitro  by  applying  the  embryoid  body  (EB)  differentiation paradigm. Upon withdrawal  of  the  cytokine  Leukemia  inhibitory  factor  (LIF), murine  ES  cells start  to  differentiate  spontaneously,  resulting  in  three‐dimensional  aggregates  designated  as EBs. EBs recapitulate various aspects of development during early mammalian embryogenesis and  finally  give  rise  to  cells  of  all  three  germ  layers,  assumed  the  initially  used  cells  are pluripotent. In vivo pluripotency of mouse ES cells can be assessed through blastocyst injection analysis. Cells get transferred into a blastocyst via microinjection and during development of the blastocyst pluripotent cells will contribute to a wide variety of tissues. If these cells are able to form  tissue  of  the  germ  line  their  genetic  heritage  can  be  passed  on  to  the  next  generation (Bradley  et  al.,  1984).  The  gold  standard  for  analyzing  pluripotency  though  is  the  tetraploid complementation assay (Nagy et al., 1990). Cells  to be  tested  for pluripotency, get  transferred into a tetraploid blastocyst and only pluripotent cells will contribute to the developing organism, as tetraploid cells are only capable of forming extra‐embryonic tissue. ES cells can be well characterized in vivo and in vitro through the expression of a wide variety of pluripotency markers such as the cell surface marker Alkaline Phosphatase (AP), the glycolipid Stage‐specific embryonic antigens (SSEA) as well as the transcription factors Oct3/4, Nanog and Sox2. Moreover, ES cells, in contrast to most somatic cells, possess telomerase activity.  1.1.3 Derivatives of ES cells Due to the capability of ES cells to give rise to cells of all three germ layers (Evans and Kaufman, 1981;  Martin,  1981;  Thomson  et  al.,  1998)  these  cells  hold  great  potential  and  could  be beneficial for the treatment of several degenerative diseases where cell replacement therapy can be  applied.  Researchers  were  able  to  derive  various  cell  types  from murine  ES  cells  such  as cardiac muscle cells (Klug et al., 1996; Wobus et al., 2002), insulin‐producing cells (Soria, 2001), and hematopoietic cells (Wiles and Keller, 1991) as well as cells of the nervous system (Brustle et al., 1999; Okabe et al., 1996). Differentiation paradigms observed in murine ES cells could be transferred to their human counterparts as well, as the derivation of multiple somatic cell types from the heart (Kehat et al., 2003), the liver (Lavon et al., 2004), the blood (Kaufman et al., 2001) and  the  nervous  system  (Reubinoff  et  al.,  2001;  Zhang  et  al.,  2001)  was  feasible.  Promising transplantation  experiments  on  rats  conducted  by  Keirstead  and  colleagues  (Keirstead  et  al., 2005) may lead to the first FDA approved phase I clinical trial in the near future with human ES cell derived oligodendrocytes by the Geron Corporation. 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1.2 Extrinsic signals governing pluripotency In  order  to  understand  the  state  of  pluripotency  and  to  develop  differentiation  paradigms  a profound  knowledge  of  the  signaling  networks  governing  pluripotency  is  essential.  The following  chapter will  provide an overview on  signaling pathways  found  in murine as well  as human  ES  cells.  Finally  a  short  paragraph will  deal with  a  newly  derived  embryonic  cell  line established from the epiblast.  1.2.1 Murine ES cells Pluripotency of ES cells under cell culture conditions is maintained through extrinsic as well as intrinsic key molecules. For the cultivation of murine ES cells the extrinsic cytokine LIF plays an essential role (Smith et al., 1988; Williams et al., 1988) as well as a second extrinsic factor, Bone morphogenetic protein  (BMP), when cultivating cells under serum‐free conditions  (Ying et al., 2003a).  




1.2.1.2 BMP signaling Ying and colleagues were the first to address the topic of culturing murine ES cells under more defined conditions  than cultivation  in  the presence of  inchoate FCS (Ying et al., 2003a). Under serum‐free conditions, i.e. in N2B27 medium (Ying et al., 2003b) LIF is not capable to maintain murine ES  cells  in  a pluripotent  state,  as  the  cells  tend  to  take on a neuronal  fate. Only when supplemented with  BMP,  ES  cells  under  before mentioned  conditions  can  be  propagated  in  a pluripotent  state,  as  BMP  is  able  to  suppress  the  neuronal  differentiation  through  SMAD mediated  expression  of  Inhibitor  of  differentiation  (Id)  genes.  In  particular  BMP  triggers  the dimerization of two complexes of BMP receptors type I (BMPRI) and II (BMPRII). This complex of BMPRI and BMPRII phosphorylates Smad1, 5 and 8. These Smads subsequently bind co‐Smad 4,  and  this  heteromeric  complex  is  translocated  into  the  nucleus  to  drive  gene  expression  by binding  to  promoter  regions  of  BMP  target  genes,  in  this  case  Id  genes  (Fig.  4).  In  ES  cells cultivated in N2B27 medium without LIF and BMP the sole overexpression of Nanog enables the cells  to  still  express  Id1  and  Id3  indicating  that  Nanog  influences  the  expression  levels  of  Id genes (Ying et al., 2003a). Another proposed role for BMP is the inhibition of p38, which would otherwise inhibit the expression of genes sustaining with pluripotency (Qi et al., 2004). The paradigm of dependence of murine ES cells on extrinsic stemness signals such as the above‐mentioned LIF and BMP was challenged though (Ying et al., 2008).  By the use of small molecules inhibiting  differentiation  cues  initiated  by  Mitogen‐activated  protein  kinase  (MAPK)  and Glycogen synthase kinase 3 (GSK‐3) signaling, it is possible to maintain pluripotency in murine ES cells  in  the absence of LIF and BMP. The derivation and propagation of ES cells genetically devoid of Stat3 under these de‐differentiating conditions  is  feasible,  indicating autonomy from extrinsic LIF signaling.  1.2.2 Human ES cells Although human ES cells and their murine equivalents share various properties, the mechanism underlying pluripotency surprisingly differs. Human ES cells as we know them do not respond to the cultivation with LIF in the absence of mouse embryonic fibroblasts (MEFs) (Thomson et al., 1998)  although  they  express  the  corresponding  receptor  and  the  STAT3  signaling  cascade  is functional (Daheron et al., 2004; Humphrey et al., 2004). Instead human ES cells depend on basic fibroblast  growth  factor  (bFGF)  (Amit  et  al.,  2000), Activin A  ‐  a member of  the  transforming 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growth  factor β  (TGF‐β)  family  (Beattie  et  al.,  2005;  James et  al.,  2005) as well  as  insulin‐like growth factor (IGF) (Wang et al., 2007) enabling them to maintain their undifferentiated state.  
1.2.2.1 Basic FGF signaling Initially  Amit  and  colleagues  assigned  a  distinct  role  in  human  pluripotency  to  bFGF,  as  it  is needed for prolonged undifferentiated proliferation of human ES cells (Amit et al., 2000). bFGF signaling  in  general  is  considered mainly  to  drive  proliferation;  the  exact mechanism  of  how bFGF  signaling  sustains  pluripotency  remains  poorly  understood  though  (Fig.  4).  When cultivated  in  medium  supplemented  with  serum  replacement  and  on  Matrigel,  a  solubilized membrane preparation, which  contains  extracellular matrix proteins  among other  constituent parts,  high dosage of bFGF  seems  to be  sufficient  to maintain pluripotency  in human ES  cells. However, bFGF is not able to sustain stemness in human ES cells when cultivated in conditioned medium without Matrigel or  in  the absence of Activin  (Vallier et al., 2005). An additional  role proposed  for  bFGF  is  the  establishment  of  a  niche  in  human  ES  cell  culture.  Spontaneously differentiating human ES cells give rise to fibroblast‐like cells, which secrete supporting proteins such  as  IGF  upon  bFGF  stimuli.  IGF  then  triggers  PI3  kinase  signaling  in  human  ES  cells inhibiting differentiation cues (Bendall et al., 2007).  Furthermore it has been shown that bFGF stimulates MEFs to release TGFβ, which additionally can support self‐renewal of human ES cells (Greber et al., 2007).  




1.2.2.3 IGF signaling IGF  receptors  (IGFR)  are present  on  the  cell  surface of  human ES  cells  and  are  susceptible  to insulin.  Insulin  signaling  is  mediated  via  the  PI3  kinase‐Akt  pathway  resulting  either  in inhibition of GSK‐3 signaling or activation of MAPK signaling (Fig. 4), both involved in sustaining pluripotency.  Insulin  is  a  common  and  very  potent  supplement  in  cell  culture  promoting proliferation  and  cell  survival  but  a  distinct  role  in  self‐renewal  of  human  ES  cells  was  only discovered  recently.  Blocking  of  IFGR  results  in  reduced  self‐renewal  and  promotes differentiation of human ES cells (Wang et al., 2007).  
 
Figure 4: Signaling pathways influencing pluripotency of murine and human ES cells 
Extrinsic factors operate molecular switches inside ES cells. Murine ES cells rely on LIF- and BMP 
signaling whereas their human counterparts depend on FGF, Activin and IGF. In contrast to murine 
ES cells the application of BMP leads towards differentiation in human ES cells (adapted from 
Ptaszek and Cowan, 2009).  1.2.3 Epiblast stem cells The  long  sustained  believe  that  the  diversity  of  murine  and  human  ES  cells  originated  from species  differences,  was  challenged  by  the  discovery  of  epiblast  stem  (EpiS)  cells.  Two independent work groups accomplished the establishment of stem cells derived from the post‐implantation  epiblast  of  the mouse  and  the  rat  (Brons  et  al.,  2007;  Tesar  et  al.,  2007).  These 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newly generated stem cells mirror properties of human ES cells, i.e. the morphology on the one hand  and  on  the  other  hand  the  dependence  on  Activin  signaling  to  maintain  pluripotency. Additionally EpiS cells express stemness markers like SSEA‐1, Nanog, Oct3/4 and Sox2 but tend to have  early  germ  layer markers  as well  as  epiblast markers up‐regulated. By  contrast  these stem cells  show weaker or no expression  for genes  characteristic  for  the  ICM  like Pecam1, or Tbx3.  With  this  stem  cell  population  at  hand,  the  question  is  now  whether  the  differences between murine and human ES cells might not originate from species disparity but rather both types  of  ES  cells might  represent  a  different  developmental  stage  dependent  of  the  time  and mode  of  derivation.  Interestingly,  Hayashi  and  colleagues  could  show  that  ES  cells  are  not  a group of uniform cells, since they appear to be floating in a metastable state and shift between ES‐ and epiblast‐like states. A variety of factors can shift this equilibrium in either way (Hayashi et al., 2008).  
1.3 Intrinsic stemness factors While describing the extrinsic factors needed to sustain pluripotency in both murine and human ES  cells,  intrinsic  factors  regulating  stemness  already  have  been  mentioned.  A  triad  of  key regulators, i.e. Oct3/4, Sox2 and Nanog, mainly governs the grid of stemness.  1.3.1 Oct3/4 The Oct3/4 protein was discovered almost 20 years ago and is encoded by the Pou5f1 gene. It belongs to the POU transcription factor family (Okamoto et al., 1990; Rosner et al., 1990; Scholer et  al.,  1990)  and  is  expressed  in  toti‐  and  pluripotent  cells  passing  through  early  embryonic development (Nichols et al., 1998; Palmieri et al., 1994; Rosner et al., 1990; Scholer et al., 1990; Yeom et al., 1996). Oct3/4 expression is restricted to the ICM as it is down‐regulated in cells of the TE by Cdx2  (Niwa et al.,  2005).  In  the artificial  situation of ES  cell  culture  this expression pattern  seems  to  be  sustained.  The  induction  of  differentiation  cues  leads  to  the down‐regulation of Oct3/4. During gastrulation the expression of Oct3/4 vanishes and can only be detected in primordial germ (PG) cells (Pesce and Scholer, 2000). Apart from ES cells, Oct3/4 is expressed in embryonic carcinoma (EC) cell lines as well as in germ cell lines. The restriction of  Oct3/4  to  toti‐  and  pluripotent  cells  assigns  an  important  role  regarding  stemness  to  this transcription  factor.  Blastocysts  deficient  for  Oct3/4  seem  to  develop  normally  but  their  ICM fails to give rise to ES cells (Nichols et al., 1998). Conditional knockout of Oct3/4 in PG cells leads to apoptosis (Kehler et al., 2004) and the RNAi mediated down‐regulation of Oct3/4 in ES cells leads  to  TE  differentiation  (Hay  et  al.,  2004;  Hough  et  al.,  2006).  The  precise  level  of  Oct3/4 expression  is  essential,  as  ES  cells  exhibiting  a  50%  down‐regulation  already  tend  towards 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1.3.3.1 Expression and cellular activities A  third  key  player  of  pluripotency  could  be  identified  through  the  functional  analysis  of  the interaction between extrinsic and intrinsic stemness signals of ES cells. When cultivating murine ES  cells  LIF  usually  is  indispensable  (Smith  et  al.,  1988;  Williams  et  al.,  1988),  and  several genetic studies have shown that this extrinsic signal of self‐renewal  is mediated intracellularly by  Stat3  (Boeuf  et  al.,  1997).  Overexpression  of  Nanog,  named  after  the  celtic  expression  for ‘land  of  the  ever  young’,  enables murine  ES  cells  to  abolish  LIF‐dependence  (Chambers  et  al., 2003;  Mitsui  et  al.,  2003).  The  expression  of  Nanog  can  be  detected  in  the  ICM  of  murine blastocysts and the epiblast in vivo as well as in vitro in ES cells. With the onset of differentiation, Nanog is generally down‐regulated. It is still expressed in germ cells as well as in tumorous cell lines  though  (Chambers  et  al.,  2003;  Hart  et  al.,  2004).  The  expression  of  Nanog  is  not homogeneously distributed between ES cells.  It mirrors a mosaic‐like pattern in which Nanog‐high populations  as well  as Nanog‐low but Gata6‐positive populations  can be detected within the culture dish. This particularly depicts the situation observed in the ICM of the blastocyst at stage  E3.5,  where  the  expression  of  Nanog  and  Gata6  resembles  a  salt‐and‐pepper  pattern (Singh et al., 2007). The Nanog protein encloses a homeodomain, exhibiting a structure, which it shares  with  members  of  the  Nk‐2  gene  family  in  terms  of  the  position  of  the  homeodomain although more than half of the amino acids differ (Mitsui et al., 2003). While there is homology between  its  orthologs  within  different  species,  the  Nanog  homeoprotein  seems  to  be  unique (Pan and Thomson, 2007).  





Figure 5: Schematic overview of the murine stemness factor Nanog 
The Nanog transcription factor is a three-domain protein consisting of an N-terminal part, a 
homeodomain and a C-terminal domain. The C-terminal part itself is composed of the three 
subdomains CD1, CD2 and a tryptophan-rich repeat termed WR. N: N-terminal domain; HD: 
homeodomain; C: C-terminal domain; CD: C-terminal subdomain exhibiting strong activation 
capability; WR: tryptophan repeat; aa: amino acid.  Recent  research  by  Wang  et  al.  shed  light  on  potential  co‐activators  or  Nanog‐protein interactors. Various binding partners of Nanog, such as Oct4, Nac1, Rif1, Dax1, and Zfp281, could be  identified  by  co‐immunoprecipitation  (Wang  et  al.,  2006).  Torres  and Watt  provided  first indications  of  a  presumable  homodimerization  of Nanog  as  they  could  observe Nanog–Nanog interaction via GST pull‐down experiments. Moreover, they reported that Nanog is able to bind NFkB, which leads to the inhibition of pro‐differentiation activities and consequently maintains pluripotency (Torres and Watt, 2008). Lately the exact position of the dimerization site within the Nanog protein was identified. The results stand to reason that Nanog self‐association takes place within the WR (Mullin et al., 2008). This finding was confirmed by another study (Wang et al.,  2008b) where  the authors performed size  chromatography of ES  cell nuclear extracts  that revealed  putative  Nanog  dimers.  The  use  of  various  truncated  Nanog  versions  for  co‐immunoprecipitation  allocated  the  position  of  the  dimerization  domain  to  the WR.  A mutant Nanog protein, incapable to selfdimerize, did not confer LIF‐independent selfrenewal to murine ES cells as  judged by colony  formation assay.  In contrast  the  forced expression of a  functional but  artificial  Nanog  dimer  was  able  to  keep  the  ES  cells  self‐renewing  independent  of  LIF, whereas  overexpression  of  the  mutant  non‐dimerizing  Nanog  protein  did  result  in differentiation. Upon cultivation with LIF, the Nanog dimer as well as the monomeric variant did increase  the percentage of undifferentiated colonies  though,  indicating enhanced self‐renewal. In order to be able to  interact with other stemness proteins, as shown for Zfp281, Sall4, Dax1, and Zfp198, Nanog should be available in its dimeric form as judged by co‐immunoprecipitation experiments (Wang et al., 2008b). Beyond that, Nanog has been reported to physically interact with Smad1 thereby blocking BMP‐induced mesoderm differentiation of murine ES cells (Suzuki et  al.,  2006).  In  addition  Nanog  operates  as  a  direct  activator  of  transcription  for  the  Rex‐1 promoter  in  conjunction with Sox2  (Shi  et  al.,  2006). Another  factor purified within  a protein complex  together  with  Nanog  was  Sall4.  Within  this  complex  Nanog  positively  controls  its expression as well as that of Sall4 (Wu et al., 2006). In order to limit steady‐state levels of Nanog 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mRNA, protein and promoter activity within murine ES cells Tcf3 activity is needed (Pereira et al., 2006). Furthermore, Nanog in concert with Oct3/4 is able to recruit a complex called NODE (Nanog and Oct4 associated deacetylase). Through this interaction Nanog and Oct3/4 are able to mediate  repressive  influence  to  the  chromatin  remodeling  machinery,  as  NODE  possesses histone  deacetylase  (HDAC)  activity  (Liang  et  al.,  2008).  In  human  ES  cells  NANOG  promoter activity seems to be positively regulated via SMAD2/3 mediated signaling, which is governed by TGFβ. Interestingly the overexpression of NANOG can bypass the requirement for TGFβ/Activin and bFGF (Xu et al., 2008) under defined conditions.  
1.3.3.3 Genetic analysis of Nanog activity As mentioned before,  the overexpression of Nanog empowers murine ES cells  to self renew in the absence of the cytokine LIF. The ability of two known reagents to induce differentiation, i.e. retinoic  acid  and  3‐methoxybenzamide,  is  reduced  in  Nanog‐overexpressing  cells. Differentiation  cues  mediated  during  EB  formation  are  hampered  as  well  in  those  cells. Restoration of wild‐type expression levels of Nanog lead to full differentiation potential in those cells,  which  was  analyzed  by  blastocyst  injection  (Chambers  et  al.,  2003).  Since  different signaling pathways are active in murine and human ES cells only few data is indicating that the function  of  Nanog  could  be  conserved  (Daheron  et  al.,  2004).  As  the  enhanced  expression  of NANOG  in  human  ES  cells  enables  them  to  feeder‐free  growth  in  unconditioned medium,  an important  role  is  assigned  to  NANOG  in  the  human  system  as  well  (Darr  et  al.,  2006).  The influence of  enhanced expression of Nanog  in non‐ES  cells  is  analyzed only  insufficiently.  Cell fusion  experiments  as well  as  the  iPS  cell  generation  assign Nanog  a  role  in  the  induction  of pluripotency in somatic cells though. Increased expression of Nanog is able to promote transfer of  pluripotency  to  the  somatic  cell  genome  in  the  cell  fusion  paradigm  (Silva  et  al.,  2006). Moreover  Nanog  seems  to  influence  the  process  of  reprogramming  of  human  somatic  cells (Ebert et al., 2009; Liao et al., 2008; Yu et al., 2007) although Nanog is expendable and is likely to have  only  a  promoting  effect.  A  potential  role  of  Nanog  in  cellular  reprogramming  might  be disclosed by experiments of ectopic Nanog expression  in stem cells as well as  in somatic cells. Studies by Zhang and colleagues indicated a possible role of NANOG in cell cycle regulation, as the  authors  observed  that  NANOG  is  able  to  influence  S‐phase  entry  in  human  ES  cells  by transcriptional regulation of CDK6 and CDC25A,  two prominent cell cycle mediators (Zhang et al., 2009). Ablation of Nanog leads to decelerated cell growth of murine ES cells, supporting the idea of Nanog influencing the cell cycle (Mitsui et al., 2003). Ectopic expression of Nanog in NIH 3T3 cells  leads to  increased proliferation by promoting the entry  into S phase of  the cell cycle (Zhang et al., 2005). Additionally Piestun et al. observed an  increased growth rate  in NIH 3T3 cells  overexpressing  Nanog.  Furthermore,  the  ectopic  expression  of  Nanog  resulted  in  a 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transformed phenotype as  judged by cell  foci  formation (Piestun et al., 2006). Loss‐of‐function studies revealed additional insights into the role of Nanog. Ablation of Nanog leads to the loss of pluripotency accompanied by an induction of extraembryonic marker gene expression, namely Gata6  (Mitsui  et  al.,  2003)  as  well  as  an  up‐regulation  of  CDX2,  a  trophectodermal  marker (Hyslop et al., 2005). The down‐regulation of Nanog via RNAi induces the expression of markers for mesoderm, ectoderm and neural crest cells (Ivanova et al., 2006). While Nanog, Oct3/4 and Sox2 share a high percentage  in  their  target genes, Nanog appears  to  fulfill  a distinct  function within  the  stem  cell  machinery.  As  stated  before  Nanog  exhibits  a  heterogeneous  expression pattern  in  the morula  during  development  (Dietrich  and Hiiragi,  2007).  The  same  expression pattern is found in ES cells. Murine ES cells expressing high levels of Nanog also express other pluripotency markers such as Oct4, whereas Nanog‐low cells also exhibit marker expression for primitive endoderm (Singh et al., 2007). The fluctuative expression pattern of Nanog in ES cells may indicate varying subsets of the pluripotency state. A clue to the distinct role of Nanog in the stem cell machinery was reported by Chambers et al., who could show that Nanog‐null ES cells still  possess  the  ability  to  self  renew,  although  these  cells  are  more  likely  to  be  prone  to differentiation. After aggregation of Nanog‐/‐ cells with wild‐type morulae, Nanog‐deficient cells are still able to give rise to post‐natal chimeras. The developmental potential of Nanog‐null ES cells was further assessed as the authors analyzed the persistence of Nanog‐null cells during PG cell development. Nanog‐deficient cells could be detected in the soma of the genital ridge until stage  E11.5  of  murine  embryogenesis.  Therefore,  Nanog  seems  to  be  required  for  PG development  beyond  E11.5  (Chambers  et  al.,  2007).  In  conclusion,  these  data  indicates  that Nanog  is  dispensable  for  the maintenance  of  pluripotency but  does play  a  distinct  role  in  the establishment and construction of the ICM as well as germ cell development. While Oct3/4 and Sox2  are  needed  to  mediate  stemness,  Nanog  seems  to  be  expendable  for  the  housekeeping machinery of pluripotency.  
1.3.3.4 Analysis of stemness factors target genes Applying  genome‐wide  location  analysis,  a  multitude  of  target  genes  for  OCT3/4,  SOX2  and NANOG could be identified in the human genome (Boyer et al., 2005). These three transcription factors  co‐occupy a  substantial  amount of  target  genes.  In  an autoregulatory manner  the  core transcription  factors  regulate  their  own  expression.  A  feedforward  mechanism  additionally initiates events corresponding  to  the maintenance of stemness,  like proliferation, activation of transcription  factors  and  chromatin  modifiers  as  well  as  stemness  signaling.  Furthermore, factors involved in the process of differentiation get down‐regulated, thereby inhibiting ES cells to adopt an ectodermal, mesodermal or endodermal fate. A similar interplay and share of target genes  of  Oct3/4  and  Nanog  could  be  observed  in  murine  ES  cells.  A  multitude  of  pathways 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governing pluripotency via REST, self‐renewal like in the case of nMyc, genome surveillance as for Trp53, as well as cell fate determination seem to be controlled by Nanog and Oct3/4 (Loh et al., 2006). Additionally the polycomb group (PcG) proteins could be identified as transcriptional repressors in murine ES cells (Boyer et al., 2006).  For  a  schematic  overview  on  the  influence  of  changes  in  Oct3/4,  Sox2  and Nanog  expression levels on cellular fate, see Figure 6.  
 
Figure 6: Oct3/4, Sox2 and Nanog intrinsically govern embryonic stem (ES) cell properties 
ES cells are derived from the inner cell mass (ICM) of the blastocyst. The triad of stemness factors, 
namely Oct3/4, Sox2 and Nanog, controls pluripotency within ES cells. An alteration of expression 
levels of these transcription factors leads to differentiation (loss-of-function indicated by red arrows, 
gain-of-function indicated by blue arrows) towards specific lineages (adapted from Bosnali et al., 
2009). 
 
1.4 Cellular reprogramming For a long time scientists from all around the globe had the vision of turning back the wheels of time  cell  biologically  spoken.  The  experiments  performed  by  John  Gurdon  in  1962  (Gurdon, 1962)  firstly  indicated  the  feasibility  to  reprogram  and  smoothened  the  way  for  upcoming nuclear transfer experiments, which  led to the well‐known sheep Dolly  in 1997 (Wilmut et al., 1997).  Since  then,  the  technique  of  somatic  cell  nuclear  transfer  (SCNT)  was  successfully adapted  to many  different  species,  including mice  (Wakayama  et  al.,  1998)  as  well  as  calves (Kato et al., 1998). Another paradigm applied in order to reprogram is cell fusion. ES cells, when fused to somatic cells are able to revert the cellular memory thereof albeit resulting in tetraploid 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hybrid  cells  (Tada et  al.,  2001). Additionally Silva and  colleagues  could  show  that  an elevated level of Nanog turns out to be beneficial for the reprogramming process of cell fusion (Silva et al., 2006).  The  two  above‐mentioned  techniques  to  reprogram  cells  harbor  certain  moral  and therapeutic  regards  though.  The  groundbreaking  experiment  by  Takahashi  and  Yamanaka  in 2006 opened up  a new way  to  reprogram cells  thereby overcoming  concerns  associated with SCNT  and  cell  fusion.  Through  the  retroviral  introduction  of  4  transcription  factors,  namely Oct3/4,  Sox2,  Klf4  and  c‐myc  into  murine  fibroblasts  the  researchers  were  able  to  induce  a pluripotent state in somatic cells (Takahashi and Yamanaka, 2006). Those cells were termed iPS cells. Since then it was not only possible to reprogram various cells with fewer factors (Huangfu et al., 2008; Kim et al., 2009b; Kim et al., 2008; Nakagawa et al., 2008) but the technique could also be applied to human cells  (Takahashi et al., 2007; Yu et al., 2007).  Interestingly Thomson and colleagues could induce pluripotency in human cells with a slightly different combination of transcriptions factors than Takahashi and Yamanaka. They made use of Oct3/4, Sox2, Nanog and Lin‐28 (Yu et al., 2007). Up to now, many laboratories successfully reprogrammed cells with this combination of factors (Ebert et al., 2009; Liao et al., 2008). It seems to be of great importance regarding  the efficiency of  cellular  reprogramming, which  type of  cell  is  actually used  for  this purpose (Eminli et al., 2009). The more differentiated a cell  is,  the harder  this cell  is  to revert into  a  pluripotent  state.  As  the  retroviral  transduction  leads  to  an  altered  host  genome, researchers are still eager to find a way to circumvent this obstacle. The use of non‐integrating genetic  techniques  to  reprogram  cells  (Kaji  et  al.,  2009;  Soldner  et  al.,  2009;  Stadtfeld  et  al., 2008b;  Woltjen  et  al.,  2009;  Yu  et  al.,  2009)  was  a  first  step  towards  iPS  cells,  which  could eventually be of use in cell replacement therapies one day. Another step towards safe iPS cells was made by  the application of small molecules  (Lyssiotis et al., 2009; Shi et al., 2008) on the one hand or  recombinant proteins  (Kim et  al.,  2009a; Zhou et  al.,  2009) on  the other hand  to partially or even completely replace virally transduced reprogramming factors. In a very recent publication Ichida and colleagues could identify a small compound, i.e. a TGFβ  inhibitor named RepSox,  able  to  replace  Sox2  and  c‐myc  during  the  reprogramming  process  of  murine fibroblasts. The TGFβ inhibitor initiates expression of endogenous Nanog when applied 11 days post viral  transduction with Oct3/4, Klf4 and c‐myc (Ichida et al., 2009). Multiple publications could show that manipulating the cell cycle via down‐regulation of key molecules like the tumor suppressor  p53  (Hong  et  al.,  2009;  Kawamura  et  al.,  2009;  Marion  et  al.,  2009)  significantly enhances reprogramming efficiency, although likely resulting in chromosomal aberrations of the target  cells.  Cultivation  of  cells  under  hypoxic  conditions,  which  basically  also  affects proliferation of cells showed similar results (Yoshida et al., 2009). Nevertheless, the process of cellular reprogramming is still inefficient and not well understood at a molecular level. 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1.5 Cellular senescence Leonard Hayflick, who could show that somatic cells can only be cultivated for a distinct period of time before they stop proliferating,  initially observed cellular senescence. Although the cells did not divide anymore  they were  still  viable  for a prolonged period of  time  (Hayflick, 1965). This phenomenon was termed Hayflicks’ limit and is also known as replicative senescence. Due to the fact that many carcinogenic cell lines are able to proliferate indefinitely, senescence can be regarded  as  a  tumor‐suppressor mechanism  on  the  one  hand.  On  the  other  hand,  senescence may be seen as an artificial form of ageing in vitro as the ability for tissue regeneration declines over  time  in  vivo.  Senescence  is  characterized  by  various  indications.  The  most  prominent hallmark  is  the  inability of senescent cells  to proceed through the cell cycle,  i.e. growth arrest. These cells exhibit DNA content typical for G1 phase while still displaying an active metabolism (Di Leonardo et al., 1994; Herbig et al., 2004; Ogryzko et al., 1996; Serrano et al., 1997). Another feature  of  senescent  cells  is  a  resistance  towards  some  apoptotic  cues. Human  fibroblasts  for example  can  withstand  apoptotic  signals  caused  by  removal  of  growth  factors  and  oxidative stress but will undergo apoptosis mediated by the Fas death receptor (Chen et al., 2000; Tepper et al., 2000). Moreover senescent cells exhibit tremendous changes in gene expression (Shelton et  al.,  1999;  Trougakos  et  al.,  2006;  Yoon  et  al.,  2004).  A  marker  widely  used  to  identify senescent  cells  is  senescence‐associated  (SA)  β‐galactosidase  (Dimri  et  al.,  1995).  SA 
β‐Galactosidase marker expression allows distinguishing between senescent and quiescent cells, which is not possible when using for instance 5‐bromodeoxyuridine (BrdU) in order to check for DNA replication.  SA β‐Galactosidase expression  is  induced as well by prolonged confluent  cell culture  conditions  though,  so  other  markers  are  required.  p16INK4a  expression  can  serve  as another marker for senescence (Krishnamurthy et al., 2004), although it is not expressed in all cells  exhibiting  a  senescent  phenotype  (Itahana  et  al.,  2003).  Various  signals  can  shift  a  cell towards senescence like dysfunctional telomeres (Martens et al., 2000), damage to the DNA per se (Di Leonardo et al., 1994), disorganization of chromatin (Ogryzko et al., 1996) or oncogene activity  (Zhu  et  al.,  1998).  These  signals  get  mediated  either  via  the  p16INK4a‐Retinoblastoma protein (pRb) pathway or the p53 pathway. Still there are few instances of senescence that seem to be independent of these two pathways (Michaloglou et al., 2005; Olsen et al., 2002).  
1.6 Protein transduction In  order  to  genetically  modify  cells,  thereby  analyzing  the  function  of  proteins  in  a ‘gain‐of‐function’ scenario, several conventional methods are available nowadays. Transfection, i.e. lipofection or electroporation as well as microinjection and viral transduction of nucleic acids represent  the  techniques most commonly used. These methods suffer  from certain  limitations 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though,  as  primary  cells  tend  to  be  hard  to  transfect,  hampering  the  overall  transfection efficiency. Additionally toxic side effects can occur, and maybe the biggest limitation is posed by the risk of insertional mutagenesis. Although the protein transduction paradigm may still be in its infancy, it represents a promising alternative approach, which is able to overcome several of the  above‐mentioned  limitations.  The  protein‐of‐interest  is  thereby  fused  to  a  protein transduction domain (PTD) enabling the cellular uptake. Since now, transducible proteins have been widely used to analyze gene function as shown for example for Oct3/4, Sox2, HoxB1 as well as p27KIP1 and other proteins (Bosnali and Edenhofer, 2008; Elliott and O'Hare, 1999; Ezhevsky et  al.,  1997;  Hall  et  al.,  1996;  Nagahara  et  al.,  1998).  Moreover,  it  seems  like  cellular reprogramming could be achievable applying  the  transducible  reprogramming  factors Oct3/4, Sox2, Klf4 and c‐myc (Kim et al., 2009a; Zhou et al., 2009) although the results published have to be reproduced. To  confer  the  ability  of  translocation  to  proteins‐of‐interest  mainly  three  different  PTDs, otherwise  also  called  cell‐penetrating  peptides  (CPP)  are  employed,  i.e.  a  16  aa  polypetide derived from the third helix of the Antennapedia (Antp) homeodomain (Derossi et al., 1994), a basic 34 aa peptide emerging from VP22 herpes simplex virus type 1 (HSV‐1) tegument protein (Elliott  and  O'Hare,  1997)  and  an  11  aa  polypeptide  originating  from  the  human immunodeficiency virus (HIV) transactivator of transcription (TAT) domain (Frankel and Pabo, 1988;  Green  and  Loewenstein,  1988).  In  this  thesis  the  TAT‐PTD  is  used  to  generate transducible  fusion  proteins  since  the  work  on  a  transducible  variant  of  the  site‐specific recombinase  Cre  and  Flp  harboring  TAT‐PTD has  led  to  convincing  results  in  our workgroup (Haupt et al., 2007; Nolden et al., 2006; Patsch et al., 2010; Peitz et al., 2007; Peitz et al., 2002). Moreover  the multitude  of  transducible  proteins makes  use  of  the  TAT‐PTD  (Dietz  and Bahr, 2004). The  exact  molecular  mechanism  is  still  not  completely  elucidated  but  basic  events  during protein  transduction  have  been  unraveled  (for  review  see  (Patsch  and  Edenhofer,  2007). Wender and colleagues could show that the guanidinium groups of the arginins found within the TAT‐PTD play an important role in facilitating cellular uptake through electrostatic interaction as they possess a high charge at physiological pH (Wender et al., 2000). In addition the TAT‐PTD requires  the  expression  of  negatively  charged  glycosaminoglycans,  i.e.  heparan  sulfate proteoglycans on the target cells to initiate binding to the cell surface (Console et al., 2003; Tyagi et al., 2001). As these glycosaminoglycans are expressed on the majority of mammalian cellular surfaces  most  cells  are  susceptible  to  protein  transduction.  Through  a  process  called macropinocytosis,  a  subtype  of  endocytosis,  TAT  fusion  proteins  were  shown  to  internalize. Macropinocytosis  is  a  rapid,  lipid  raft‐dependent  but  receptor‐independent  process,  which requires macropinosomes,  i.e.  actin membrane  bulges  enclosing  the  PTD‐fused  cargo  thereby 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Figure 7: Illustration of the process of protein transduction 
(A) Proteins fused to a cell penetrating peptide (CPP) bind to heparan sulfate proteoglycans on the 
surface of the target cell. (B) Through electrostatic interactions the protein becomes internalized to the 
endosomes. Endosomes accumulate around the nucleus in a perinuclear pattern. (C) Release of the 
CPP-fused protein from the endosomes occurs spontaneously but can be mediated by different cues 
facilitating endosomal escape as well (adapted from Patsch and Edenhofer, 2007). 




1.7 Aim of the thesis For  detailed  analysis  of  the  Nanog  function,  especially  in  somatic  cells,  the  cell  permeable version  of  Nanog  shall  be  applied  in  further  cell  culture  paradigms.  In  order  to  assess  the specificity  of  Nanog  protein  transduction  in  ES  and  somatic  cells,  a  control  protein  shall  be designed  and  purified.  This  control  fusion  protein  should mirror  Nanog‐TAT,  but  lacking  the homeodomain of the full‐length Nanog fusion protein, representing an essential functional part of  the protein  (ΔNanog‐TAT). An optimized purification protocol  for both  recombinant Nanog proteins  has  to  be  developed  applying  an  imidazole  gradient,  which  shall  be  analyzed  by immunoblot  and  SDS‐PAGE  indicating  for  optimal  purification  conditions.  The  recombinant Nanog fusion proteins shall be further examined for their biochemical properties, i.e. the ability to  recognize  and  bind  to  a  Nanog  consensus  sequence  as  well  as  the  proteins’  capability  to translocate into mammalian cells. The phenomenon of enhanced proliferation of primary murine cells upon Nanog‐TAT cultivation shall be analyzed at a molecular level to link this phenotypical observation to molecular changes inside the cell. Furthermore, Nanog‐TAT shall be applied onto human primary cells to assess in more detail  the protein’s partial  trans‐species  function observed upon  treatment of human ES cells  with  Nanog‐TAT.  Underlying  molecular  events  shall  be  elucidated  by  whole  genome expression  analysis.  Finally,  a  potential  influence  of  Nanog‐TAT  on  the  process  of  cellular reprogramming shall be analyzed. 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2 Materials and Methods 
2.1 Materials 2.1.1 Chemicals All  chemicals  were  obtained  from  Sigma‐Aldrich,  Fluka  and  Carl  Roth  GmbH.  Any  case  of exception is mentioned.  2.1.2 Equipment Incubator used for expression of bacteria innova 44; New Brunswick (Nürtingen, Germany) innova 4300; New Brunswick (Nürtingen, Germany) EB KS‐15; Johanna Otto GmbH (Hechingen, Germany) TH 15 incubator hood; Johanna Otto GmbH (Hechingen, Germany)  Chemiluminescence detection Chemidoc XRS; Biorad (Munich, Germany)  Thermocycler T3 Thermocycler; Biometra (Göttingen, Germany)  Electrophoresis Standard PowerPack P25; Biometra (Göttingen, Germany) Powerpack 200; Biorad (Munich, Germany) Agagel Mini; Biometra (Göttingen, Germany) Agagel Midi‐Wide; Biometra (Göttingen, Germany) Agagel Maxi; Biometra (Göttingen, Germany) ProteanIII MiniGel System; Biorad (Munich, Germany)  Incubators for cell culture Heracell; Heraeus (Hanau, Germany) 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Microscope Axiovert 25; Zeiss (Göttingen, Germany) Axiovert 135; Zeiss (Göttingen, Germany)  pH‐meter CG840; Schott (Mainz, Germany)  Photometer BioPhotometer; Eppendorf (Hamburg, Germany) NanoDrop; Peqlab (Erlangen, Germany)  Shaker Roto‐Shake Genie; Scientific Industries (New York, USA) Vortex‐2 Genie; Scientific Industries (New York, USA)  Sonicator Sonoplus HD 2070; Bandelin electronics (Berlin, Germany)  Sterile workbenches Herasafe; Heraeus (Hanau, Germany)  Plasticware Cell culture dish 15 cm    TPP (Trasadingen, Switzerland) Cell culture dish 10 cm    BD Falcon (Bedford, USA) Cell culture dish 6 cm      BD Falcon (Bedford, USA) Cell culture dish 3.5 cm    BD Falcon (Bedford, USA) 6 well cell culture plate    Nunc (Roskilde, Denmark) 12 well cell culture plate    Nunc (Roskilde, Denmark) 24 well cell culture plate    Costar (Corning, USA) Petri dish 10 cm      BD Falcon (Bedford, USA) 15mL centrifuge tubes    Greiner Bio (Frickenhausen, Germany) 50mL centrifuge tubes     Greiner Bio (Frickenhausen, Germany) 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cryo vials        Nunc (Roskilde, Denmark) Cell scraper        Costar (Corning, USA) Plastic pipets (1mL – 25mL)    Costar (Corning, USA) Sterile filter (0,2µm)      Whatman (Dassel, Germany)  UV transilluminators GelVue GVM20; Syngene (Cambridge, UK) GelDoc EQ; Biorad (Munich, Germany)  Scales LA310S; Sattorius (Göttingen, Germany) BL610; Sattorius (Göttingen, Germany)  Centrifuges 5416 R; Eppendorf (Hamburg, Germany) 5415 D; Eppendorf (Hamburg, Germany) Biofuge pico; Heraeus (Hanau, Germany) Megafuge 1.0R; Heraeus (Hanau, Germany) RC5B plus; Thermo (Waltham, USA) RC26 plus; Thermo (Waltham, USA) RC6 plus; Thermo (Waltham, USA)  2.1.3 Enzymes Restricion endonucleases; NEB (Frankfurt, Germany) GoTaq polymerase; Promega (Mannheim, Germany) Phusion polymerase; NEB (Frankfurt, Germany) iScript Reverse Transcriptase; Biorad (Munich, Germany) Benzonase; Novagen (Darmstadt, Germany) Lysozyme; Sigma‐Aldrich (Munich, Germany) T4 DNA Ligase; NEB (Frankfurt, Germany) Shrimp alkaline phosphatase; Roche (Mannheim, Germany) 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2.1.5 Buffers, markers and medium Denaturing purification buffers 
Washing buffer 0.5%    Triton‐X100 [v/v] 50mM    Tris‐HCl, pH 8.0 100mM  NaCl 0.1%    sodium azid  
Resuspension buffer 50mM    Tris‐HCl, pH 8.0 100mM  NaCl  
Solubilization buffer 6M    Guanidine HCl 50mM    Tris‐HCl, pH 8.0 100mM  NaCl 10mM    EDTA 10mM    DTT  
Refolding buffer 1 50mM    MES, pH 6.0 9.6 mM  NaCl 0.4mM   KCl 2mM    MgCl2 2mM    CaCl2 0.75M    Guanidine HCl 0.5%    Triton‐X100 [v/v] 1mM    DTT  
Refolding buffer 2 50mM    MES, pH 6.0 9.6 mM  NaCl 0.4mM   KCl 2mM    MgCl2 2mM    CaCl2 0.5M    Arginine 0.05%    PEG 3550 1mM    GSH 0.1mM   GSSH 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Refolding buffer 3 50mM    MES, pH 6.0 9.6 mM  NaCl 0.4mM   KCl 1mM    EDTA 0.4M    Sucrose 0.75M    Guanidine HCl 0.5%    Triton‐X100 [v/v] 0.05%    PEG 3550 1mM    DTT  
Refolding buffer 4 50mM    MES, pH 6.0 240mM  NaCl 10mM    KCl 2mM    MgCl2 2mM    CaCl2 0.5M    Arginine 0.5%    Triton‐X100 [v/v] 1mM    GSH 0.1mM   GSSH  
Refolding buffer 5 50mM    MES, pH 6.0 240mM  NaCl 10mM    KCl 1mM    EDTA 0.4M    Sucrose 0.75M    Guanidine HCl 1mM    DTT  
Refolding buffer 6 50mM    MES, pH 6.0 240mM  NaCl 10mM    KCl 1mM    EDTA 0.5M    Arginine 0.4M    Sucrose 0.5%    Triton‐X100 [v/v] 0.05%    PEG 3550 1mM    GSH 0.1mM   GSSH 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Refolding buffer 7 50mM    MES, pH 6.0 240mM  NaCl 10mM    KCl 2mM    MgCl2 2mM    CaCl2 0.75M    Guanidine HCl 0.05%    PEG 3550 1mM    DTT  
Refolding buffer 8 50mM    Tris‐HCl, pH 8.5 9.6 mM  NaCl 0.4mM   KCl 2mM    MgCl2 2mM    CaCl2 0.4M    Sucrose 0.5%    Triton‐X100 [v/v] 0.05%    PEG 3550 1mM    GSH 0.1mM   GSSH  
Refolding buffer 9 50mM    Tris‐HCl, pH 8.5 9.6 mM  NaCl 0.4mM   KCl 1mM    EDTA 0.5M    Arginine 0.75M    Guanidine HCl 0.05%    PEG 3550 1mM    DTT  
Refolding buffer 10 50mM    Tris‐HCl, pH 8.5 9.6 mM  NaCl 0.4mM   KCl 2mM    MgCl2 2mM    CaCl2 0.5M    Arginine 0.4M    Sucrose 0.75M    Guanidine HCl 1mM    GSH 0.1mM   GSSH 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Refolding buffer 11 50mM    Tris‐HCl, pH 8.5 9.6 mM  NaCl 0.4mM   KCl 1mM    EDTA 0.5%    Triton‐X100 [v/v] 1mM    DTT  
Refolding buffer 12 50mM    Tris‐HCl, pH 8.5 240mM  NaCl 10mM    KCl 1mM    EDTA 0.05%    PEG 3550 1mM    GSH 0.1mM   GSSH  
Refolding buffer 13 50mM    Tris‐HCl, pH 8.5 240mM  NaCl 10mM    KCl 1mM    EDTA 0.5M    Arginine 0.75M    Guanidine HCl 0.5%    Triton‐X100 [v/v] 1mM    DTT  
Refolding buffer 14 50mM    Tris‐HCl, pH 8.5 240mM  NaCl 10mM    KCl 2mM    MgCl2 2mM    CaCl2 0.5M    Arginine 0.4M    Sucrose 0.75M    Guanidine HCl 0.5%    Triton‐X100 [v/v] 0.05%    PEG 3550 1mM    GSH 0.1mM   GSSH 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Refolding buffer 15 50mM    Tris‐HCl, pH 8.5 240mM  NaCl 10mM    KCl 2mM    MgCl2 2mM    CaCl2 0.4M    Sucrose 1mM    DTT  Native purification buffers 
Lysis buffer for Nanog­TAT and ΔNanog­TAT 500mM  NaCl   2mM    Imidazole 1x    PTB pH 8.0  
Washing buffer for Nanog­TAT 500mM  NaCl 30mM    Imidazole 1x    PTB pH 8.0  
Washing buffer for ΔNanog­TAT 500mM  NaCl 100mM  Imidazole 1x    PTB pH 8.0  
Elution buffer for Nanog­TAT and ΔNanog­TAT 500mM  NaCl 250mM  Imidazole 1x    PTB pH 8.0  
Nanog­TAT glycerol buffer 50%    Glycerin [v/v] 1M    NaCl 1mM    DTT 1mM    EDTA 20mM    HEPES 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TBS (Tris Buffered Saline) buffer 50mM    Tris‐HCl, pH 7.4 150mM  NaCl  TBS‐T buffer 50mM    Tris‐HCl, pH 7.4 150mM  NaCl 0.05%    Tween 20 [v/v]  TBS‐TT buffer 50mM    Tris‐HCl, pH 7.4 150mM  NaCl 0.05%    Tween 20 [v/v] 0.2%    Triton X‐100 [v/v]  LB medium For 1L of LB medium prepare the following 10g    Tryptone/Peptone 5g    Yeast extract 10g    NaCl Solve ingredients in 800mL dH2O and adjust pH to 7.5 with NaOH. Thereafter fill up to 1L with dH2O and sterilize by autoclaving.  TB medium For 1L of TB medium prepare two solutions:  Solution 1 12g    Tryptone/Peptone 24g    Yeast Extract 4mL    Glycerol Solve ingredients in 900mL of dH2O.  Solution 2 2.31g    KH2PO4 12.54g   K2HPO4 Solve ingredients in 100mL of dH2O. Combine both solutions after autoclaving. 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SOB medium 0.5%    Yeast extract 2%    Tryptone/Peptone 10mM    NaCl 2.5mM   KCl 10mM    MgCl2 10mM    MgSO4  Dissolve in nanopure water and autoclave.  TB buffer 10mM    PIPES 15mM    CaCl2 250mM  KCl  Dissolve in nanopure water and adjust the pH to 6.7 before adding MnCl2 to a final concentration of 55mM. Afterwards TB buffer is sterilized by filtration with a 0.45µm filter and stored at 4°C.   Protein Marker Prestained Protein Marker; NEB (Frankfurt, Germany) Color Plus Protein Prestained Marker; NEB (Frankfurt, Germany) Perfect Protein Marker; Novagen (Darmstadt, Germany) 6x His Ladder; Qiagen (Hilden, Germany)  DNA ladders 1kb ladder; NEB (Frankfurt, Germany) 100bp ladder; NEB (Frankfurt, Germany)  TAE (Tris‐acetate‐EDTA) buffer 40mM    Tris 20mM    Acetic acid 1mM    EDTA pH of 50xTAE  has to be adjusted to 8.4 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TBE (Tris‐borate‐EDTA) buffer 89mM    Tris 89mM    Boric acid 2mM    EDTA pH of 10xTBE has to be adjusted to 8.3  Agarose gel loading buffer 30% Glycerin Spatula tip of bromophenol blue Spatula tip of xylenxyanol  5x SDS‐PAGE loading buffer 250mM    Tris‐Cl, pH 6.8 10%    SDS [w/v] 50%    glycerol [w/v] 0.02%    bromphenol blue [w/v] Add 10% [v/v] β‐mercaptoethanol prior to use.  10x SDS‐PAGE electrophoresis buffer 0.25M    Tris 1.92M    Glycine 1.0%    SDS, pH 8.3  4 x Tris/SDS buffer pH 8.8: 1.5M    Tris‐Cl, pH 8.8 0.4%    SDS  4 x Tris/SDS buffer pH 6.8: 0.5M    Tris‐Cl, pH 6.8 0.4%    SDS  SDS‐PAGE stacking gel (for 5mL): 2.85mL  H2O 0.83mL  30%/0.8% acrylamide/bis‐acrylamide 1.25mL  4x Tris/SDS buffer, pH 6.8 0.075mL  10% APS [w/v] 0.0015mL  TEMED  SDS‐PAGE separating gel (for 10mL exhibiting 10%): 4.1mL    H2O 3.33mL   30%/0.8% acrylamide/bis‐acrylamide 2.5mL     4x Tris/SDS buffer, pH 8.8 0.075mL  10% APS [w/v] 0.0015mL  TEMED 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Native Gel (for 30mL exhibiting 5%) 3mL    10xTBE buffer 5mL    acrylamide/bisacrylamide 22mL    H2O 125µL    10% APS 17µL    TEMED  Immunoblot (wet) transfer buffer 25mM    Tris 192mM    Glycin 20%    Methanol  Stripping buffer for immunoblot: 2%    SDS 100mM    β‐mercaptoethanol 50mM    Tris‐Cl, pH 6.8  Cell culture stock solutions  L‐Glutamin     200mM; Gibco (Karlsruhe, Germany) catalogue number 25030‐024  Non‐Essential Amino Acids  100x; Gibco (Karlsruhe, Germany) catalogue number 11140‐035 (NEAA)  
β‐mercaptoethanol   50mM; Gibco (Karlsruhe, Germany) catalogue number 31350‐010  Insulin Transferin Selenin G  100x ; Gibco (Karlsruhe, Germany) catalogue number 41400‐045 (ITS)   D‐MEM      Gibco (Karlsruhe, Germany) catalogue number 41966‐029       supplemented with L‐Glutamine, 110mg/L sodium pyruvat        and 4500mg/L D‐glucose  KnockOut D‐MEM    Gibco (Karlsruhe, Germany) catalogue number 10829‐018       supplemented with L‐Glutamine, 110mg/L sodium pyruvat        and 4500mg/L D‐glucose 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Advanced D‐MEM    Gibco (Karlsruhe, Germany) catalogue number 12491‐015       supplemented with 110mg/L sodium pyruvat and 4500mg/L        D‐glucose  FCS used for ES cells  PAN (Aidenbach, Germany) catalogue number 3302‐P260719  FCS used for MEFs    Gibco (Karlsruhe, Germany) catalogue number 10270‐106  Puromycin [1mg/mL]  Gibco (Karlsruhe, Germany)  MEF cell culture medium 88mL    D‐MEM (final concentration 88%) 10mL    FCS for MEFs (final concentration 10%) 1mL    L‐Glutamine (final concentration 2mM) 1mL    NEAA (final concentration 1x) 200µL    β‐mercaptoethanol (final concentration 100µM)  ES cell culture medium 85mL    KnockOut D‐MEM (final concentration 85%) 15mL    FCS for ES cells (final concentration 15%) 1mL    L‐Glutamine (final concentration 2mM) 1mL    NEAA (final concentration 1x) 200µL    β‐mercaptoethanol (final concentration 100µM) 100µL    Puromycin if needed (final concentration 1µg/mL)  ESGRO LIF from Millipore (Schwalbach/Taunus, Germany)  is added at a dilution of 1:10.000 if required. The same applies for LIF inhibitor (LI), which is used at a dilution of 1:500 (according to  functional analysis performed by Dr. Michael Peitz). Prior to all experiments, Oct3/4 GiP ES cells were cultivated in the presence of puromycin, diluted 1:1000 (stock solution 1mg/mL) to ensure a stringent pluripotent ES cell population.  Advanced medium 94mL     Advanced D‐MEM (final concentration 94%) 5mL    FCS for ES cells (final concentration 5%) 1mL    L‐Glutamine (final concentration 2mM) 0,5mL    ITS (final concentration 1x) 200µL    β‐mercaptoethanol (final concentration 100µM) 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2x Advanced medium 94mL    Advanced D‐MEM (final concentration 94%) 2mL    FCS for ES cells (final concentration 2%) 2mL    L‐Glutamine (final concentration 2mM) 1mL    NEAA (final concentration 1x) 1mL    ITS (final concentration 1x) 200µL    β‐mercaptoethanol (final concentration 100µM)  2x Freezing medium for ES cells 20%    DMSO (final concentration 10%) 40%    FCS for ES cells 40%    ES cell culture medium (supplemented with LIF)  2x Freezing medium for somatic cells 20%    DMSO (final concentration 10%) 40%    FCS for MEFs 40%    MEF medium  4%PFA (Paraformaldehyde) In order to assemble 500mL of 4%PFA heat 200mL of nanopure water to 80°C and place on a stir plate  inside a hood. While  stirring add 20g of PFA and drop‐wise add 1N NaOH until PFA crystals are dissolved. Subsequently add 210mL of 0.2M sodium dibasic phosphate buffer and 40mL of 0.2M sodium monobasic phosphate buffer. Adjust pH to 7.4 and  fill up  the volume to 500mL with nanopure water. Finally 4%PFA is filtered and can be stored at ‐20°C.  Mounting Medium 1: Solve  2.4g Moviol  in  4.8mL  glycerol.  Then  add  6mL H2O  and  stir  overnight. Moviol mounting medium can be stored at ‐20°C.  Mounting Medium 2: Vectashield fluorescence mounting medium; Vector Laboratories (Burlingame, USA) 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2.1.6 Bacterial strains DH5α (Gibco BRL, Karlsruhe, Germany) Used for cloning purposes. DH5α  bacteria  cells  possess  high  transformation  efficiency.  By  the  endA1  mutation  internal nucleases  are  inactivated.  The  hsdR17  mutation  leads  to  the  elimination  of  another endonuclease. Mutation in recA1 prevents homologous recombination. Genotype: E.coli F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 Δ(lacZYA-
argF)U169, hsdR17(rK- mK+), λ–  BL21(DE3) GOLD (Agilent Technologies, Waldbronn, Germany) Used for the expression of all constructs. BL21(DE3)  GOLD  bacteria  cells  are  improved  derivates  of  BL21  competent  cells.  The  major advancement of these cells is increased transformation efficiency, i.e. >1 x 108 cfu/μg of pUC18 DNA through the presence of Hte phenotype. High expression levels are achieved by utilizing the T7 RNA polymerase promoter. Furthermore these bacteria cells lack the Lon protease as well as a second protease, namely OmpT. Genotype: E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte  2.1.7 Cell lines Somatic cell lines CV1 (Jensen et al., 1964) This  fibroblasts  cell  line  is  derived  from  the  kidney  of  the  vervet  monkey  (Cercopithecus Aethiops). These cells were used to assess the translocation ability of the recombinant proteins Nanog‐TAT  and  ΔNanog‐TAT  since  fibroblasts  exhibit  beneficial  properties  regarding  the protein transduction technique, i.e. big cell surface.   Oct3/4 GiP Mouse Embryonic Fibroblasts (Yeom et al., 1996) This heterozygous primary MEF cell line was established from fetuses derived from breeding of Oct3/4 GiP mice with C57BL/6J  (Black6) mice  (Jackson Laboratory, Main, USA). As  these cells carry  the  transgene encoding  for GFP and a gen conveying resistance  to puromycin under  the regulatory sequence of  the murine Oct3/4 promoter,  these cells were preferentially employed for  reprogramming  experiments,  as  they  will  turn  on  transgene  expression  upon dedifferentiation. These cells were used for cell cycle analysis as well. 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MP‐AF (Peitz 2007; lab stock) This cell line is a wild type human dermal fibroblast line. The cells were derived from a 34‐year‐old  healthy  male.  A  skin  biopsy  taken  from  the  patient  was  cultivated  in  MEF  medium  and dermal  fibroblasts  started  to  migrate  out  of  the  biopsy  patch.  Cells  were  then  trypsinized, subsequently expanded and cryopreserved at an early passage number (passage 5). These cells were used in order to investigate the functionality of Nanog‐TAT on human cells.  ES cell lines Oct3/4 GiP (Ying et al., 2002) This hybrid murine ES  cell  line  (129 X MF1)  carries a  transgene encoding  for GFP  linked  to a resistance gene to puromycin via an  internal ribosomal entry site (IRES) under  the regulatory sequence  of  the  murine  Oct3/4  promoter.  Pluripotent  cells  therefore  will  exhibit  GFP fluorescence and are resistant to puromycin.  2.1.8 Expression vectors Nanog‐TAT – This vector, employing the pTriEx1 vector from Novagen (Darmstadt, Germany) as a backbone, harbors the genetic information for a NLS, the murine Nanog, the TAT PTD as well as  an  8xHistidin  tag  (Nanog‐TAT).  The  vector  can  be  used  to  express  recombinant  protein  in 
E.coli,  as  well  as  in  insect  cells  or mammalian  cells.  The  plasmid was  verified  by  sequencing (Peitz, 2007).  
ΔNanog‐TAT – This vector, employing the pTriEx1 vector from Novagen (Darmstadt, Germany) as a backbone, harbors the genetic information for murine Nanog lacking its homeodomain. The insert  for  ΔNanog‐TAT  (without  NLS,  PTD‐TAT  and  Histidin‐Tag)  was  amplified  using  a construct already present  in  the workgroup (Münst, 2005). The vector can be used to express recombinant proteins in E.coli, as well as in insect cells or mammalian cells. 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2.1.9 Oligonucleotide primers Table 1: Primers used for sequencing 
pTriEx-F 5’-TAA TCC GGG ACC TTT AAT TC 
pTriEx-R 5’-GC TCA AGG GGC TTC ATG ATG Table 2: Primers used for cloning 
Nanog-F 5’-GGC CTA GGA GTG TGG GTC TTC CTG GTC C 
Nanog-R 5’-GTG CTA GCT ATT TCA CCT GGT GGA GTC AC 
ΔNanog-TAT-F 5’-CTG AAC CAT GGG CGC TAA AAA AAA GAG GAA AGT GAG TGT GGG TCT TCC TGG 
TC 
ΔNanog-TAT-R 5’-CAT GCT CGA GTT AGT GAT GGT GAT GGT GAT GAC CGC CAG GCG GAC GCG ACG 
TTG GCG ACG TTT CTT GCG TAT TTC ACC TGG TGG AGT CAC Table 3: RT‐PCR primers 
GAPDH-F 5’-GCA CAG TCA AGG CCG AGAAT 
GAPDH-R 5’-GCC TTC TCC ATG GTG GTG AA 
p16INK4a-F 5’-GCT GCA GAC AGA CTG GCC A 
p16INK4a-R 5’-GTC CTC GCA GTT CGA ATC TG 
p21CIP/WAF-F 5’-CTG AGG ATG AAC AGT AAC AAC CG 
p21CIP/WAF-R 5’-CTG GGA AGA TAG AGC GAA GCC 
p27KIP1-F 5’-TCT CTT CGG CCC GGT CAA T 
p27KIP1-R 5’-GGG GCT TAT GAT TCT GAA AGT CG 
p53-F 5’-TGA AAC GCC GAC CTA TCC TTA 
p53-R 5’-GGC ACA AAC ACG AAC CTC AAA 
FGF-receptor 1-F 5’-GGT GCT TCA TCT ACG GAA TGT C 
FGF-receptor 1-R 5’-TGA TGG GAG AGT CCG ATA GAG T Table 4: Primer for silencing and re‐activation of pluripotency markers 
tg-Oct3/4-F 5’-CCC CAC TTC ACC ACA CTC TAC 
tg-Oct3/4-R 5’-TTT ATC GTC GAC CAC TGT GC 
tg-Sox2-F 5’-GCC CAG TAG ACT GCA CAT GG 
tg-Sox2-R 5’-CCC CCT TTT TCT GGA GAC TA 
tg-c-myc-F 5’-CAG AGG AGG AAC GAG CTG AAG CGC (Takahashi and Yamanaka, 2006) 
tg-c-myc-R 5’-CTT GTA CAA GAA AGC TGG GT 
tg-Klf4-F 5’-AGG CAC TAC CGC AAA CAC AC 
tg-Klf4-R 5’-TTT ATC GTC GAC CAC TGT GC 
endo-Oct3/4-F 5’-TCT TTC CAC CAG GCC CCC GGC TC (Takahashi and Yamanaka, 2006) 
endo-Oct3/4-R 5’-TGC GGG CGG ACA TGG GGA GAT CC (Takahashi and Yamanaka, 2006) 
endo-Sox2-F 5’-TAG AGC TAG ACT CCG GGC GAT GA (Takahashi and Yamanaka, 2006) 
endo-Sox2-R 5’-TTG CCT TAA ACA AGA CCA CGA AA (Takahashi and Yamanaka, 2006) 
endo-Nanog-F 5’-CAG GTG TTT GAG GGT AGC TC (Takahashi and Yamanaka, 2006) 
endo-Nanog-R 5’-CGG TTC ATC ATG GTA CAG TC (Takahashi and Yamanaka, 2006)  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2.2 Nucleic acids 2.2.1 Generation of competent E.coli Pipettes and tubes used should be pre‐chilled at ‐20°C. 
E.coli  bacteria  cells  can  be  made  competent  following  an  adapted  protocol  from  Inoue  and colleagues  (Inoue et al., 1990). First, bacteria cells were cultivated on a LB‐agar plate without antibiotics at 37°C over night. Then a dozen of the emerging colonies were picked from the plate and  250mL of  SOB medium were  inoculated with  those  bacteria  cells.  Cells were  grown over night at 18 to 20°C until they reach an OD600 of 0.5. The beaker containing the bacteria culture was  then  put  on  ice  for  10 minutes.  Subsequently  cells  were  centrifuged  at  4000rpm  for  10 minutes at 4°C. The bacteria pellet was gently re‐suspended in 80mL of ice‐cold TB buffer and stored  again  on  ice  for  10 minutes.  The  cells were  pelletized  again  applying  4000rpm  for  10 minutes at 4°C. Thereafter  the bacteria pellet was re‐suspended  in 20mL of  ice‐cold TB buffer and  1.4mL  of  DMSO  was  added  drop‐wise  to  the  solution.  The  competent  cells  finally  were aliquoted  in a volume of 100µL and shock  frozen using  liquid nitrogen. Competent cells  could then be put on ‐80°C for long‐term storage. The transformation efficiency i.e. competency of the cells can be calculated using the following equation: # colonies on plate/ng of DNA plated x 1000ng/µg  2.2.2 Transformation of E.coli 100µL of competent E.coli  cells were  taken  from ‐80°C and  thawed on  ice  for 10 minutes. For protein  expression  cultures,  BL21(DE3)  GOLD were  used, whereas  DH5α  cells were  used  for cloning  purposes.  Subsequently  100ng  of  the  desired  plasmid  was  added  to  the  competent bacteria  cells.  In  case  of  transforming  ligation  assays  5µL  thereof  were  used.  Mixing  of  the solution was accomplished by tipping the Eppendorf tube. Bacteria cells were then incubated on ice for 20 minutes. Thereafter cells were put on 42°C for 40 seconds using a water bath. The cells were then directly incubated on ice for 2 minutes. 900µL of SOC medium was added and the cells were grown at 37°C for 45 minutes.  2.2.3 Preparation of small amounts of DNA Colonies cultivated on a LB‐agar plate supplemented with the appropriate antibiotic were used to  inoculate  a  volume of  3mL of  LB medium  supplemented with  the  appropriate  antibiotic  as well.  These  small  cultures were  grown over night  at  a  temperature  of  37°C  and 100rpm. The next day bacterial cells were pelletized and subjected to the PureLink Quick Plasmid Miniprep Kit from Invitrogen (Karlsruhe, Germany) according to the manufacturer’s protocol. 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2.2.4 Preparation of large amounts of DNA Either  colonies  growing  on  a  LB‐agar  plate  supplemented  with  the  appropriate  antibiotic  or freshly  prepared  transformation  assays  were  used  to  inoculate  100mL  of  over  night  culture consisting  of  LB  and  the  appropriate  antibiotics.  Cells  were  grown  over  night  at  37°C  and 120rpm. The next day bacteria cells were harvested via centrifugation and subjected  to either the  PureLink  HiPure  Plasmid  Maxiprep  Kit  from  Invitrogen  (Karlsruhe,  Germany)  or  the NucleoBond Xtra Maxi Kit from Machery‐Nagel (Düren, Germany).  2.2.5 Photometric measurement of DNA content For  the  measurement  of  DNA  content  two  different  systems  were  used.  When  using  the Eppendorf Biophotometer 50µL of DNA samples were subjected to UV‐cuvettes from Eppendorf (Hamburg, Germany) for instant measurement. If the amount of DNA was limited, the NanoDrop system from peqlab (Erlangen, Germany) was used. Here only 1µL is needed for measurement of DNA content, as this system is  independent of cuvettes.  In general  the DNA concentration was determined  measuring  at  a  wavelength  of  260nm  as  nucleic  acids  possess  their  maximum absorption at this wavelength.  Additionally a measurement at a wavelength of 280nm was done to  analyze  for  protein  contaminations  as  aromatic  amino  acids  absorb  light  the  most  at  this wavelength. The ratio of OD260/280 therefore defines the purity of the DNA solution where a ratio >1,8 is regarded as pure.  2.2.6 Cloning techniques 
2.2.6.1 Restriction hydrolysis For  digesting  of  plasmids,  PCR  fragments,  etc.  restriction  endonucleases  were  used  at  a concentration  of  2  to  5  unites  of  enzyme per  µg  of DNA. All  reactions were  performed  in  the appropriate  NEB  buffer  supplemented  with  1%  of  BSA  if  needed  at  the  temperatures recommended by the manufacturer. For analytical purposes digestion reactions were performed for 1 to 2 hours. This time frame was extended up to 16 hours for preparative approaches.  
2.2.6.2 Purification of DNA For  purifying  DNA  from  restriction  hydrolysis  analyzed  in  agarose  gel  or  PCR  reactions  the Wizard SV Gel and PCR Clean‐Up Kit purchased from Promega (Mannheim, Germany) was used. The ability of DNA to bind to silica membranes in the presence of chaotropic salts is utilized in this procedure. Contaminations, which were not able to bind to the membrane, were washed off. 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Finally,  DNA was  eluted  using  either water  or  10mM of  Tris‐Cl  pH  8.5  and  could  be  used  for downstream applications.  
2.2.6.3 Dephosporylation Recirculation of plasmid DNA can be suppressed by removing 5’phosphates of both ends of the linearized  DNA.  To  this  end  1U  of  Shrimp  Alkaline  Phosphatase  (SAP)  was  employed  to dephosphorylate 1pmol of  linear DNA at 37°C for 20 minutes. After inactivation of the SAP for 15 minutes at 65°C the plasmid DNA was directly subjected to  ligation reaction,  in which DNA fragments with 5’terminal phosphates could be effectively ligated to dephosphorylated DNA.  
2.2.6.4 Ligation Ligase  catalyzes  the  formation  of  phosphodiester  bonds  between  juxtaposed 5’phosphate  and 3’hydroxyl termini of DNA. In order to introduce DNA fragments into linearized DNA T4 ligase is used. For blunt end ligation reactions were performed for 2 hours at RT, whereas cohesive end ligation  was  conducted  for  10  minutes.  T4  ligase  activity  was  heat  inactivated  through incubation  at  65°C  for  10  minutes.  Afterwards,  the  ligation  reaction  was  directly  used  in  a transformation assay.  2.2.7 Polymerase chain reaction In order  to amplify DNA  fragments polymerase  chain  reaction  (PCR)  is  commonly used.  In an initial  step  double  stranded  DNA  is  denatured  applying  high  temperatures.  Subsequently  the temperature  gets  lowered  allowing  the  oligonucleotide  primers  to  anneal  to  the  now  single stranded DNA. Next,  temperature  is raised to 72°C, which represents  the optimal  temperature for DNA polymerase to exhibit functionality. Primers, which do anneal to the single DNA strand, get elongated until an exact match of the template DNA is amplified. These steps are repeated in cycles until an abundant amount of DNA is produced. 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Conditions for the PCR performed in a Thermocycler were as follows:   I. Initial denaturation at 98°C for 30 sec II. Denaturation at 98°C for 7 sec III. Annealing at 45°C to 72°C for 20 sec IV. Extension at 72°C for 25 sec (repetition of step II. to IV. for 30 cycles) V. Final extension at 72°C for 8 min VI. Hold at 4°C  2.2.8 Reverse transcriptase polymerase chain reaction Reverse  transcriptase  (RT)‐PCR  is  a  technique  in which DNA  is  amplified  from mRNA, which initially was isolated from cells (see 2.4.2). This allows a transcriptional analysis of the cells. The RNA is used as a template to derive complementary DNA (cDNA). This reverse transcription was conducted  using  a  modified  enzyme  called  reverse  transcriptase  from  the  Moloney  Murine Leukemia Virus, i.e. iScript from Biorad (Munich, Germany). Random primers with a length of 6 to 10 bases were used for the synthesis of the cDNA. Conditions for the reverse transcription performed in a Thermocycler were as follows:   I. 25°C for 5min II. 42°C for 42min III. 85°C for 5min IV. Hold at 4°C  The  synthesized  cDNA  was  then  used  as  a  template  for  the  PCR  reaction.  Corresponding gene‐specific primers (see Table 3) were used for the transcriptional analysis. cDNA was diluted to a final concentration of 200ng. Subsequently, 1μL of cDNA was subjected to the PCR reaction. 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Conditions for the PCR performed in a Thermocycler were as follows: 
  I. Initial denaturation 95°C II. Denaturation 95°C III. Annealing 55°C IV. Extension 72°C V.Final extension at 72°C for 8min VI. Hold at 4°C  For the amplification of GAPDH 25 cycles were used. All other factors were amplified using 30 cycles.  2.2.9 Electrophoresis in agarose gels DNA  fragments  can  be  separated  according  to  their  size  applying  an  electric  current  to  an agarose gel harboring  the DNA. As  the phosphate backbone of  the DNA  is negatively  charged, DNA will move towards the anode within the electrical field. Thereby the speed of the movement is inversely proportional to the logarithm of the molecular weight of the DNA fragment. Applying an intercalating dye, namely ethidium bromide, the DNA can be visualized within the gel using UV  light exhibiting a wavelength of 254nm. For  this purpose agarose was dissolved  in boiling 1xTAE  buffer.  Depending  on  the  size  of  the  DNA  fragments  different  percentages  of  agarose ranging  from  0.5%  to  2%  [m/v]  were  used.  After  cooling  of  the  agarose  solution,  ethidium bromide was  added  in  a  ratio  of  1:10.000  (c=10mg/mL)  and  subsequently  poured  into  a  gel chamber with slot combs. After loading of the samples diluted with an agarose gel loading buffer in a ratio of 1:10 first, and a DNA ladder that served as a migration standard an electric current was applied. For analysis the gel was put on a UV table or into the GelDoc system from Biorad (Munich, Germany).  2.2.10 Retroviral infection and iPS induction Plasmids  of  pMXs‐Oct3/4,  pMXs‐Sox2,  pMXs‐c‐myc  and  pMXs‐Klf4  were  obtained  from ADDGENE.  Retroviruses  were  generated  using  Plat‐E  packaging  cells  as  previously  described (Takahashi et al., 2007). Plat‐E cells were seeded at a density of 1x105 cells per well in a six‐well plates.  24  hours  after  transfection,  the  supernatant  containing  the  viruses  encoding  for  the reprogramming  factors,  was  collected  and  filtered  using  a  0.45µm  cellulose  acetate  filter. Oct3/4,  Sox2,  Klf4  and  c‐Myc  viruses were  combined  in  equal  shares  and  supplemented with 
Materials and Methods 
46 
polybrene at a final concentration of 4µg/mL. Oct3/4‐GiP MEFs were incubated with the viruses encoding  for  OKSM  for  16  hours.  Then  the  supernatant  containing  the  viruses was  removed. After 5 days cells were splitted onto  irradiated  feeder cells. The experiments were stopped at indicated time points and the cells were fixed applying 4% PFA and subsequently analyzed by fluorescence microscopy. These experiments were performed in collaboration with M. Thier. For analysis  of  silencing  of  transgenes  genomic  DNA  of  generated  iPS  cell  lines  was  harvested employing  the DNeasy  Blood  and  Tissue Kit  from Qiagen  (Hilden,  Germany)  according  to  the manufacturer’s instruction.  
2.3 Proteins 2.3.1 Expression of recombinant fusion proteins After  transformation of  the various expression vectors  into  the bacterial expression strain  the transformation  was  used  to  inoculate  an  overnight  culture,  consisting  of  LB  medium, supplemented with  glucose  at  a  final  concentration  of  0.5%  [v/v]  and  carbenicillin  at  a  final concentration of 50µg/mL. The next day, the densely grown overnight culture (OD600 >2.0) was centrifuged  and  the  bacteria  pellet  is  re‐suspended  in  fresh  LB  medium  in  order  to  remove 
β‐lactamase otherwise dissolving the antibiotics used. Afterwards, these bacteria cells were used to  inoculate  the  expression  culture.  The  expression  culture  consisted  of  TB  medium supplemented  with  glucose  at  a  final  concentration  of  0.5%  [v/v]  and  ampicillin  at  a  final concentration of 100µg/mL. Measuring OD600 monitors the growth of the expression culture. As soon as an OD600 of 1.5 was reached, expression became induced through the application of IPTG at a  final concentration of 0.5mM. After 1 hour bacteria cells were harvested using a SLA3000 rotor  running  at  5000rpm  (≈ 4.200g) with  a  temperature  of  4°C  for  10 minutes.  Bacteria  cell pellets  were  then  frozen  until  purification  of  the  recombinant  fusion  proteins.  A  general overview of the expression of recombinant protein can be seen in this video protocol (Munst et al., 2009).  2.3.2 Imidazole gradient In order to analyze a fusion protein for its optimal washing conditions an imidazole gradient was applied. A bacteria pellet corresponding to 1L of expression culture was lysed in 20mL of lysis buffer. After treatment of the solution with lysozyme and benzonase (see 2.3.3) the solution was centrifuged  in  a  SS34  rotor  at  15000rpm  (≈  26.900g)  running  at  4°C.  The  supernatant  was collected, 1mL of 50% Ni‐NTA slurry was added and the solution was incubated for 1 hour on an over‐head rotor at 4°C. This allowed for binding of the His‐Tag of the fusion protein to the Nickel ions.  Afterwards  the  solution  was  applied  onto  an  Econo  Pac  column  from  Biorad  (Munich, 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Germany)  and  allowed  to  run  through  by  gravity  flow.  1mL  of  50% Ni‐NTA  results  in  a  bed volume of 0.5mL. Subsequently 0.5mL,  i.e. 1 bed volume of buffers containing 1x PTB, 500mM NaCl  and  a  step‐wise  increasing  concentration  of  imidazole  were  applied.  The  imidazole concentration  had  a  range  of  10mM  to  240mM,  increasing  by  10mM  of  imidazole  each  step. Throughout  the  imidazole  gradient  samples  for  SDS‐PAGE  and  immunoblot  analysis  were collected.  2.3.3 Purification of recombinant fusion proteins 
2.3.3.1 Denaturing purification A  bacteria  cell  pellet  corresponding  to  1L  of  expression  was  resuspended  in  15mL  PBS  and sonicated  on  ice  to  lyse  the  cells.  The  crude  inclusion bodies were  pelleted  at  12.000g  for  30 minutes  and  the  supernatant was discarded. The pellet was  resuspended  in 15mL of washing buffer. The inclusion bodies were centrifuged at 25.000g for 10 minutes. The last two steps were repeated  4  to  5  times  until  the  pellet  step‐wise  exhibited  a  slightly  whiter  color.  In  a  final washing step the pellet was resuspended in resuspension buffer containing no Triton‐X100. The purified  inclusion bodies were dissolved  in  solubilization buffer,  i.e.  the pellet was broken up using a pipette tip and was then put on an over‐head shaker at 4°C over night. Once the inclusion bodies  were  fully  dissolved,  the  solution  was  centrifuged  at  25.000g  for  20  minutes.  The supernatant was  carefully  transferred  into  a  fresh  15mL  tube  and  applied  to  a  rapid  dilution refolding approach. 15 different buffer conditions were tested. 50µL of the supernatant obtained were diluted drop‐wise  into 950µL of  the corresponding refolding buffer while gently shaking the  solution.  Functional  refolding  buffers were  buffer  6,  8  and  11.  Refolded  protein was  then subjected  to Ni‐affinity  chromatography  and  the  recombinant  protein was  displaced  from  the column employing native lysis buffer. Subsequently buffer exchange was performed using PD10 desalting columns from GE Healthcare (Freiburg, Germany).   
2.3.3.2 Native purification A  temperature  of  4°C  is  essential while  purifying  all  fusion  proteins  analyzed  in  this work.  A bacteria pellet corresponding to 1L of expression culture was lysed for 20 minutes using 20mL of  lysis  buffer.  Afterwards  1mg/mL  of  lysozyme  was  added  and  incubated  for  20  minutes. Subsequently 25U/mL of benzonase were added for another 20 minutes. Samples of the crude lysate  as  well  as  of  the  pellet  fraction  for  SDS‐PAGE  were  taken.  The  crude  lysate  was  then centrifuged  for  30  minutes  at  15.000rpm  (≈  26.900g)  in  a  Sorvall  SS34  rotor  from  Thermo Scientific (Bonn, Germany) running at 4°C. A sample of the supernatant was taken for SDS‐PAGE analysis.  The  supernatant  was  transferred  into  clean  50mL  centrifuge  tubes.  1mL  of  50% 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Ni‐NTA slurry from Invitrogen (Karlsruhe, Germany) or Qiagen (Hilden, Germany) per 20mL of supernatant was added and incubated for 1 hour. 1mL Ni‐NTA results in 0.5mL column bed. The suspension was then poured onto an Econo pac column and allowed to run through by gravity flow. Washing buffer was applied one time with a volume of 10 times the column bed‐volume. Elution was carried out applying 5 times the column bed volume. The  eluate  fraction was dialysed 2  times  for  1  hour  against  PBS  at  4°C.  Subsequently  dialysis over night at 4°C against KnockOut D‐MEM medium from Invitrogen (Karlsruhe, Germany) was conducted.  Netx,  dialysate  was  centrifuged  for  30  minutes  at  6000rpm  (≈  6.240g)  at  4°C. Concentration was then assessed via Bradford.  In  the  case  of  ΔNanog‐TAT  the  exchange  of  medium  was  conducted  via  a  PD10  desalting column. Briefly, the column was washed with 25mL of PBS and was equilibrated with 25mL of KnockOut D‐MEM medium thereafter. Subsequently 2.5mL of eluate fraction were applied onto the  column.  The  protein  was  dissolved  from  the  PD‐10  desalting  column  with  3.5mL  of KnockOut D‐MEM medium. Dialysate fraction was then sterile‐filtrated. Afterwards it was diluted with 2x Advanced Medium in a ratio of 1:1. Thereafter the solution was put on 37°C for 2 hours for pre‐incubation to force proteins  prone  to  precipitate  under  cell  culture  conditions  to  do  so  beforehand.  The medium containing the fusion protein was then centrifuged for 30 minutes at 6000rpm (≈ 6.240g) at 4°C. After  sterile‐filtration,  the medium was  supplemented with  the missing  4%  of  FCS  from  PAN (Aidenbach, Germany) to reach a final concentration of 5% of FCS. The fusion protein could now be applied in cell culture experiments.  2.3.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS‐PAGE) allows the separation of proteins according to their size. This process is enabled by the fact that sodium dodecyl sulfate acts as a strong anionic detergent and denatures the secondary and tertiary structure of proteins and at the same time charges the proteins negatively according to their size. Disulfide bonds are reduced  by  β‐mercaptoethanol.  Two  polyacrylamide  gel  parts  with  varying  pH‐values  are stacked when performing discontinuous SDS‐PAGE. The upper part, called stacking gel exhibits bigger pore sizes due to the low amount of (bis)acrylamide used, and all proteins concentrate in a small part of the stacking gel before uniformly entering the separating gel. Because of the high amount  of  (bis)acrylamide  the  separating  gel  possesses  smaller  pores,  which  leads  to  a separation of the proteins according to their molecular mass.  The  separating  gel  was  poured  into  a  tightly  assembled  gel  chamber  first,  and  after polymerization of the separating gel the stacking gel was stratified on top. A comb was inserted 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into  the  stacking  gel.  For  SDS‐PAGE  the  gel was  transferred  into  a  gel  chamber  containing 1x SDS‐PAGE  running  buffer.  The  SDS‐PAGE  samples  were  heated  at  95°C  for  5  minutes  and subsequently  centrifuged  before  loading  into  the  gel  slots.  5µL  were  used  per  sample  of recombinant  proteins,  for  whole  protein  lysates  obtained  from  cell  culture  the  amount corresponding  to  50  µg  was  loaded.  Additionally  at  least  one  slot  was  loaded  with  (Color) Prestained  Protein  Marker,  a  defined  marker  ranging  from  a  molecular  mass  of  175  to  7. Electrophoresis was carried out at 200V for 45 minutes. After completion of the gel run, the gel was washed 3  times  for 5 minutes  in H2O before  it was  incubated with  Imperial Protein Stain Solution  from  Perbio  (Bonn,  Germany)  for  5  minutes  up  to  16  hours.  This  coomassie  R‐250 based  staining  solution  offers  high  sensitivity,  since  6ng  of  protein  per  lane  can  be  detected. Afterwards the gel was decolorized with H2O for 15 minutes to 16 hours. The longer this process lasts, the less background staining remains.  2.3.5 Immunoblot In order to doubtlessly identify a protein of interest, immunoblot is the method of choice. A soon as SDS‐PAGE was finished the gel became transferred into immunoblot (wet) transfer buffer and incubated for 10 minutes. Thereafter the immunoblot was assembled. The cassette was placed on  a  clean  surface with  the  black  side  down. One  pre‐wetted  ‐  also  incubated  in  immunoblot (wet)  transfer  buffer  ‐  fiber  pad  was  put  on  the  black  side  of  the  cassette,  followed  by  2 Whatman filter papers. Next  the equilibrated gel was put on top followed by a pre‐wetted ‐  in immunoblot  (wet)  transfer  buffer  as  well  ‐  nitrocellulose  membrane  from  Carl  Roth  GmbH (Karlsruhe, Germany). The assembly was  completed by 2  additional  filter papers  and another pre‐wetted fiber pad. The assembly was then closed and put into the Mini Trans‐Blot buffer tank together with a Bio‐Ice cooling unit. The buffer tank was filled with immunoblot (wet) transfer buffer and an electrical current of 100V was applied for 1 hour. Alternatively, the blotting can be performed  at  30V  for  16  hours.  After  the  blotting  procedure  was  completed  the  blot  was disassembled.  Staining  of  the  membrane  was  performed  with  Ponceau  S  from  Sigma‐Aldrich (Munich,  Germany),  which  is  able  to  stain  all  proteins  transferred  onto  the  nitrocellulose membrane.  Thereby  equal  loading  of  all  protein  samples  could  be  evaluated.  Destaining  of Ponceau S was performed by application of PBS to the membrane for 3 times for 5 minutes. The nitrocellulose membrane was then incubated in TBS for 10 minutes before the membrane was subjected to a suitable blocking solution, according to the instructions of the manufacturer of the antibody  used.  After  blocking  of  the  immunoblot  the  membrane  was  washed  3  times  for  10 minutes in TBS‐T. Subsequently the membrane was transferred to the primary antibody solution for  different  durations  according  to  the  manufacturer  of  the  antibody.  3  washing  steps  with TBS‐T  lasting  for  10 minutes were  performed  thereafter.  The membrane was  then  incubated 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with  the secondary antibody solution  for different durations according  to  the manufacturer of the antibody. A final washing of the membrane was performed for 3 times 10 minutes in TBS‐TT. Subsequently the immunoblot could be analyzed by the application of a substrate solution. For recombinant proteins SuperSignalWest Pico Substrate from Perbio (Bonn, Germany) was used, for the detection of proteins extracted from cells SuperSignal West Femto Substrate from Perbio (Bonn, Germany) was employed, as it possesses a higher sensitivity than the before‐mentioned substrate.  The  actual  detection was  carried  out  using  the  ChemiDoc  XRS  system  from Biorad (Munich,  Germany),  which  harbors  a  CCD  camera  able  to  detect  the  emerging chemiluminescence.  Immunoblot stripping protocol In order to use a nitrocellulose membrane for the detection of another protein of interest with a different primary and secondary antibody, the primary antibodies initially used can be removed, i.e.  stripped  off  the membrane.  To  this  end  the  nitrocellulose membrane was  incubated with pre‐warmed stripping buffer for 30 minutes at 50°C in a hybridization oven. Heat combined with strong  detergents  strips  antibodies  off  the  blot.  Afterwards  the  blot was  rinsed with  TBS  for several times. Successful stripping of the membrane could be checked through the application of chemiluminescent  substrate.  No  signal  should  be  detectable.  The  immunoblot  could  then  be treated as a freshly blotted membrane.  2.3.6 Electrophoretic Mobility Shift Assay An electrophoretic mobility shift assay (EMSA) allows investigating whether a protein, i.e. in this special case a transcription factor is able to bind to a specific DNA or RNA sequence. In order to analyze  the  biological  activity  of  the  purified  recombinant  fusion  proteins  Nanog‐TAT  and 
ΔNanog‐TAT, a shift assay was performed. Briefly, the protein to be analyzed was incubated with a specific DNA sequence, mostly a promoter or enhancer regulatory element, which is known to be  bound  by  the  transcription  factor  Nanog.  Complexes  of  Protein  and  DNA  migrate  slower through a polyacrylamide gel than free DNA. This phenomenon is termed shift. The oligo sequences (Pan and Pei, 2005) chosen for the EMSA were as follows: 5’‐TCGACACCCTTCGCCGATTAAGTACTTAAG  (sense) 5’‐TCGACTTAAGTACTTAATCGGCGAAGGGTG (antisense) EMSA  was  performed  with  the  Lightshift  Chemiluminescent  EMSA  Kit  from  Thermofisher Scientific (Bonn, Germany) according to the given instructions. Binding of 100ng of recombinant proteins and 0.5ng of biotinylated or non‐biotinylated oligonucleotides was performed in 20µL 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binding buffer (10mM Tris, 50mM KCl, 1mM DTT, 2.5% glycerol, 5mM MgCl2, 1µg poly(dI‐dC), 0.05% NP‐40). Binding reactions were separated by native PAGE and subsequently blotted on a positively  charged  nylon  membrane  from  Roche  (Mannheim,  Germany).  Streptavidin‐labeled horseradish  peroxidase was  then  used  for  detection  purpose.  Signals were  detected with  the CCD camera of a ChemiDoc XRS documentation system from Biorad (Munich, Germany). All  materials  used  were  washed  thoroughly  beforehand  to  ensure  complete  absence  of  SDS, which would consequently lead to the denaturation of the proteins to be analyzed. Prior to loading of the binding reactions the gels was allowed to pre‐run for 1 hour at 100V.  2.3.7 Immunocytochemistry In  order  to  detect  proteins  inside  or  on  the  surface  of  cells,  immunocytochemistry  (ICC) was conducted.  Cells  were  fixed  and  subsequently  stained  for  the  expression  of  the  protein  of interest.  Briefly,  the  cell  culture medium was  aspired  and  cells  were washed  twice with  PBS from Gibco (Karlsruhe, Germany). Subsequently cells were fixed with 4% PFA for 10 minutes at RT.  PFA  cross‐links  proteins  via  formaldehyde.  Thereafter,  cells  were washed  3  times  for  10 minutes with PBS to remove the remaining PFA. All of these steps were performed under a fume hood.  Cells were  then  either  stored  at  4°C  or  directly  subjected  to  ICC.  In  order  to  block  free binding sites, a blocking solution consisting of 5% FCS diluted in PBS was applied onto the cells for  60  minutes.  Subsequently  a  washing  step  with  PBS  was  performed  before  the  primary antibody was applied over night at 4°C. The next day unbound antibody was washed off with PBS 3  times  for 60min at RT.  Subsequently  the  second antibody,  diluted  in 5% FCS/PBS, was applied for 2 hours at RT in darkness. Cells were finally washed 3 times with PBS for 10 minutes. DAPI  was  applied  for  5 minutes  prior  to  covering  cells  with  a  microscope  glass  slide.  Either Moviol  or  Vectashield  mounting  medium  was  used  to  preserve  the  cells.  Cells  were  then analyzed by fluorescence microscopy. Afterwards cells were stored at 4°C in darkness to prevent fading of the staining. Alkaline Phosphatase staining of cells was performed with the Alkaline Phosphatase Kit III from Vector Laboratories (Burlingame, USA). At a glance, staining solution was composed as specified by the manufacturer. Staining solution was applied onto fixed cells and staining procedure was conducted for 30 minutes. Staining solution was then aspirated and cells were stored in PBS. Senescence‐associated β‐Galactosidase staining was performed as  follows. After  fixation of  the cells, fibroblast cells were incubated with freshly prepared SA β‐Galactosidase staining solution for a maximal  time period of 16 hours at 37°C without CO2. The staining solution consisted of 1mg  of  5‐bromo‐4‐chloro‐3‐indolyl  β‐D‐galactoside  (X‐Gal)  per  mL/40mM  citric  acid/sodium phosphate,  pH  6.0/5mM  potassium  ferrocyanide/5mM  potassium  ferricyanide/150mM 




2.4.1.1 Passaging of cells Fibroblast  as  well  as  ES  cells  were  passaged  according  to  their  confluency.  Briefly,  culture medium was  aspirated  from  the  cells  and  the  cells were washed  once with  pre‐warmed PBS. Subsequently, a sufficient amount of TrypLE Express from Gibco (Karlsruhe, Germany) to cover the bottom of the dish was added to the cells and the cell culture dish was incubated at 37°C for at least 5 minutes. If 5 minutes had not been sufficient to dissolve all cells from the bottom of the culture dish, another 5 minutes of incubation at 37°C were conducted. Dissolved cells were then carefully re‐suspended to obtain a single cell  solution allowing  to count  them. Thereafter cells were  transferred  into  a  15mL  centrifuge  tube  and  centrifuged  at  1000rpm  (≈  170g)  for  3 minutes  at  4°C.  The  supernatant was  aspirated  and  the  cells were  re‐suspended  in  fresh  cell culture  medium  and  seeded  onto  the  corresponding  plates.  ES  cells  were  seeded  onto gelatin‐coated  dishes;  fibroblasts  were  seeded  onto  untreated  dishes.  In  order  to  coat  cell culture dishes with gelatin, 0.1% gelatin solved in PBS was applied for 20 minutes at 37°C.  
2.4.1.2 Counting cells A cell suspension was prepared directly from the cell culture and depending on the density this suspension was  further  diluted.  10µL  of  the  suspension were mixed  thoroughly with  10µL  of 0.4%  trypan  blue  from Gibco  (Karlsruhe,  Germany).  Living  cells will  not  take  up  trypan  blue, whereas dead cells will. So  living cells will appear  in bright  light within  the counting chamber under  the  binocular,  dead  cells  stain  blue  instead.  Approximately  15µL  of  the  solution  were transferred  to  the  Fuchs‐Rosenthal  chamber  sheeted with  a  cover  plate  and  the  solution was allowed  to  fill  in  by  capillary  forces.  Using  a  binocular,  viable  cells  were  counted.  A  Fuchs Rosenthal chamber contains 16 big squares, each further subdivided into 16 small squares. Cells within  two  big  squares  were  counted,  average  value  thereof  was  determined  and  the  cell number according  to  the  following equation was calculated.  If  too  few or  too many cells were present, the cell suspension was diluted accordingly. 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cells/mL = average cell count per square x dilution factor x 104  total cells = cells/mL x original volume of fluid from which cell sample was removed  
2.4.1.3 Freezing and thawing cells Using cryovials, 1.2 x 106  to 3.0 x 106 ES cells were cryopreserved  in 500µL of ES cell  culture medium and 500µL of 2x‐freezing medium as well as LIF if needed. It is important to (I) slowly add the ice‐cold 2x‐freezing medium to the ES cells and to (II) take care not to re‐suspend the cells more than once after that. After that cryovials were stored at ‐80°C in a Cryo 1°C Freezing container  from  Nalgene  (Roskilde,  Denmark)  filled  with  isopropanol  guaranteeing  slow  and gentle freezing of the cells. The next day cells were transferred into liquid nitrogen. For somatic cells the protocol was basically the same, except the cells were frozen in 500µL of MEF medium supplemented with 500µL of 2x freezing medium. In order  to  thaw cells,  a  cryovial was  taken  from  the  liquid nitrogen and put on 37°C using  a water bath. Gentle agitation of the vial was performed until only a small ice crystal in the middle of the cryovial remained. Cells were then transferred from the cryovial  into a 15mL centrifuge tube containing pre‐warmed cell culture medium. Cells were centrifuged at 800rpm (≈ 110g) for 3 minutes at 4°C. Supernatant was aspirated and the cells were carefully resuspended and finally seeded on the appropriate cell culture dish.  
2.4.1.4 Embryoid body formation iPS cells generated in the presence of Nanog‐TAT were cultivated employing mouse ES medium supplemented  with  LIF  for  15  to  25  passages  on  irradiated  MEFs.  Cells  were  splitted  and replated on gelatine‐coated dishes for 2 days in the same medium. On the third day, cells were carefully  trypsinized  and  transferred  onto  10cm petri  dishes  in mouse ES media without  LIF. The  suspension  cultures  were  kept  for  several  days  until  EBs  formed.  EBs  were  plated  and cultivated  for  additional  3  to  7  days.  Staining  for  the  three  germ‐layers  was  conducted  after fixation of the plated EBs.  2.4.2 Protein transduction 
2.4.2.1 Oct3/4 GiP MEFs and CV1 fibroblast cells For maintenance cultures of MEFs resp. CV1 cells, cells were cultivated in MEF medium on 10cm dishes and cells were splitted using TrypLE Express from Gibco (Karlsruhe, Germany) every 3 to 4 days prior to becoming confluent. Change of medium was conducted every other day. For cell 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cycle  analysis  of  MEFs  cultivated  with  Nanog‐TAT,  ΔNanog‐TAT  or  control  medium  via immunoblot, 750.000 cells exhibiting passage number 5 were seeded on a 10cm dish. In order to synchronize  the  fibroblasts,  cells were  first put under serum starvation,  i.e. a concentration of 0.2%  FCS,  for  48  hours.  This  led  to  an  accumulation  of  cells  in  G0  phase  of  the  cell  cycle. Subsequently MEFs were cultivated in MEF medium supplemented with 4µg/mL aphidicolin for another  16  hours  to  finally  synchronize  cells  in  S  phase  of  the  cell  cycle,  since  aphidicolin efficiently  inhibits  DNA  polymerase  α.  Afterwards  MEFs  were  washed  twice  with  PBS  and cultivated with 100nM of Nanog‐TAT, 50nM of ΔNanog‐TAT or control medium for the indicated time points. Cells were then washed once with ice‐cold PBS and thereafter ‐  in the presence of 7mL of ice‐cold PBS ‐ scratched from the dish using a cell scraper. Cells were transferred into a 15mL centrifuge tube and the tube was put on ice. Additional 3mL of ice‐cold PBS were used to wash remaining cells  from the dish and  these cells were  transferred  into  the 15mL centrifuge tube already harboring the 7mL of cell suspension. Cells were then centrifuged at 4000rpm (≈ 2.770g) for 10 minutes at 4°C. PBS was aspirated and cells were resuspended in  ice‐cold RIPA buffer  supplemented  with  HALT  protease  inhibitors  from  Thermo  Fisher  Scientific  (Bonn, Germany). The solution was transferred into an Eppendorf tube and put on an over‐head rotator for  30  minutes  at  4°C.  Thereafter  the  solution  was  centrifuged  at  13.000rpm  at  4°C  for  30 minutes. The supernatant,  i.e.  the whole protein  lysate, was  transferred  into a new Eppendorf tube and the protein concentration was determined via Bradford assay. The volume accounting for a  total of 50µg of protein was diluted with  the appropriate amount of 5x SDS‐PAGE buffer and was  then  heated  up  at  96°C  for  5 minutes.  Samples were  then  ready  to  be  applied  onto SDS‐PAGE followed by immunoblot analysis. For  harvesting  RNA  of MEFs,  250.000  cells  were  seeded  onto  a  6cm  dish  and  the  cells  were synchronized as described above. Thereafter MEFs were washed twice with PBS and cultivated with  100nM of Nanog‐TAT,  50nM of ΔNanog‐TAT or  control medium  for  indicated periods  of time.  Cells  were  then  washed  again  with  PBS  and  trypsinized  using  TrypLE  Express  and centrifuged at 4°C for 5 minutes at 1000rpm (≈ 170g). MEFs were then directly applied to RNA purification  with  the  RNeasy  Mini  Kit  from  Qiagen  (Hilden,  Germany)  according  to manufacturer’s instructions. For protein  transduction of CV1  fibroblast cells, 1x104 cells were seeded per 12 well dish and protein transduction medium containing either 100nM of Nanog‐TAT or 50nM of ΔNanog‐TAT was applied. After 5 hours cells were washed 3 times with 0.5mg/mL of Heparin at 37°C to strip off  recombinant  proteins  attached  to  the  cellular  surface.  Thereafter  cells  were  fixed  and subjected to ICC. In  order  to  analyze  for  nuclear  translocation  of  the  recombinant  protein,  CV1  cells  cultivated with 50nM of ΔNanog‐TAT  for 2 days were harvested and nuclear extracts were prepared. To 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this end, cells were put directly on ice and subsequently washed twice with ice‐cold PBS. Cells were  harvested  using  a  cell  scraper  and  transferred  into  a  15mL  centrifuge  tube.  Cells  were centrifuged  for  5  minutes  at  4°C  at  1000rpm  (≈  170g).  The  supernatant  was  discarded.  Cell debris  is resuspended in buffer A (10mM Tris, pH 7.8; 1.5mM MgCl2, 10mM KCl) by vortexing. Cell  suspension  is  transferred  into  a  new  1.5mL  centrifuge  tube  and  incubated  on  ice  for  15 minutes. Cell suspension was centrifuged again at 6000rpm (≈ 3220g) at 4°C for 5 minutes and the supernatant was again discarded. To transfer nuclear proteins into aqueous solution 150µL of high molecular buffer C (20mM Tris, pH 7.8; 420mM KCl; 1.5mM MgCl2; 20% glycerol [v/v]) was  added.  The  pellet was  resuspended  and  incubated  on  ice  for  30 minutes.  Afterwards  the nuclei were centrifuged down and the solution containing the nuclear proteins was subjected to immunoblot analysis.  
2.4.2.2 MP­AF primary human dermal fibroblasts For maintenance culture of human dermal fibroblasts, cells were cultivated with MEF medium. Cells  were  splitted  every  2  to  3  days  prior  to  confluency  using  TrypLE  Express.  Change  of medium was  conducted  every  other  day.  For  growth  curve  analysis,  250.000  cells  exhibiting passage number 6 were seeded on a 6cm dish. As soon as cells reached 90% confluency, the cells were splitted and again 250.000 cells were seeded. Cell numbers were accessed and  to  finally analyze  growth  properties,  cumulative  cell  numbers were  determined.  For  the  analysis  of  SA 
β‐Galactosidase expression, cells at passage 16, already cultivated with 100nM of Nanog‐TAT for 2 weeks were seeded at a density of 250.000 cells. The next day, cells were fixed and stained for SA β‐Galactosidase in order to prevent the cells from becoming confluent and thereby eventually distorting SA‐βGalactosidase expression. For the assessment of whole genome RNA expression, cells were treated as described for growth curve analysis. The starting cell population exhibited passage  number  9.  After  5  passages,  cells  were  trypsinized  and  subjected  to  RNA  extraction using  the RNeasy Mini Kit  from Qiagen  (Hilden,  Germany).  RNA was  then processed with  the Illumina TotalPrep‐96 RNA Amplification Kit from Ambion (Darmstadt, Germany) according to the manufacturer’s instruction. Subsequently the labeled RNA was loaded onto Illumina Whole Genome Expression Chips and processed as described by the manufacturer.  
2.4.2.3 Oct3/4 GiP ES cells Murine  ES  cells  were  cultivated  on  gelatine‐coated  dishes  or  plates.  Prior  to  all  experiments involving Oct3/4 GiP ES cells, cells were cultivated in the presence of puromycin for one week to obtain  stringent  pluripotent  ES  cell  populations.  5000  cells were  seeded  per well  of  a  6‐well plate  and  cultivated with  control medium  or medium  containing ΔNanog‐TAT  ‐  either  in  the 






3 Results The technique of protein transduction offers an attractive alternative to manipulate cellular fate by  non‐genetic  means  in  contrast  to  conventional  methods  employing  transfection  or  viral transduction for example. The transducible protein has to fulfill distinct requirements though in order to be successfully transferred into cell culture paradigms. Already at the very beginning of the  production  of  a  transducible  protein  one  has  to  focus  on  several  potentially  limiting parameters. In case the fusion protein should exhibit toxic side effects, affecting the condition of the expression system a suitable expression host has to be chosen. Especially in the beforehand mentioned  case  the  basal  expression  of  the  recombinant  protein  before  induction  has  to  be minimized as well. The expression of  the protein of  interest  then has  to be  inducible and one should  carefully  check  for  the  stability  of  the  desired  fusion  protein  during  the  phase  of induction. A protocol  for  the optimized purification of  a Histidin‐tagged  fusion protein  can be established best when applying an imidazole gradient analyzed by SDS‐PAGE and immunoblot, which will indicate the adequate washing conditions in order to obtain recombinant protein of high purity. The transfer of the fusion protein into physiological conditions then is a pivotal step during  the  process  of  protein  purification  as  the  protein‐of‐interest  may  precipitate.  For  the analysis  of  biological  activity  of  the  recombinant  fusion  proteins  several  assays  can  be performed.  So  as  to  investigate  the  translocation  capability  of  the  recombinant  protein  cells transduced  therewith  can  be  analyzed  immunocytochemically.  Nuclear  extracts  of  cells transduced  with  the  recombinant  protein  can  be  explored  via  immunoblot.  Moreover,  an electrophoretic mobility shift assay can indicate binding of the fusion protein, i.e. a transcription factor,  to  a  specific  consensus  sequence.  Only  if  the  recombinant  fusion  protein  fulfills  these preconditions, experiments in cell culture should be conducted.   
3.1 Recombinant Nanog fusion proteins Initial  studies  in our workgroup employing  recombinant Nanog protein  fused  to peptides  like Thioredoxin  (LaVallie  et  al.  1993),  Maltose  Binding  Protein  (Bedouelle  and  Duplay,  1988)  or NusA (Davis et al., 1999) failed for the proper expression of Nanog (Peitz, 2007). Expression of the  full‐length Nanog fusion protein could be achieved though by using a construct, where the protein  exhibits  an  NLS  at  the  N‐terminus,  followed  by  the  genetic  information  for  murine Nanog.  Then  the  TAT  protein  transduction  domain  and  the  Histidin‐Tag  are  attached  to  the C‐terminus  of  the  protein  (Fig.  8A).  This  recombinant  protein  was  named  Nanog‐TAT  (Peitz, 2007). It is highly desirable to have pure protein at hand when working in cell culture, since this would  for  example  allow  for  the  labeling  of  the  fusion  protein with  fluorescent  dyes.  This,  in consequence, would  enable  the  analysis  of  living  cells  transduced with  the  labeled protein,  in 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order to investigate the cellular uptake since fixation of cells may lead to artificial distribution of the recombinant protein. Furthermore, the specificity of the potentially observed effect could be linked more  easily  to  the  recombinant  fusion  protein  than  to  any  contaminations.  Hence,  the need for optimizing the purification process of the Nanog‐TAT fusion protein was accentuated. A bacterial  expression  system was  chosen  for Nanog‐TAT.  For  expression purposes  the plasmid encoding for Nanog‐TAT was transformed into E.coli.. Bacteria cells containing the plasmid were grown over night and used to inoculate the expression culture, which was induced via IPTG. As Nanog‐TAT became degraded over prolonged  time of  induction  (data not  shown)  the bacteria cells were harvested 1 hour after induction. As  for  a  proper  experimental  setup  a  control  protein  was  missing,  a  variant  of  Nanog‐TAT lacking its homeodomain was generated, since up to now no point mutation leading to a loss of Nanog functionality is known. 
 
 
Figure 8: Schematic overview of Nanog fusion proteins 
(A) Cellular uptake of the full-length Nanog protein is expected through the addition of TAT to the 
recombinant stemness factor. For enhanced nuclear translocalization a Simian Virus 40 NLS is added. 
The Histidin-Tag enables Ni-affinity chromatography. (B) Nanog control protein consists of two 
domains. The ommitance of the 65 aa long homeodomain should disable binding of the deletion 
mutant to the DNA, i.e. ΔNanog-TAT should not exhibit functionality. Cellular uptake of the protein is 
assured through the addition of TAT to the recombinant control protein. The Histidin-Tag enables Ni-
affinity chromatography. aa: amino acids; NLS: nuclear localization sequence; N: N-terminal domain; 
W: tryptophan repeat; C: C-terminal domain; TAT: transactivator of transcription domain; HIS: 
Histidin-Tag  The mutant Nanog control protein, named ΔNanog‐TAT, comprises a NLS at  the N‐terminus, a truncated  variant  of  the  murine  Nanog,  as  well  as  a  TAT  PTD  and  the  Histidin‐Tag  at  the C‐terminus.  Comparably  to  Nanog‐TAT  a  bacterial  expression  system  was  chosen  for 
ΔNanog‐TAT  as  well.  For  expression  purposes  the  plasmid  encoding  for  ΔNanog‐TAT  was 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Figure 9: Analysis of Nanog-TAT expression and imidazole gradient  
(A) SDS-PAGE analysis reveals expression of recombinant Nanog-TAT. During washing steps the 
fusion protein can be enriched (black arrowhead). Upon application of washing buffer containing 
100mM (indicated by *) of imidazole Nanog-TAT shows least contaminating bands. Black arrowhead 
shows the recombinant protein. (B) Immunoblot analysis employing α-Nanog antibody indicates 
expression of recombinant Nanog-TAT in the CL fraction. A major part of Nanog-TAT is detected in the 
insoluble fraction. Throughout the washing fractions Nanog-TAT detection is visible up to 
concentrations of 170mM of imidazole. Black arrowhead shows the recombinant protein. SDS-PAGE 
and immunoblot were performed with a gel exhibiting a concentration of 10% (bis)acrylamide. M: 
marker; CL: crude lysate; P: pellet; SN: supernatant; FT: flow through; 10-240: increasing 
concentrations of imidazole in mM; *: 100mM of imidazole; #: 30mM of imidazole  The crude lysate (Fig. 9A ‐ lane 2) fraction shows an induction of expression of Nanog‐TAT at a molecular mass of approximately 43. The calculated molecular weight for Nanog‐TAT is 38kDa. Most of the fusion protein is insoluble (Fig. 9A ‐ lane 3) and seems to be trapped within inclusion bodies.  A minor  part  of  the  protein  remains  in  the  soluble  fraction  (Fig.  9A  ‐  lane  4)  though. Although a small amount of the Nanog‐TAT fusion protein gets washed off, a major part of the contaminations  accompanying  Nanog‐TAT  can  be  eliminated  through  washing  with  buffers containing concentrations of up to 100mM of imidazole (Fig. 9A ‐ lanes 6 to 15). Washing with buffers  containing more  than  100mM  of  imidazole  results  in  a  relatively  pure  fusion  protein containing almost only very few high‐molecular contaminations (Fig. 9A ‐  lane 16). In order to identify the Nanog‐TAT fusion protein the samples of the imidazole gradient were also subjected to  SDS‐PAGE  followed  by  immunoblot  analysis.  Via  immunoblot  analysis  applying  a α‐Nanog 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Figure 10: SDS-PAGE and immunoblot analysis of denaturing purification 
(A) SDS-PAGE. Inclusion bodies were purified and subsequently subjected to a refolding paradigm 
using a rapid dilution approach. Buffer conditions were analyzed via SDS-PAGE. 3 out of 15 refolding 
conditions showed highly pure Nanog fusion protein. (B) The same samples were analyzed via 
immunoblot applying a α-His antibody in order to identify the recombinant fusion protein. (C) 
Chronologically gained samples from denaturing purification, refolding and dialysis were analyzed via 
immunoblot employing a α-His antibody. SDS-PAGE and immunoblot were performed with a gel 





Figure 11: SDS-PAGE and immunoblot analysis of optimized native purification conditions 
Washing with 5x column bed volumes of buffer containing 100mM of imidazole led to a highly pure 
Nanog fusion protein, which could be identified by immunoblot analysis applying α-Nanog antibody. 
SDS-PAGE and immunoblot were performed with a gel exhibiting a concentration of 10% 




Figure 12: SDS-PAGE and immunoblot indicate that highly pure Nanog-TAT is not stable under 
physiological conditions 
(A) SDS-PAGE. The eluate fraction can be concentrated via dialysis and vivaspin columns up to over 
1mg/mL. Dialysis of the eluate fraction against a glycerol buffer leads to a 6-fold concentration of 
Nanog-TAT. Subsequent centrifugation of the glycerol stock solution using a vivaspin column leads to a 
final concentration of 1mg/mL of recombinant fusion protein (B) Immunoblot. When diluting an amount 
of Nanog-TAT - corresponding to the amount available after elution - from the glycerol stock into readily 
supplemented cell culture medium the protein almost completely precipitates. SDS-PAGE and 
immunoblot were performed with a gel exhibiting a concentration of 10% (bis)acrylamide. M: marker; 




Figure 13: Adapted purification protocol for Nanog-TAT 
(A) SDS-PAGE. A chronological loading of samples taken during the process of purification of 
Nanog-TAT under optimized conditions is shown. Washing with 10x column bed volume of buffer 
containing 30mM of imidazole results in a relatively pure Nanog-TAT fusion protein that can be 
enriched in the eluate fraction (black arrowhead). (B) Immunoblot analysis applying anti-Nanog 
antibody identifies Nanog-TAT and confirms the results obtained in SDS-PAGE analysis. SDS-PAGE 
and immunoblot were performed with a gel exhibiting a concentration of 10% (bis)acrylamide. M: 
marker; CL: cleared lysate; P: pellet; SN: supernatant; FT: flow through; W: washing; E: eluate; DA: 
densitometric analysis  With  the  adapted  purification  protocol  Nanog‐TAT  can  be  enriched  in  the  eluate  fraction  as shown  in  the  SDS‐PAGE. The  amount  of Nanog‐TAT  fusion protein  lost  during washing of  the column is minimized (Fig. 13B – lane 5) compared to washing steps performed with 100mM of imidazole  (Fig.  11  –  lanes  3  and  4).  In  addition  to  the  Nanog‐TAT  fusion  protein,  2  high molecular contaminations are detectable within the eluate fraction at a molecular mass of 60 to 70. Furthermore, 2 low molecular contaminations stain in the SDS‐PAGE at a molecular mass of around 25 (Fig. 13A – lane 7). None of these contaminations are detected in the corresponding immunoblot (Fig. 13B – lane 7). Densitometric analysis reveals a share of 39.8% of Nanog‐TAT within  the  eluate  fraction  (Fig.  13A  –  lane  8).  An  additional  weak  band  is  seen  on  the immunoblot  within  the  crude  lysate  at  a  molecular  mass  of  130  (Fig.  13B  –  lane  1).  This additional band results from unspecific binding of the antibody, as the appearance of the band is stated  in  the datasheet provided by  the manufacturer of  the antibody. A minor amount of  the Nanog‐TAT fusion protein is lost in the flow through fraction, as shown in the immunoblot (Fig. 13B  –  lane  5).  If  the  concentration  of  imidazole within  the  lysis  buffer  is  further  lowered,  in order to avoid loss of Nanog‐TAT in the flow through fraction, additional contaminating bands appear in the eluate fraction analyzed by SDS‐PAGE (data not shown). The Nanog‐TAT fusion protein  is  then dialyzed at 4°C against physiological buffer to get rid of the imidazole exhibiting toxicity and to provide salt concentrations necessary for the cultivation of  mammalian  cells.  A  part  of  the  fusion  protein  is  lost  during  dialysis.  Adjustment  of  the 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temperature  to  37°C  further diminishes  the  amount  of Nanog‐TAT  fusion protein  as  only  one fifth  of  the  remaining  Nanog‐TAT  originating  from  the  dialysis  is  soluble  then.  Nanog‐TAT  is relatively  stable under  cell  culture  conditions,  i.e.  cell  culture medium consisting of Advanced DMEM supplemented with 5% FCS at 37°C, if pre‐incubated at 37°C for 2 hours before usage in cell culture experiments. Dot blot analysis revealed that Nanog‐TAT exhibited a concentration of 100nM.  After  48  hours  in  vitro  only  around  50%  of  the  Nanog‐TAT  fusion  protein  could  be detected  via  immunoblot  compared  to  0  hours.  Co‐incubation  of  the  fusion  protein with  CV1 fibroblasts  for  24  hours  led  to  a  reduction  of  the Nanog‐TAT  signal  to  50%  as well  (Fig.  14). Therefore a change of medium was conducted every 24 hours in all experiments performed with the Nanog‐TAT fusion protein.  
 
Figure 14: Stability of Nanog-TAT under cell culture conditions is 24h 
Nanog-TAT was applied onto fibroblast cells. After indicated time points samples for immunoblot 
analysis were taken and analyzed applying α-Nanog antibody. After 24h the intensity of the Nanog 
band is diminished to approximately 50%. Immunoblot was performed with a gel exhibiting 10% 




Figure 15: SDS-PAGE analysis of ΔNanog-TAT subjected to an imidazole gradient  
(A) The expression of recombinant ΔNanog-TAT can be detected in the fraction of the crude lysate 
within the SDS-PAGE. Approximately 50% of the protein is found within the pellet fraction. Increasing 
concentrations of imidazole in the washing buffer enriches the fusion protein. Upon application of 
washing buffer containing 100mM (marked by *) of imidazole, ΔNanog-TAT shows least contamination 
bands. A relatively pure protein band indicating for ΔNanog-TAT can be detected in buffers containing 
concentrations of 110 to 240mM of imidazole. Black arrowhead shows the recombinant protein. (B) 
Induction of expression of recombinant ΔNanog-TAT can be detected in the CL fraction via 
immunoblot. A major part of ΔNanog-TAT is detected within the insoluble fraction as well as in the flow 
through. ΔNanog-TAT detection is visible throughout all fractions of the imidazole gradient. Black 
arrowhead shows the recombinant protein. Immunoblot was performed with a gel exhibiting a 
concentration of 10% (bis)acrylamide. M: marker; CL: crude lysate; P: pellet; SN: supernatant; FT: flow 




ΔNanog‐TAT  can  be  identified  through  the α‐Nanog  antibody  exhibiting  a molecular mass  of around  33.  The  calculated  molecular  weight  of  the  protein  is  30.2kDa.  The  expression  of 
ΔNanog‐TAT  can  be  strongly  detected  within  the  crude  lysate  (Fig.  15B  ‐  lane  2).  A  high proportion  of  about  50%  of  the  recombinant  protein  is  found  in  the  pellet  fraction,  i.e.  the insoluble part of the fusion protein (Fig. 15B ‐ lane 3). Obviously the fusion protein appears to be trapped in inclusion bodies. As the SDS‐PAGE does not reveal the loss of a substantial amount of 




Figure 16: Optimized purification protocol for ΔNanog-TAT analyzed by SDS-PAGE and 
immunoblot 
(A) A chronological loading of samples taken during the process of purification of ΔNanog-TAT under 
optimized conditions is shown in the SDS-PAGE. Washing with 100mM of imidazole yields a pure 
ΔNanog-TAT fusion protein that can be enriched in the eluate fraction (black arrowhead). (B) 
Immunoblot analysis applying α-Nanog antibody identifies ΔNanog-TAT and verifies the results 
obtained in SDS-PAGE analysis. SDS-PAGE and immunoblot were performed with a gel exhibiting 
15% (bis)acrylamide. M: marker; CL: cleared lysate; P: pellet; SN: supernatant; FT: flow through; W: 





Figure 17: Stability of ΔNanog-TAT under cell culture conditions is 24h 
ΔNanog-TAT was applied onto fibroblast cells. After indicated time points samples for immunoblot 
analysis were taken and analyzed applying α-Nanog antibody. After 24h the intensity of the Nanog 
band is diminished to 41% determined by densitometric analysis. Immunoblot was performed with a 
gel exhibiting 15% (bis)acrylamide.  Stability  of  ΔNanog‐TAT  was  assessed  via  immunoblotting  (Fig.  17).  After  incubation  of fibroblasts with ΔNanog‐TAT  for  1  hour  and  24  hours,  samples were  taken  and  compared  to medium stored at 4°C. After 1 hour at 37°C almost no protein is lost compared to medium stored at 4°C. 59% of the control protein is lost after incubation for 24 hours at 37°C on fibroblast cells (Fig.  17  ‐  right  lane).  Therefore  a  change  of  medium  was  conducted  every  24  hours  in  all experiments performed with the ΔNanog‐TAT fusion protein. Dot blot analysis revealed that the final concentration of ΔNanog‐TAT under cell culture conditions was approximately 50nM. The concentration  of ΔNanog‐TAT  could  not  be  further  increased  using  fewer  volumes  of  elution buffer,  since  there  appears  to  be  a  certain  threshold  of maximal  soluble  recombinant  control protein as observed for Nanog‐TAT. In  conclusion,  ΔNanog‐TAT  could  be  reproducibly  expressed  in  and  purified  from  E.coli  and could be brought to physiological conditions at a final concentration of 50nM. These established conditions represent a robust basis to perform experiments with ΔNanog‐TAT in cell culture.  
3.2 Functional validation of Nanog­TAT and ΔNanog­TAT 3.2.1 Recombinant Nanog‐TAT specifically binds to consensus sequence Since Nanog, being a transcription factor, can exert its main functionality only when capable of binding  to distinct DNA sequences  the  recombinant Nanog‐TAT as well  as  the  control protein 





Figure 18: EMSA reveals binding of Nanog-TAT to consensus sequence 
Nanog-TAT was subjected to an EMSA employing a specific Nanog consensus sequence. A shift of 
the protein-DNA complex is observed. The shift can be prevented by the addition of excess unlabeled 
DNA (competitor). No shift is observed in case of the control protein ΔNanog-TAT. The binding reaction 
containing 100ng of recombinant protein respectively was subjected to a native PAGE exhibiting 5% 
(bis)acrylamide. After the gel run was completed the protein-DNA complexes were transferred onto a 
corresponding membrane and the shift was detected using streptavidin-HRP conjugates.  A  clear  shift  could  be  observed  in  lane  2  of  the  blot,  indicating  recognition  and  consequently binding of Nanog‐TAT to the corresponding consensus sequence (Fig. 18). The specificity of the protein‐DNA binding was verified by  the addition of  excess unlabeled DNA seen  in  lane 3. No shift was observed when Nanog‐TAT was omitted  from the binding reaction as seen  in  lane 1, which served as a control. Free DNA probe is accumulated at the bottom of the blot in all three lanes.  In  contrast,  the  control  protein ΔNanog‐TAT was  not  capable  of  binding  to  the  Nanog consensus sequence (Fig.18 ‐ lane 4). No shift was visible if the control protein or an excess of unlabeled DNA was present in the binding reaction as seen in lane 5 (Fig. 18). Free DNA probe could be detected at the very bottom of the blot. 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3.2.2 Nanog‐TAT as well as ΔNanog‐TAT is able to translocate into mammalian cells After demonstrating that recombinant Nanog‐TAT is able to specifically bind to DNA in vitro, the ability to translocate into cultured cells was explored. The cell membrane poses a natural barrier for molecules trying to enter the cell. Through the addition of the protein transduction domain TAT  to  both  fusion  proteins  the  ability  to  cross  this  frontier,  i.e.  to  translocate  into  the  cell, should  be  conferred.  To  investigate  the  ability  of  Nanog‐TAT  as  well  as  ΔNanog‐TAT  to accomplish  TAT‐mediated  trans‐membrane  transport  into  mammalian  cells,  the  two  fusion proteins were applied onto CV1 fibroblast cells. After 5 hours cells were washed with heparin, fixed  with  4%  PFA  and  analyzed  by  ICC  employing  α‐Nanog  antibody,  which  represents  a standard  protocol  for  the  evaluation  of  cellular  uptake  (Kaplan  et  al.,  2005).  Washing  with heparin ensures the stripping of recombinant fusion protein from the cellular surface.  
 
Figure 19: Assessing cellular translocation of Nanog fusion proteins into mammalian cells 
(A and B) 100nM of Nanog-TAT as well as 50nM of ΔNanog-TAT were subjected onto fibroblast cells 
(CV1) for 5h. Cells were then washed using heparin and fixed. Immunocytochemistry employing an 
α-Nanog antibody revealed translocation of both fusion proteins into CV1 cells. A high-resolution 
picture of a single cell cultivated with Nanog-TAT (A*) and ΔNanog-TAT (B*) for 5h is shown. Nuclei 
were counterstained with DAPI. Scale bar 25µm. (C) A quantification of CV1 cells staining positive for 
Nanog is depicted. Nanog-TAT can be detected in >95% of all cells analyzed, whereas cells cultivated 
with ΔNanog-TAT exhibited 80% positive cells. (D) Like for Nanog-TAT (Peitz, 2007), within nuclear 
extracts of CV1 cells cultivated with ΔNanog-TAT, the recombinant control protein was detectable via 
immunoblot, whereas nuclear extracts of control cells did not show any signal. Immunoblot was 
performed with a gel exhibiting 10% (bis)acrylamide; c: control.  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After 5 hours of cultivation with 100nM of Nanog‐TAT over 95% of the cells stained vastly for cytoplasmatic  vesicles  enriched  for Nanog  (Fig.  19A,  C)  and  the  recombinant  protein  strongly accumulated in a perinuclear pattern, which can be seen in detail at a higher magnification of a single  transduced  cell  (Fig.  19A*).  In  contrast,  after  5  hours  of  cultivation  with  50nM  of 
ΔNanog‐TAT  only  80%  (Fig.  19B,  C)  of  CV1  cells  stained  positive  for  Nanog,  basically  in  the cytoplasm  though.  Only  a  minority  of  the  fibroblast  cells  already  displayed  a  staining  in  a perinuclear pattern. The process of TAT‐mediated trans‐membrane trafficking for ΔNanog‐TAT seems  to  be  decelerated,  when  compared  to  cells  tranduced with  Nanog‐TAT.  Eventually  the lower concentration of 50nM of ΔNanog‐TAT compared to 100nM of Nanog‐TAT might be causal for the observation above, although Nanog‐TAT exhibits similar or even more articulate effects when  applied  at  50nM  or  100nM  in  a  foci  formation  assay  on  NIH  3T3  cells  (Winnemöller, 2007). For a more detailed view of a single cell cultivated with ΔNanog‐TAT for 5 hours, see Fig. 19B*. Additionally, ΔNanog‐TAT is detectable by immunoblot applying α‐Nanog antibody within nuclear  extracts  of  CV1  cells  cultivated  for  2  days with  50nM of  recombinant  control  protein (Fig.19  D).  Just  as  ΔNanog‐TAT,  Nanog‐TAT  is  detectable  within  nuclear  extracts  of  CV1 fibroblast cells (Peitz, 2007), suggesting transport of both recombinant fusion proteins into the nucleus of mammalian cells. Taken together, these results lead to the assumption that both fusion proteins were able to cross the cellular membrane. The washing step performed with heparin excludes the possibility that extracellular recombinant protein was detected in ICC analysis.  3.2.3 Direct delivery of Nanog‐TAT specifically circumvents LIF dependence of murine ES cells Initial studies in our workgroup showed that Nanog‐TAT is able to liberate murine ES cells from LIF dependence, a feature known from murine ES cells overexpressing Nanog (Chambers et al., 2003). Nanog‐TAT is able to sustain ‘undifferentiated’, AP‐positive ES cells in the absence of LIF, the addition of  the peptide TAT‐HA2 was required though. TAT‐HA2  is known to promote  the process  of  protein  transduction,  but  unexpectedly  the  addition  of  TAT‐HA2  also  led  to precipitation of Nanog‐TAT. In the absence of TAT‐HA2, Nanog‐TAT is able to maintain mixed ES cell colonies over 3 days (Fig. 20A; black arrowhead). A pluripotent population arises as judged by activity of the Oct3/4 promoter region driving GFP expression upon cultivation of Oct3/4 GiP ES cells in the absence of LIF and in the presence of 100nM of Nanog‐TAT (Peitz, 2007). In order to assess the morphological effect of Nanog‐TAT on murine ES cells, cells were fixed and ES cell colonies  were  classified  into  three  categories.  The  first  category,  termed  ‘undifferentiated’, encompassed compact colonies with sharp edges strongly staining for AP. The second category 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comprised  colonies,  which  already  lost  the  sharp  edges  and  stained  partially  for  AP.  This category  was  named  ‘mixed’.  The  third  category  was  named  ‘differentiated’  and  contains colonies, which already lost the compact, three‐dimensional structure and did not stain for AP. 
 
Figure 20: Nanog-TAT sustains pluripotency in ES cells in the absence of LIF 
(A) 100nM of Nanog-TAT was subjected onto C57BL/6 ES cells for 3 days either in the absence or 
presence of cytokine LIF. Experiments performed in the absence of LIF additionally contained LIF 
inhibitor (Vernallis et al., 1997) to completely exclude LIF signaling. Namely, LIF activity is expected to 
occur upon spontaneous differentiation in a paracrine manner. Over a 3-day period cells cultivated 
without LIF and in the presence of Nanog-TAT start to differentiate but still show mixed colonies (black 
arrowhead). ES cells cultivated with control medium differentiate. Scale bar: 50µm (B). After 3 days, 
ES cells were fixed and stained for alkaline phosphatase. In the presence of LIF and 100nM of 
Nanog-TAT only undifferentiated ES colonies are present, whereas ES cells cultivated in the absence 
of LIF and the presence of 100nM of Nanog-TAT contain mixed colonies. Scale bar: 100µm. (C) After 3 
passages, Oct3/4 GiP ES cells cultivated in the absence of LIF and in the presence of 100nM of 
Nanog-TAT still exhibit mixed colonies. (D) A quantification of the morphological effect of Nanog-TAT 
on C57BL/6 ES cells cultivated for 5 days in different concentrations of Nanog-TAT in the presence or 
absence of LIF is shown. For classification see text. LIF: leukemia inhibitory factor, LI: LIF inhibitor, 
AP: alkaline phosphatase (in collaboration with M. Peitz, unpublished data)  In  the  presence  of  LIF  the  amount  of  undifferentiated ES  cell  colonies  increases  from 60%  to over  95%.  In  the  absence  of  LIF,  differentiation  of  ES  cells  is  inhibited.  In  the  presence  of Nanog‐TAT,  25%  of  mixed  colonies  are  still  observed,  whereas  the  complete  absence  of Nanog‐TAT  leads  to  full  differentiation  (Fig.  20D).  In  order  to  investigate  whether  the  effect observed  on  C57BL/6  ES  cells  is  also  apparent  on  Oct3/4  GiP  ES  cells,  cells  were  cultivated either in the presence or absence of the cytokine LIF together with 100nM of Nanog‐TAT. After 3 passages in the absence of LIF, ES like colonies are still present (Fig. 20C). 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Figure 21: ΔNanog-TAT is not able to sustain pluripotency in ES cells in the absence of LIF 
(A) 50nM of ΔNanog-TAT was subjected onto Oct3/4 GiP ES cells for 1 to 3 days either in the absence 
or presence of cytokine LIF. Experiments performed in the absence of LIF additionally contained LIF 
inhibitor (Vernallis et al., 1997) to completely exclude LIF signaling, as LIF activity is expected to occur 
upon spontaneous differentiation in a paracrine manner. Over a 3-day period cells cultivated without 
LIF start to differentiate just like cells cultivated with control ES cell medium (B). In the presence of LIF 
no visible difference between cells treated with ΔNanog-TAT or control ES cell medium is apparent. 
Magnification 5x. d: day, LIF: leukemia inhibitory factor, LI: LIF inhibitor  Murine  ES  cells  cultivated  with  ΔNanog‐TAT  in  the  absence  of  the  cytokine  LIF  start  to differentiate  over  the  time  course  of  3  days  (Fig.  21A,  upper  row).  ES  cell  colonies  lose  the three‐dimensional structure as well as the distinct edges otherwise shining brightly. In contrast, ES  cells  cultivated  for  3  days  with  ΔNanog‐TAT  and  LIF  form  compact,  three‐dimensional colonies with bright  edges  (Fig.  21A,  lower  row). ES  cells  cultivated  in  control medium  in  the absence of LIF differentiate, i.e. they lose the three‐dimensional, pluripotent phenotype resulting in  cells  growing  as  a monolayer  first,  before  they  finally  differentiate.  These  cells  also  do  not exhibit  bright  edges  (Fig.  21B,  upper  row). Murine  ES  cells  cultivated with  LIF,  instead  show 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densely  packed,  three‐dimensional  colonies  exhibiting  brightly  shining  edges.  The  colonies appear to be slightly bigger then the ES cells cultivated with ΔNanog‐TAT and LIF.  3.2.5 ES cells cultivated with ΔNanog‐TAT show similar expression of alkaline phosphatase as control ES cells In order to analyze for the capability of sustaining pluripotency, the amount of ‘undifferentiated’ ES cell colonies of each condition was determined by staining for AP after 3 days of cultivation. Elevated  expression  of  this  enzyme  is  associated with  undifferentiated  pluripotent  stem  cells. Colonies were classified into the 3 different categories described in chapter 3.2.3.  
 
Figure 22: ΔNanog-TAT treated ES cells show similar AP expression pattern compared to cells 
treated with control medium 
(A) Murine Oct3/4 GiP ES cells were cultivated with either ΔNanog-TAT or control medium for 3 days 
in the absence or presence of the cytokine LIF. Cells were then fixed and stained for Alkaline 
Phosphatase (AP), a marker associated with pluripotency. Cells cultivated in the absence of LIF 
differentiated almost completely, whereas cells cultivated in the presence of LIF remained 
undifferentiated. (B) A quantification of the AP staining is depicted. 3 types of colonies are 
distinguished. For classification see text. Magnification in A: 5x  After  3  days,  ES  cells  cultivated with ΔNanog‐TAT  in  the  absence  of  LIF  did  not  contain  any ‘undifferentiated’  colonies.  22% of  the  colonies  displayed  a  ‘mixed’  phenotype;  the  remaining 78% of the colonies were  ‘differentiated’ (Fig. 22A, upper  left and Fig. 22B). Cells treated with 
ΔNanog‐TAT  and  LIF  contained  76%  of  ‘undifferentiated’  colonies.  22%  of  the  colonies  are ‘mixed’  and  2%  of  all  colonies  are  ‘differentiated’  (Fig.  22A,  lower  left  and  Fig.  22B).  ES  cells 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Figure 23: RT-PCR analysis of Nanog-TAT-treated MEFs 
MEFs were synchronized and afterwards cultivated with control medium, ΔNanog-TAT and Nanog-TAT 
respectively. After 5h, 8h and 21h the fibroblasts were harvested and the expression levels of different 
key molecules involved in proliferation as well as cell cycle regulation were assessed via RT-PCR. 
After 5h 8h and 21h no striking change in transcription levels is apparent for p53, p21CIP/WAF, p16INK4a 
and FGF-receptor 1. GAPDH serves as loading control. FGF-R: FGF receptor 1; GAPDH: 




Figure 24: Cell cycle analysis of Nanog-TAT-treated MEFs via immunoblot 
The expression levels of different key molecules involved in the cell cycle control were assessed. 
MEFs were synchronized and treated with Nanog-TAT-supplemented medium. After 1h, 5h and 
24h the fibroblasts were harvested and subjected to immunoblot analysis with the corresponding 
antibodies. Fibroblasts treated with Nanog-TAT show no striking differences in expression of p53, 
Cyclin D1 or p21CIP/WAF compared to MEFs treated with control medium or to cells at 0h. Actin 
serves as a loading control. SDS-PAGE and immunoblot were performed with a gel exhibiting 10 





Figure 25: Nanog-TAT delivery results in decreased RNA expression levels of p27KIP1 
(A) MEFs were synchronized and afterwards cultivated in the presence of control medium, 
ΔNanog-TAT and Nanog-TAT. After indicated time points RNA expression levels were analyzed via 
RT-PCR. GAPDH served as a loading control. A slight down-regulation of p27KIP1 is already observed 
after 5h. (B) Treatment with Nanog-TAT leads to a distinct down-regulation of p27KIP1after 8h and 21h. 
Expression of p27KIP1 was quantified densitometrically. Results are normalized to GAPDH. Expression 
levels of p27KIP1 are down-regulated to 69% after 8h of Nanog-TAT treatment compared to untreated 
fibroblasts. (C) After 21h the expression decreases to 27% in cells cultivated with Nanog-TAT. GAPDH: 
Glyceraldehyde 3-phosphate dehydrogenase  After 5 hours of Nanog‐TAT treatment the expression of p27KIP1 was reduced to 91% compared to  fibroblasts  cultivated  in  control  medium.  The  incubation  with ΔNanog‐TAT  led  to  a  slight reduction of p27KIP1 as well. The expression was down‐regulated to 89% (Fig. 25A). 8 hours of application of Nanog‐TAT  resulted  in  a diminished  expression of  p27KIP1  to 69% compared  to fibroblasts  incubated  with  control  medium,  whereas  cells  treated  with  ΔNanog‐TAT  only showed  a  decrease  of  p27KIP1  expression  to  87%  (Fig.25B).  After  21  hours  of  cultivation  of fibroblasts  with  Nanog‐TAT  the  expression  of  p27KIP1was  vastly  down‐regulated  to  27% compared  to  cells  incubated  with  control  medium.  The  expression  of  p27KIP1  in  fibroblasts treated  with  ΔNanog‐TAT  was  decreased  to  88%  compared  to  MEFs  cultivated  in  control medium (Fig. 25C). In order to verify the results obtained by RT‐PCR, changes of p27KIP1 protein expression levels were  analyzed  by  immunoblot.  Fibroblast  cells were  cultivated  for  distinct  time  points  in  the 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presence  of  control  medium  or  Nanog‐TAT.  Cells  were  then  harvested  and  subsequently subjected to SDS‐PAGE followed by immunoblot using an antibody directed against p27KIP1 (Fig. 26).  
 
Figure 26: Expression of p27KIP1 decreases upon Nanog-TAT treatment 
(A) MEFs were synchronized and incubated with control medium and Nanog-TAT. After indicated time 
points, MEFs were harvested and subjected to immunoblot analysis. A representative immunoblot is 
shown. Actin serves as a loading control. (B) Densitometric analysis of p27KIP1 expression levels is 
presented. Quantification is normalized to Actin. Upon treatment with Nanog-TAT, p27KIP1 expression is 
down-regulated after 5h as well as after 24h. n=3. SDS-PAGE and immunoblot were performed with a 
gel exhibiting 15% (bis)acrylamide.  Cultivation of MEFs with Nanog‐TAT resulted in a clear reduction of p27KIP1 expression after 5 hours  and  24  hours  (Fig.  26A).  Results  from  3  independent  experiments  were  used  for densitometric  quantification.  After  5  hours  of  Nanog‐TAT  treatment,  protein  expression  of p27KIP1 diminished  to 56%. 24 hours of  incubation with Nanog‐TAT  further decreased protein expression levels of p27KIP1 to 43% (Fig. 26B). To test for the specificity of this effect, cells incubated with ΔNanog‐TAT were analyzed as well. The  expression  of  p27KIP1  is  reliably  down‐regulated  upon  cultivation  of  fibroblast  cells  with Nanog‐TAT  after  5,  8  and  21  hours  (Fig.27  A).  After  5  hours  of  Nanog‐TAT  treatment  the expression of  p27KIP1 was decreased  to 45%,  after 8 hours p27KIP1  expression was  reduced  to 71% and  after  21  hours  of Nanog‐TAT  cultivation  p27KIP1  expression was  diminished  to  64% (Fig.  27B).  No  down‐regulation  of  p27KIP1  was  observed  upon  ΔNanog‐TAT  treatment independent of the time point analyzed (Fig. 27A). The densitometric analysis even indicates a 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slightly  higher  protein  expression  level  of  p27KIP1  in  MEFs  treated  with  control  protein compared to fibroblasts cultivated with control medium (Fig. 27B). 
 
 
Figure 27: Cultivation of MEFs with ∆Nanog-TAT does not induce a down-regulation of p27KIP1 
(A) MEFs were synchronized and incubated with control medium, control protein as well as 
Nanog-TAT for indicated periods of time. Upon cultivation of MEFs with Nanog-TAT, p27KIP1 expression 
is down-regulated after 5h, 8h and 21h. Cultivation of MEFs with ∆Nanog-TAT does not change protein 
expression levels of p27KIP1 compared to cells treated with control medium (B). The immunoblot was 
quantified densitometrically and quantification of p27KIP1expression is depicted. After 5h of Nanog-TAT 
treatment the expression of p27KIP1 is decreased to 45%, after 8h p27KIP1 expression is reduced to 
71% and after 21h of Nanog-TAT cultivation p27KIP1 expression is diminished to 64%. SDS-PAGE and 





Figure 28: Nanog-TAT enhances expression levels as well as phosphorylation of 
Retinoblastoma protein 
(A) After 8h of cultivation with Nanog-TAT, MEFs exhibit an increase in pRb expression as well as 
enhanced phosphorylation of pRb compared to MEFs cultivated with control medium. A similar 
observation was made after 24h of Nanog-TAT treatment. A representative immunoblot is shown. (B) 
Densitometric quantification of pRb signals observed in immunoblot analysis is presented. Results are 
normalized to α-tubulin. SDS-PAGE and immunoblot were performed with a gel exhibiting 7.5% 
(bis)acrylamide.  Upon  treatment  with  Nanog‐TAT,  MEFs  exhibit  a  higher  protein  level  of  pRb,  both  the unphosphorylated  as  well  as  the  phosphorylated  variant,  compared  to  cells  cultivated  with control  medium  after  8  hours  (Fig.  28A).  Densitometric  analysis  reveals  an  increase  in  fold change of total pRb expression by the factor of 1.87 (Fig. 28B). After 24 hours cells treated with recombinant  Nanog  fusion  protein  still  exhibit  a  higher  protein  expression  level  of unphosphorylated  and  phosphorylated  pRb  (Fig.  28A).  Quantification  of  the  immunoblot indicates an elevated expression level by the factor 1.35 (Fig. 28B). 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3.2.10 Analysis of Nanog function in human somatic cells Although the homology between murine Nanog and human Nanog on basis of aa  is only about 55%  (Hart  et  al.,  2004),  Nanog‐TAT  exhibited  functionality  on  human  ES  cells  by  inhibiting differentiation thereof (Peitz, 2007). Hence, the question whether or not delivery of Nanog‐TAT would also exhibit an effect on human somatic cells was addressed.  3.2.11 Nanog protein transduction enhances proliferation of human somatic cells MP‐AF cells, (primary human dermal fibroblasts) were cultivated with Nanog‐TAT over several passages to analyze the effect of Nanog in human somatic cells. After each passage, cell numbers were determined in order to assess the proliferation rate. To determine a potential juvenescent effect of Nanog‐TAT, fibroblasts cultivated with the transducible stemness factor were analyzed for the expression of senescence‐associated (SA) β‐Galactosidase.  
 
Figure 29: Nanog-TAT promotes proliferation of human dermal fibroblasts 
(A) Human dermal fibroblasts (MP-AF) were cultivated in the presence or absence of Nanog-TAT. After 
each passage cells were counted. A representative proliferation analysis via growth curve is depicted. 
Cumulative cell numbers are shown. (B) Pictures of fibroblast cells cultivated with control medium or 
Nanog-TAT are shown. (C) Cells cultivated with control medium exhibit SA β-Glactosidase activity 
whereas fibroblasts cultivated with Nanog-TAT do not stain for SA β-Galactosidase. Magnification for 
B: 5x; Magnification for C: 20x; BF: bright field; SA: senescence-associated. 
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Nanog protein transduction into human dermal fibroblasts resulted in an increased proliferation rate, which mirrors  the effect observed  in MEFs. From a starting cell number of 250.000 cells, Nanog‐TAT  treated  fibroblasts  exhibit  a  final  cumulative  cell  number  of  8x1011  after  10 passages.  In contrast 250.000 MP‐AF  fibroblast cells cultivated with control medium only give rise  to  1.5x109  after  10  passages  (Fig.  29A).  Representative  pictures  after  14  days  of  both experimental conditions are shown in Fig. 29B. Nanog‐TAT‐treated cells grow densely packed. Additionally, fibroblast cells cultivated with Nanog‐TAT undergo a change in morphology. They adopt  an  even  more  spindle‐like  shape  and  the  ratio  of  cytoplasm  to  nucleus  declines.  The observation  of  enhanced  proliferation  might  indicate  that  Nanog  eventually  suppresses senescence.  In order  to assess  senescence  in Nanog‐TAT‐treated cells  a  senescence‐associated 




Figure 30: Selection of genes modulated in MP-AF fibroblasts upon Nanog-TAT cultivation 
Human somatic fibroblast cells were treated with or without Nanog-TAT. RNA was then isolated and 
microarray analysis was performed. A selection of gene expression modulated upon Nanog-TAT 
cultivation is depicted. Red bars indicate up-regulation, blue bars show down-regulation. 
 Among the genes up‐regulated in fibroblast cells cultivated with Nanog were PI16, the peptidase inhibitor  16  (fold  change  31.2),  COMP,  the  cartilage  oligomeric  matrix  protein  (fold  change 28.5),  ACTC1,  an  abbreviated  gene  symbol  for  actin  alpha  cardiac muscle  (fold  change  22.1), HSPB7, the heat shock 27kDa protein family, member 7 (fold change 16.4) and MGP, the matrix gla protein (fold change 14.5), as well as ID1, the inhibitor of differentiation (Fig. 30). Moreover, CCDN1  expression,  which  represents  the  abbreviated  gene  symbol  for  Cyclin  D1  was up‐regulated. The fold change for ID1 was 3.8 and was enhanced for Cyclin D1 by the factor 2.7 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compared  to  untreated  cells.  Besides  that,  collagen  alpha‐1  (IV)  chain  (COL4A1)  and metalloproteinase inhibitor 3 (TIMP3) were up‐regulated additionally by the factor 7.0 and 3.6 respectively (Fig. 30). Genes that became down‐regulated upon Nanog‐TAT treatment of dermal fibroblasts are listed in Figure 30 as well. IL8, interleukin‐8 was down‐regulated (fold change 68.8 and 30.2) in cells cultivated with Nanog‐TAT as well as CXCL6, the chemokine (C‐X‐C motif) ligand 6 (fold change 52.1  and  32.4)  and  CCL2,  which  represents  the  chemokine  (C‐C motif)  ligand  2  (fold  change 20.0).  Moreover  IL6,  interleukin‐6,  was  down‐regulated  (fold  change  12.5)  upon  Nanog‐TAT treatment in dermal fibroblasts as well as the mitochondrial superoxide dismutase 2 (SOD2) and MMP9,  the  matrix  metallopeptidase  9.  Moreover,  retinoic  acid  receptor  responder  protein  2 (RARRES2)  and  the  chemokine  (C‐X‐C motif)  ligand 5  (CXCL5)  as well  as  IL35,  interleukin‐35 were  down‐regulated  upon  Nanog‐TAT  treatment.  Furthermore,  Podoplanin  (PDPN), Metallothionein‐1G (MT1G) and Stromelysin‐1 (MMP3) were down‐regulated.  
3.3 The influence of Nanog on the process of reprogramming As cellular  reprogramming cannot only be achieved  through  the  classical  factors Oct3/4, Klf4, Sox2  and  c‐myc  (OKSM)  identified  by  Takahashi  and  Yamanaka  (Takahashi  and  Yamanaka, 2006), but with a combination of Oct3/4, Sox2, Nanog and Lin‐28 as well, the share of Nanog on the process of  reprogramming  is of great  interest;  especially as a  role  is assigned  to Nanog  in governing  the  gateway  to  a  ground  state  of  pluripotency  (Chambers  et  al.,  2007)  ‐  a  function most  likely pivotal  in  the process of  reprogramming. There  are  few publications, which  reach out to analyze the function of Nanog in the act of cellular reprogramming; a clear understanding is  still  missing  though.  Therefore  the  influence  of  Nanog  on  the  process  of  cellular reprogramming was addressed using Nanog‐TAT fusion protein. To assess whether the influence of Nanog‐TAT on the proliferation of somatic cells could have a promoting  effect  on  the  reprogramming  efficiency,  MEFs  retrovirally  transduced  with  OKSM, were  incubated  with  Nanog‐TAT  either  before  retroviral  transduction  or  for  5  days  post 
infection.  No  significant  increase  in  reprogramming  efficiency  was  observed  judged  by  the number  of  evolving  iPS  cell  colonies  (data  not  shown). Moreover,  an  enduring  application  of Nanog‐TAT  to  MEFs  virally  transduced  with  OKSM  did  not  provoke  an  enhancing  effect  on reprogramming efficiency. This finding was strengthened by observations made in MEFs virally transduced with OKSM plus an additional retroviral vector carrying the genetic information for murine Nanog (Marc Thier, personal communication), which basically resulted in an enhanced transformation rate of the cells to be reprogrammed. With the Nanog‐TAT fusion protein at hand it was  feasible  to apply Nanog  in a  time‐dependent manner without  limitations posed by viral 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Figure 31: Application of Nanog-TAT at day 10 enhances reprogramming  
(A) The experimental setup used is depicted. MEFs were virally transduced with OKSM and 100nM of 
Nanog-TAT was applied after 6, 8 and 10 days post infection until the end of the experiment. At day 15 
cells were fixed and analyzed. (B) Typical examples of morphology used to classify iPS cells are 
shown. For details on the classification see text. The pictures originate from an experiment involving 
Nanog-TAT applied from day 10 onwards. (C) The fold change in efficiency of generating iPS cells was 
assessed. A fold change in efficiency of generating iPS cells by the factor of 1.7 was achieved upon 
Nanog-TAT application from day 10 onwards compared to the corresponding control condition from 
day 10. The quantification is based on 3 independent experiments. PC: phase contrast; GFP: green 
fluorescent protein. Scale bar: 100µm  Under all temporal conditions the amount of GFP‐positive iPS cells was higher when Nanog‐TAT was  present  in  the  cell  culture  medium.  In  the  experimental  setup  where  Nanog‐TAT  was applied from day 6 onwards, only very few iPS cell colonies could be observed. In contrast no iPS cell  colonies  fulfilling  both  criteria  are  visible  in  the  control  experiment  at  day  6.  When 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Nanog‐TAT  is  applied  from  day  8  to  day  15,  the  rate  of  iPS  cells  is  still  low,  although more colonies form compared to the experimental setting where Nanog is applied at day 6. Again, the control experiment from day 8 does not harbor any iPS colonies exhibiting high GFP expression as well  as  colony‐like morphology  (see Table  5).  A  fold  change  in  efficiency  of  generating  iPS cells  by  the  factor  of  1.7  was  achieved  when  Nanog‐TAT  was  applied  from  day  10  onwards compared to the control condition from day 10. 
Table 5: Amount of colonies fulfilling the different criteria mentioned above observed in a 




Figure 32: Nanog-TAT increases reprogramming efficiency by the factor of 3 
(A) The experimental setup used is depicted. (B) [a to d] shows iPS colonies derived from a control 
experiment with OKSM retrovirally transduced MEFs. Colonies show ES-like morphology but exhibit 
low GFP expression. In contrast, retrovirally OKSM transduced MEFs cultivated with Nanog-TAT from 
day 10 onwards give rise to iPS colonies exhibiting ES-like morphology and high GFP expression 
levels as seen in [e to h]. Pictures taken from red channel indicate background fluorescence. Those 
GFP-positive cells [i & l] also stain positive for SSEA-1 as seen in [j] as well as for AP seen in [k]. Fold 
change in efficiency of generating iPS colonies is depicted [m]. 3 independent experiments were used 
for quantification. PC: phase contrast; GFP: green fluorescent protein; SSEA-1: stage-specific 






Figure 33: Validation of Nanog-TAT derived iPS 
(A) iPS cells generated in the presence of Nanog-TAT were analyzed for silencing of transgenes as 
well as for re-activation of endogenous pluripotency markers using RT-PCR. N8: Nanog-iPS clone 8; 
N9: Nanog-iPS clone 9; tg: transgene; endo: endogenous. (B) Stable clone generated in the presence 
of Nanog-TAT exhibits high GFP expression after prolonged cultivation. One representative clone of 
passage 18 is shown. Scale bar: 200µm (C) Clones established employing Nanog-TAT are able to 
give rise to all three germlayers upon EB-based differentiation. Stainings for smooth muscle actin 









corresponding control protein ΔNanog­TAT A part of  this work  covers  the establishment of  a purification protocol  for Nanog‐TAT and  its corresponding  control  protein  ΔNanog‐TAT  as  well  as  the  assessment  of  the  biochemical properties of both recombinant proteins. Poor solubility of recombinant Nanog‐TAT fusion protein and formation of inclusion bodies are the  major  impediments  for  the  application  of  Nanog  protein  transduction.  The  denaturing purification of Nanog‐TAT, aiming at overcoming the poor solubility, was successful concerning the  purity  and  the  stability  of  the  recombinant  fusion  protein  under  physiological  conditions. However,  the  only  conditions  allowing  successful  refolding  of  Nanog‐TAT  contained Triton‐X100. After dialysis against PBS the recombinant protein could be applied in cell culture. Fibroblast  cells  cultivated  with  Nanog‐TAT  purified  under  denaturing  conditions  underwent apoptosis  though.  Most  likely  the  Triton‐X100  molecules  attached  to  the  recombinant Nanog‐TAT protein  permeabilized  the membrane  of  the  target  cells, which would  explain  the cell  death  observed.  Detergent  removal  can  usually  be  obtained  by  three  different  methods: dialysis, gel  filtration and binding to hydrophobic gels. Triton‐X100 exhibits a very low critical micelle  concentration  (cmc),  also  indicating a  strong binding of  the detergent  to proteins.  For these reasons the first two methods mentioned therefore will not be feasible and in the case of dialysis the results obtained in this work strengthen these thoughts. A potential way to remove traces  of  Triton‐X100  molecules  would  be  the  use  of  hydrophobic  gels.  After  laborious preparation of the corresponding material, the detergent could eventually be removed by mixing the  gel  material  with  the  recombinant  protein.  As  a  way  to  circumvent  this  challenging procedure, one could also try to use detergents with a higher cmc, such as octyl‐β‐glucoside. Of course cell viability assays with this substance should be performed beforehand to ensure that even the slightest amount of this detergent would not harm the target cells.  Through  the  application  of  an  imidazole  gradient  an  optimized purification procedure  for  the full‐length protein could be established. In a first attempt Nanog‐TAT was purified natively using high concentrations of imidazole resulting in a pure recombinant protein. This purified protein was  not  stable  under  cell  culture  conditions  though,  leading  to  the  assumption  that contaminations originating from E.coli are needed to stabilize Nanog‐TAT. The identification of these contaminations via tryptic digestion followed by MALDI‐TOF could be of great interest as these stabilizing peptides could be used for other hardly soluble recombinant proteins as well. Additionally  one  could  make  use  of  stabilizing  peptides,  which  have  been  shown  to  confer enhanced solubility to fusion partners. Examples for these stabilizing peptides are the Protein A 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IgG ZZ repeat domain (Zhao et al., 2005) or the Protein G B1 domain (Bao et al., 2006) as well as the synthetic solubility enhancing tag (Zhang et al., 2004). Lowering the imidazole concentration during the purification process of Nanog‐TAT resulted in a  minor  increase  in  contaminating  bacterial  proteins,  i.e.  the  potentially  stabilizing  proteins, within the eluate fraction but at the same time allowed for keeping Nanog‐TAT in a soluble state even  under  physiological  conditions  at  a  concentration  of  100nM  at  37°C.  Similar  as  well  as lower concentrations of  transducible proteins were shown to be sufficient to  induce biological effects (Asoh et al., 2002; Krosl et al., 2003; Nagahara et al., 1998). In  addition  to  the  purification  protocol  for  the  full‐length  protein,  optimized  purification conditions for ΔNanog‐TAT were established. In principle the design of the control protein was based on  the  full‐length Nanog‐TAT protein,  i.e.  a NLS at  the N‐terminal part was  included as well  as  a  TAT  domain  and  a  Histidin  tag  at  the  C‐terminal  domain  of  the  control  protein.  In contrast to Nanog‐TAT, the purity of  the control protein was higher  in the eluate fraction; still the fusion protein was stable under cell culture conditions for at least 24h. This observation may indicate  that  the omission of  the homeodomain  conferred enhanced  solubility  to ΔNanog‐TAT without  the  need  of  exogenous,  potentially  stabilizing  proteins  derived  from  E.coli.  This phenomenon could be explained on  the one hand by  the  fact  that within  the homeodomain of murine  Nanog  two  AGG  codons,  very  rarely  occurring  in  E.coli  (Chen  and  Inouye,  1994)  are present.  On  the  other  hand  two  codons  encoding  for  cysteines  are  found  within  the homeodomain as well, that likely play a role in disulfide bond formation, a process being difficult to accomplish in the E.coli environment though, unless a mutation in the thioredoxin reductase is occurring (Derman et al., 1993). The lack of the above‐mentioned codons could have led to an i) enhanced expression as well as an  ii) enhanced solubility of  the control protein even  in  the absence  of  stabilizing  bacterial  proteins.  Although  the  concentration  of  ΔNanog‐TAT  did  not exceed  50nM,  this  and  even  lower  concentrations  of  transducible  proteins were  shown  to  be sufficient to trigger biological effects (Asoh et al., 2002; Krosl et al., 2003; Nagahara et al., 1998). Based  on  the  expression  and  purification  optimization  worked  out  in  this  study  1  liter  of bacterial  expression  culture  of  Nanog‐TAT  finally  results  in  5mL  of  cell  culture  medium. Especially  in  the  case  of  reprogramming  experiments,  it  would  be  desirable  to  have  a  more efficient expression system at hand. In order to obtain more soluble Nanog‐TAT protein, several options  are  considerable.  Obviously,  expression  cultures  using  fermenters  would  lead  to  a higher  yield  of  biomass  due  to  the  circumstance  that  a  higher  optical  density  within  the expression  culture  could  be  achieved.  This  would  only  circumvent  the  causative  problem though. An approach to solve the causal reason for the poor amount of soluble Nanog‐TAT could be  i)  the  use  of  a  genetic  sequence  optimized  for  codon  usage  in  E.coli  or  the  ii)  use  of  a biochemically modified protein. 
Discussion 
97 
In  a  first  attempt,  a  variant  of  Nanog‐TAT  codon‐optimized  for  the  expression  in  E.coli  was investigated.  Employing  an  imidazole  gradient,  the  optimal  purification  conditions  were assessed. The codon‐optimized variant of Nanog could be expressed in and purified from E.coli. In contrast to Nanog‐TAT, a major part of the recombinant protein was found within the soluble fraction and although a part is lost in the flow‐through and washing fractions, still a considerable amount of codon‐optimized Nanog can be detected within the eluate fraction by SDS‐PAGE and immunoblot.  The  fact  that  more  Nanog  is  present  within  the  soluble  fraction  may  be  well explained by the optimized codon‐usage being beneficial for E.coli regarding the proper folding of the recombinant protein. It has to be further analyzed whether this enhanced fusion protein remains stable under cell culture conditions as this represents the most crucial point during the purification  process.  Via  immuno  dot  blot  assay  the  concentration  of  the  codon‐optimized construct could be compared to Nanog‐TAT in order to investigate whether or not more codon‐optimized, soluble recombinant protein  is present. Consequently the biological  functionality of the newly generated fusion protein should be analyzed. It was shown that VP16, a transactivation domain derived from herpes simplex virus, (Sadowski et al., 1988; Triezenberg et al., 1988) fused to the N‐terminal part of Nanog was able to confer higher  transactivational  activity  to  Rex‐1,  a  pluripotency‐associated  protein,  in  NIH  3T3  cells compared  to  wild‐type  Nanog  (Shi  et  al.,  2006).  Hence,  in  a  second  preliminary  attempt  to biochemically modify the recombinant Nanog protein, VP16 was fused to the C‐terminal domain of  the  full‐length  Nanog.  This  construct  could  be  expressed  in  and  purified  from  E.coli. Purification  conditions  were  analyzed  via  imidazole  gradient  by  SDS‐PAGE  and  immunoblot. Although  Nanog  fused  to  VP16  constitutes  only  20%  of  the  whole  mount  protein,  the  VP16 domain could eventually confer stabilizing properties to the fusion protein as this phenomenon was  observed  with  other  recombinant  proteins  analyzed  in  our  workgroup.  Additionally  the transactivation  of  the  newly  generated  recombinant  protein  could  be  higher  compared  to  the wild type Nanog variant. As for the codon‐optimized Nanog variant the concentration as well as the functionality of Nanog fused to the VP16 domain should be elucidated.  
4.2 Biological activity of Nanog­TAT and ΔNanog­TAT As both fusion proteins were stable under physiological conditions, the biochemical properties thereof were assessed.  In order to analyze for the DNA binding ability of Nanog‐TAT an EMSA was performed. A clear  shift was observed  that  could not be detected when ΔNanog‐TAT was subjected to an EMSA verifying the specificity of the binding. The Nanog homeodomain therefore seems to be responsible for DNA binding, a property analyzed in detail by Jauch and colleagues (Jauch  et  al.,  2008).  To  further  strengthen  the  specificity,  an  α‐Nanog  antibody  could  be subjected  to  the  binding  reaction  along  with  Nanog‐TAT,  which  should  result  in  a  so‐called 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supershift,  since  the  protein‐DNA  complex  would  additionally  be  recognized  by  the  specific anti‐Nanog antibody. Some workgroups have assigned Nanog the ability to dimerize (Mullin et al., 2008; Torres and Watt, 2008; Wang et al., 2008b), a phenomenon that could not be observed by  EMSA  in  this  work,  as  no  further  shifted  bands  were  detectable.  Since  post‐translational modifications of the fusion proteins expressed and purified in and from E.coli are not occurring, the absence thereof could also have an influence on the dimerization capability of Nanog‐TAT as this was shown to play a role for other proteins (Connors et al., 2007). Next, both  fusion proteins were analyzed  for  their ability  to  translocate  into mammalian cells. CV1 fibroblast cells were chosen for translocation studies since these cells represent a reliable and  robust  cellular  system.  Moreover,  since  for  a  major  part  of  this  work  Nanog‐TAT  and 
ΔNanog‐TAT  were  applied  on  somatic  fibroblast  cell  lines,  CV1  cells,  possessing  similar morphological  properties  compared  to  the  aforementioned  cell  types, mirror  the  target  cell’s phenotype.  Since  Nanog‐TAT  within  the  eluate  and  dialysis  fraction  still  contained  some contaminating proteins, a labeling of the fusion protein with fluorescent dye (Tunnemann et al., 2006)  was  not  appropriate,  as  it  is  not  possible  to  selectively  label  Nanog‐TAT.  The  other contaminating  proteins  would  have  been  labeled  as  well  and  distorted  the  experimental outcome.  This  procedure  would  have  allowed  for  the  analysis  on  living,  i.e.  non‐fixed  cells though.  Fixation  of  cells  is  known  to  potentially  provoke  an  artificial  internalization  of  the protein of  interest  (Richard et  al.,  2003) and hence  can only partially elucidate  the process of translocation. CV1 cells were incubated with both fusion proteins for 5h and cells were washed thereafter with Heparin,  to  ensure  no  recombinant  protein  stuck  on  the  cellular  surface,  is  detected  by  the primary antibody (Kaplan et al., 2005). Finally, cells were fixed and subsequent ICC analysis was performed.  Both  fusion  proteins  were  able  to  translocate  into  the  CV1  fibroblast  cells,  the process  of  cellular  uptake  seemed  to  be  decelerated  for  ΔNanog‐TAT  though.  After  5h, Nanog‐TAT was detectable within vesicles  inside  the cytoplasm already  forming a perinuclear pattern.  In  contrast,  ΔNanog‐TAT  could  be  detected  in  the  cytoplasm  as  well,  but  was  only starting  to  accumulate  around  the  nucleus.  The  trapping  of  the  two  fusion  proteins  inside cytoplasmic  vesicles  as  well  as  the  perinuclear  pattern  thereof  is  a  feature  also  observed  by confocal microscopy of living cells cultivated with a transducible Cre recombinase labeled with Alexa  Fluor  633  (Tunnemann  et  al.,  2006).  Using  confocal  microscopy  does  not  allow widespread detection of transducible Cre recombinase inside the nucleus though, but in contrast a sensitive reporter assay indicated Cre‐mediated recombination nevertheless. This observation is unsurprising since 99% of the cargo proteins remain inside of the macropinosomes and do not get released into the cytosol (Kaplan et al., 2005). Therefore a co‐localization of Nanog‐TAT with the nuclei of CV1 cells has to be regarded with suspicion. The deceleration of the cellular uptake 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of ΔNanog‐TAT could be due  to  the  fact  that within  the homeodomain of murine Nanog an aa sequence  is  present,  which  exhibits  62.5%  homology  to  the  16  aa  long  penetratin  domain, derived from the third helix of Antennapedia, which was shown to translocate into neural cells. In  particular,  the  tryptophan  W6  of  the  penetratin  domain  is  conserved  inside  the  Nanog homeodomain  and  is  known  to  play  a major  role  in  the  translocation  process  (Derossi  et  al., 1994). Since this sequence is missing in the control protein,  the process of translocation could likely  be  decelerated  as  no  cumulative  effect  of  the  artificial  TAT  PTD  combined  with  the homeodomain  of  Nanog,  potentially  harboring  an  endogenous  NLS,  can  take  place.  Taken together the results of the ICC analysis of Nanog‐TAT and ΔNanog‐TAT exhibit a picture similar to the observation made in living cells, indicating cellular uptake of both fusion proteins. Initial studies in our workgroup showed that Nanog‐TAT is able to liberate murine Oct3/4 GiP ES  cells  from  LIF  dependence,  a  feature  known  from  murine  ES  cells  overexpressing  Nanog (Chambers et al., 2003). Nanog‐TAT was able to sustain ‘undifferentiated’, AP‐positive ES cells in the  absence  of  LIF,  the  addition  of  the  peptide  TAT‐HA2  was  required  though.  Thereafter transduced ES cells cultivated for several passages in the absence of LIF but in the presence of Nanog‐TAT were still able to give rise to all three germ layers in an EB differentiation paradigm as well as they formed teratomas upon injection into immune‐compromised mice. Within these teratomas  tissues of  all  three  germ  layers were present. Moreover, Nanog‐TAT  transduced ES cells gave rise  to chimeric animals upon blastocyst  injection, although to a weak extent (Peitz, 2007). To test for specificity of the effect of Nanog‐TAT in Oct3/4 GiP ES cells, the same ES cells were cultivated  in medium containing 50nM of  the control protein ΔNanog‐TAT for 3 days either  in the  presence  or  absence  of  LIF.  Over  this  period  of  time,  ES  cells  in  the  absence  of  LIF differentiated independent of the application of ΔNanog‐TAT. In contrast, a major part of the ES cells  cultivated  with  LIF  retained  an  ‘undifferentiated’  phenotype,  again  independent  of 




4.3 Molecular function of Nanog­TAT in somatic cells Since the overexpression of Nanog in fibroblast cells led to apoptosis of target cells, most likely due  to  the  toxic  effect  of  the  strong Nanog  expression  (Winnemöller,  2007),  the  technique  of protein  transduction  offered  a  suitable  tool  to  investigate  the  function  of  Nanog  in  a  time‐dependent  manner.  Moreover,  the  morphology  of  fibroblast  cells  favors  them  over  ES  cells regarding protein  transduction,  since  fibroblast  cells  exhibit  a  larger  surface  combined with  a monolayer  growth  enabling  optimal  exposure  to  extrinsic  stimuli.  Additionally  fibroblast  cells represent  a  robust  and  reliable  cellular  system  for  the  investigation  of  transformation, proliferation as well as reprogramming. Previous studies in our workgroup showed that NIH 3T3 cells, typically exhibiting strict contact inhibition, gave rise to three‐dimensional foci upon cultivation with Nanog‐TAT in a reversible manner.  Soft  agar  assays  confirmed  the  results  obtained  from  transduced  NIH  3T3  cells. Additionally,  MEFs  treated  with  Nanog‐TAT  exhibited  enhanced  proliferation  rates,  thereby seeming to bypass cellular senescence. At the same time the chromosome set of the Nanog‐TAT treated  fibroblast  population  remained  stable  in  contrast  to  MEFs  cultivated  with  control medium (Winnemöller, 2007). To  investigate  the  molecular  mechanisms  behind  the  phenotype  observed  in  MEFs,  cells synchronized  for  cell  cycle  were  incubated  with  Nanog‐TAT  for  distinct  time  points  and subsequently  the RNA  expression  profile  for  several  key molecules  involved  in  senescence  as well as cell cycle regulation was assessed via RT‐PCR. No significant change in RNA expression levels as well as protein expression could be detected for p16INK4a, p21CIP/WAF, p53, FGF receptor 1 and Cyclin D1. After 21 hours a reduction of 73% in the transcription of p27KIP1 was detected though,  and  this  observation  could  be  further  verified  by  immunoblot  analysis.  In  contrast fibroblasts cultivated with control medium or ΔNanog‐TAT did not show a down‐regulation of p27KIP1,  neither  in  RT‐PCR  nor  immunoblot  analysis.  p27KIP1,  together  with  other cyclin‐dependent  kinase  inhibitors  (CKI),  is  responsible  for  regulating  cell  cycle  progression. p27KIP1  was  initially  described  as  an  inhibitor  of  Cyclin  E‐CDK2  and  Cyclin  D‐CDK4  complex activity  (Polyak  et  al.,  1994;  Toyoshima  and Hunter,  1994).  Thereby  p27KIP1  is  regulating  the transition  from  G1  to  S  phase  within  the  cell  cycle  as  it  causes  the  inhibition  of  pRb 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phosphorylation  (Ji  and  Zhu,  2005;  Sa  et  al.,  2005).  A  hyperphosphorylated  form  of  pRb  is needed in order to pass the restriction point within the cell cycle, i.e. to proliferate (Hitomi et al., 2006). Upon  translocation of p27KIP1  from  the nucleus  into  the cytosol,  a process mediated by Cyclin D2  (Susaki  et  al.,  2007), p27KIP1  is degraded by Kip1 ubiquitylation‐promoting  complex (KPC)‐dependent proteolysis (Hara et al., 2005; Kamura et al., 2004; Kotoshiba et al., 2005). In order to further investigate the molecular path of p27KIP1 in MEFs upon Nanog‐TAT treatment, it would be for  instance interesting to take a  look at the phosphorylation of p27KIP1 on serine 10 since  this  is  one  initial  step  in  the  process  of  translocation  of  p27KIP1  to  the  cytosol  where degradation  of  the  CKI  takes  place. Moreover  one  could  determine  the  activity  of  Cyclin‐CDK complexes via kinase assay to analyze direct down‐stream targets of p27KIP1. This experimental approach would close the gap between down‐regulation of p27KIP1 and the effects observed on pRb expression and phosphorylation. Namely,  upon  the  treatment with Nanog‐TAT  for  distinct  periods  of  time,  synchronized MEFs exhibited an enhanced expression as well as an increase in phosphorylation of pRb. According to the stage of the cell cycle pRb either is unphosphorylated or becomes hyperphosphorylated. In its  unphosphorylated  state  pRb  is  active  (Buchkovich  et  al.,  1989;  Knudsen  and Wang,  1996; Knudsen and Wang, 1997; Ludlow et al., 1989), i.e. it prevents the cell from progression through the cell cycle. As soon as pRb gets hyperphosphorylated the protein becomes inactive (Harbour et al., 1999; Rubin et al., 2005) and allows cell cycle transition resulting in the activation of E2F transcription  factors, which are needed during  later  stages of  the  cell  cycle  (Chellappan et  al., 1991; Kaelin et al., 1992). In G0 phase pRb exists completely unphosphorylated before it becomes hypophosphorylated on very  few  serine  and  threonine  residues  in G1 phase.  CDK4/6‐cyclin D  complexes  execute  this initial phosphorylation of pRb (Kitagawa et al., 1996). pRb gets hyperphosphorylated on  large numbers of serine and threonine residues as soon as the cell has passed beyond the restriction point  in  late  G1  phase,  a  task  fulfilled  by  CDK2‐cyclin  E  complexes  (Lundberg  and Weinberg, 1998). Throughout the rest of the cell cycle pRb remains hyperphosphorylated due to activities of CDK‐cyclin E, A and B complexes. When mitosis is finished the phosphate groups are removed from pRb via an enzyme called protein phosphatase type 1 (PP1) (Berndt et al., 1997). The cell is now ready for a new division. For a simplified scheme see Figure 33.  As pRb is a direct target of Cyclin‐CDK complex activity, resulting in phosphorylation thereof, it could be demonstrated that Nanog‐TAT is indeed influencing the expression of p27KIP1 including one of its down‐stream targets. Through the enhanced expression and phosphorylation of pRb, MEFs transduced with Nanog‐TAT were able to progress over restriction points within the cell cycle  faster  than  control  cells,  as  these  did  not  exhibit  enhanced  proliferation  and phosphorylation  of  pRb,  thus  were  not  able  to  accelerate  cell  cycle  progression.  The 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phenotypical  observations  initially  made  by  growth  curve  analysis  on  MEFs  (Winnemöller, 2007) could hereby be linked to molecular changes within the cell cycle.  
 
Figure 33: Simplified overview on cell cycle regulation by Cyclins, CDKs and CKIs 
During early G1 phase Retinoblastoma protein (Rb) is unphosphorylated, i.e. active. CDK4/6- Cyclin D 
complexes initiate hypophosphorylation of Rb during G1 phase allowing the cell to pass beyond the 
restriction point in late G1 phase. Hyperphosphorylation of Rb is mediated and sustained by other 
CDK-Cyclin complexes. Phosphorylated pRb is inactive and cells can progress through the cell cycle. 
During Mitosis pRb is dephosphorylated by PP1 and shifted back into its active state. CKIs like 
p21CIP/WAF and p27KIP1 can inhibit cell cycle progression though. Nanog, on the other hand, appears to 
be able to inhibit the expression of p27KIP1 thereby allowing cells to pass through a restriction point in 
cell cycle allowing enhanced proliferation. G0: zero gap phase; G1: first gap phase; S: synthesis 
phase; G2: second gap phase; M: mitosis; R: restriction point; PP1: protein phosphatase 1 (adapted 
from Daniel, 2002).  In  order  to  investigate  any  potential  direct  interaction  between  p27KIP1  and  Nanog co‐immunoprecipitation experiments could be conducted as of today no direct link between the stemness factor and the CKI is known. Since murine Nanog only shares a homology of 55% on aa basis (Hart et al., 2004) with human Nanog, it was interesting that Nanog‐TAT exhibited an influence on human ES cells by partially inhibiting their differentiation (Peitz, 2007). In order to investigate the influence of Nanog‐TAT on  human  somatic  cells,  dermal  fibroblasts  were  cultivated  with  Nanog‐TAT  for  several passages. These fibroblast cells showed a change in morphology compared to cells treated with 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control medium. Cells  cultivated with Nanog‐TAT exhibited a more spindle‐like shape and  the ratio  of  cytoplasm  to  nucleus  declined  compared  to  control  populations.  Although  SA 
β‐Galactosidase is widely used to detect senescent cells in vitro, younger cells also express this marker  gene  although  to  a  lower  extent  (Kurz  et  al.,  2000).  Interestingly,  human  dermal fibroblasts  cultivated with  Nanog‐TAT  exhibited  only  few  cells  expressing  SA β‐Galactosidase compared to a higher amount of SA β‐Galactosidase‐positive control cells. This observation may serve as a  first  indication  for a  juvenescent effect of Nanog‐TAT. Growth curve analysis over a period  of  10  passages  indicated  an  enhanced  proliferation  rate  for  fibroblasts  cultivated with Nanog‐TAT.  In  contrast  to  murine  fibroblasts,  human  fibroblast  cells  exhibit  a  longer,  still limited,  proliferating  life  span  in  vitro.  A  period  of  intense  proliferation  is  followed  by  a progressive  loss  thereof  until  fibroblast  cells  cease  to  proliferate  but  still  remain  viable.  This phenomenon was termed ‘replicative senescence’ (Hayflick and Moorhead, 1961). The lifespan of fibroblasts was shown to be independent of the age of the cell donor (Cristofalo et al., 1998) suggesting  independence  of  the  process  of  aging  in  vivo  from  replicative  senescence  in  vitro. Senescence in human fibroblasts was shown to be influenced by several molecules, namely p53, p21CIP/WAF, p16INK4a  as well  as pRb  (Alcorta et al., 1996; Kulju and Lehman, 1995; Rogan et al., 1995;  Tahara  et  al.,  1995; Whitaker  et  al.,  1995).  A  disruption  of  the  p21CIP/WAF  gene  enables fibroblast  cells  to  bypass  senescence  (Brown  et  al.,  1997),  an  effect  observed  as  well  upon treatment with dexamethason, which also results in a change of p21CIP/WAF expression (Li et al., 1998). So  as  to  investigate  the molecular  events  leading  to  the morphological  changes  as well  as  the enhanced proliferation observed  in human dermal  fibroblasts  in  this  thesis, RNA was  isolated thereof after  cultivation with Nanog‐TAT  for at  least 2 weeks. These unsynchronized cells did already exhibit changes in morphology as described above. Expression levels were analyzed via microarray analysis. Untreated cells served as a control. Interestingly, other factors altered their expression  in human dermal  fibroblasts cultivated with Nanog‐TAT than  in MEFs treated with the  transducible  stemness  factor,  as  no  change  in  the  expression  level  of  p27KIP1  could  be observed. Additionally, no  change  in RNA expression  levels of p16INK4a,  p21CIP/WAF,  p53 or pRb could be detected. Moreover, a recent publication suggested that Nanog exhibits a function in the G1 to S phase transition of human ES cells. The authors could link this observation to the direct interaction  of  Nanog  with  CDK6  and  the  promoter  region  of  CDC25A  as  well.  Nanog overexpressing human ES cells exhibited an increased level of CDK6 and CDC25 as analyzed by immunoblot  (Zhang et  al.,  2009). However,  analyzing  the whole genome expression of human dermal  fibroblasts  in  this  work  indicated  no  change  in  expression  of  these  two  cell  cycle regulators. 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Instead,  genes  encoding  for  inflammatory  cytokines  and  chemokines,  e.g.  interleukin‐6, interleukin‐8, interleukin‐35, chemokine (C‐X‐C motif) ligand 6 as well as chemokine (C‐C motif) ligand 2, were down‐regulated  in human dermal  fibroblasts upon cultivation with Nanog‐TAT. Additionally,  the  matrix  metallopeptidase  9,  Metallothionein‐1G  and  Stromelysin‐1  were expressed to a lower extent compared to control cells. Amongst the genes whose expression was up‐regulated upon Nanog‐TAT cultivation,  the oligomeric matrix protein (COMP),  the  inhibitor of differentiation 1 (ID1) protein as well as Cyclin D1, the metalloproteinase inhibitor 3 (TIMP3) and  collagen  alpha‐1  (IV)  chain  protein  (COL4A1)  were  found.  An  increased  expression  of Stromelysin was observed by Millis et al. in human fibroblast cells upon cellular aging (Millis et al.,  1992).  The  expression  of  matrix  proteases  as  well  as  inflammatory  chemokines  and cytokines was found to be a common feature in senescent dermal fibroblasts (Millis et al., 1992; Shelton  et  al.,  1999). Moreover,  collagen  and keratin  expression was down‐regulated  in  aging dermal  fibroblasts  (Shelton  et  al.,  1999).  West  and  colleagues  could  show  that  senescent fibroblasts expressed a relatively weak level of the metalloproteinase inhibitor (TIMP) (West et al., 1989). In accordance with this observation, TIMP‐1 expression was also found to be low in senescent fibroblasts as shown by others. Interestingly, expression thereof could not be induced by serum (Millis et al., 1992). Hence, it appears as cultivation of human dermal fibroblasts with Nanog‐TAT  leads  to  a  partially  inverted  transcription  profile  normally  observed  in  senescent human fibroblasts, further indicating a juvenescent effect of Nanog‐TAT. The strong expression of  cartilage  oligomeric matrix  protein  (COMP)  in  Nanog‐TAT  treated  fibroblasts  could  not  be linked to published data, since the expression thereof was found to be high in aging fibroblasts (Ly et al., 2000). As the age of the cell donor does not influence the fibroblast lifespan (Cristofalo et  al.,  1998),  one  should  take  into  consideration  that  the  dermal  fibroblast  cells  treated with Nanog‐TAT exhibited a passage number of 18, i.e. these cells depict a population of cells where senescence  may  still  be  in  its  early  onset.  Therefore  the  influence  of  Nanog‐TAT  on  COMP expression cannot fully be compared to completely senescent fibroblast cells analyzed by Ly and colleagues. The expression of actin alpha protein and collagen alpha‐1 (IV) protein was highly up‐regulated in cells cultivated with Nanog‐TAT and could be due to the morphological changes these  cells undergo,  although actin  type alpha  is mainly  restricted  to  cardiac muscle. Collagen alpha‐1  (IV)  is mostly  responsible  for  the membrane basement  structure  of mammalian  cells. ID1  is  generally  considered  a  protein  to  be  involved  in  cell  growth  and  senescence  and  was shown  to  delay  senescence  in  keratinocytes  (Nickoloff  et  al.,  2000),  an  observation matching findings  in  this  work.  An  up‐regulation  of  Cyclin  D1  ‐  being  part  of  the  cell  cycle  regulatory machinery ‐ upon Nanog‐TAT treatment, could indicate an extension of the replicative lifespan, as  it  was  shown  for  keratinocytes  overexpressing  Cyclin  D1  (Opitz  et  al.,  2001).  Peptidase inhibitor  16  (PI16)  is  found  to  be  expressed  in prostate  cancer  and may  eventually  suggest  a transforming event within the cell culture dish upon Nanog‐TAT treatment. Taken together, the 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RNA expression analysis of cells cultivated with Nanog‐TAT shows a pattern resembling that of juvenile fibroblasts in contrast to the control cells. It  would  be  of  great  interest  to  further  propagate  dermal  fibroblasts  in  the  presence  of Nanog‐TAT until these cells become fully senescent. Then again RNA expression analysis as well as  additional  immunoblot  analysis  should  be  conducted  to  analyze  whether  a  change  in  the expression  of  p53,  p21CIP/WAF,  p16INK4a  as  well  as  pRb  can  be  detected  to  finally  link  the phenotypic observations to molecular events known to be involved in cellular aging. Moreover, karyotypic analysis of long‐term propagated fibroblasts should be performed to check whether the stabilizing effect on the chromosome set observed in MEFs (Winnemöller, 2007) is apparent in human somatic cells as well. In  conclusion,  Nanog  activity  in  aging  human  somatic  cells  results  in  a  partially  juvenescent cellular phenotype, i.e. a high nucleocytoplasmic ratio (small cell size) as well as low expression of for instance stromelysin, inflammatory genes, extracellular matrix‐degrading enzymes and SA 
β‐Galactosidase expression.  
4.4 The role of Nanog in the process of reprogramming Given  its  crucial  role  in  the  circuitry of pluripotency  (Boyer et  al.,  2005; Loh et  al.,  2006) one may wonder  about Nanog not  being  one of  the  originally  identified 4  reprogramming  factors. Interestingly,  in a 9  factor  reprogramming approach,  including Oct3/4, Klf4,  c‐myc and Nanog but  not  Sox2,  Takahashi  and  Yamanaka  could  observe  iPS  cell  emergence  (Takahashi  and Yamanaka, 2006). Eventually the other 5 factors besides Oct3/4, Klf4, c‐myc and Nanog lowered the reprogramming efficiency, which might have resulted in missing the effective combination of Oct3/4, Nanog, Klf4  and  c‐myc.  So as Nanog appears  to be an  important,  however not pivotal factor in the act of reprogramming and no detailed understanding of the influence of Nanog on the process of reprogramming was apparent at the time, the idea was to investigate the function of  the  stemness  factor  during  cellular  reprogramming.  As Nanog‐TAT  offers  the  possibility  to modulate Nanog function in a time‐dependent manner, the effect during different phases of the process  of  reprogramming  could  be  analyzed. Moreover, Nanog‐TAT was  successfully  applied onto MEFs  during  cell  cycle  analysis  in  this work,  underlining  its  sound  protein  transduction capability as well as  its  functional abilities; especially since target cells are  the same.  In a  first instance, it was interesting to analyze whether the influence of Nanog on the cell cycle of MEFs, i.e.  the  target cells of  reprogramming,  could enhance  the efficiency of cellular  reprogramming. However, MEFs cultivated with Nanog‐TAT either prior to viral transduction with OKSM or for 5 days  post  infection  with  OKSM  did  not  show  an  increase  in  reprogramming  efficiency. Additionally,  a permanent application of Nanog‐TAT starting  from day 1 up  to day 15 did not 
Discussion 
106 
lead  to a higher reprogramming efficiency. The  first experiments showed that  the  influence of Nanog‐TAT  on  MEFs,  i.e.  the  down‐regulation  of  p27KIP1,  which  results  in  an  enhanced proliferation,  could  not  provoke  a  higher  reprogramming  efficiency.  Apart  from  that, hypothetically  it  would  not  have  been  an  enhanced  reprogramming  process  but  rather  an emergence of more iPS colonies due to better retroviral infection caused by higher proliferation rates  of MEFs. The observation of  no beneficial  effect may be due  to  the  fact  that  the  cellular noise caused by the viral transduction of OKSM simply overlays the effect caused by Nanog‐TAT observed  in MEFs.  The  introduction  of  c‐myc  alone  results  in  drastic  cellular  changes,  like  an enhanced  proliferation.  Namely,  the  overexpression  of  c‐myc  enables  melanoma  cells  to suppress  senescence  (Zhuang  et  al.,  2008)  whereas  the  depletion  of  c‐myc  inhibits  the proliferation of tumor cells (Wang et al., 2008a). Moreover,  the  introduction of c‐myc together with simian virus 40 large T antigen is able to immortalize human fibroblasts (Kim et al., 2001), emphasizing the striking potential of c‐myc. On the other hand, c‐myc individually was found to also  promote  the most  ES‐like  expression  pattern  in  fibroblasts  compared  to  the  other  three reprogramming  factors  Oct3/4,  Klf4  and  Sox2  (Sridharan  et  al.,  2009).  Probably  the  protein transduction technique in the case of Nanog‐TAT, as it is today, is limited in this matter, as it can hardly  compete  against  the  major  cellular  alterations  evoked  by  the  integration  of  four retroviruses  initially  resulting  in  a  cellular  chaos  that  can  lead  to  several  cell  fates  besides reprogramming  like  apoptosis,  transformation  or  reprogramming‐induced  senescence  (RIS), which  stands  in  contrast  to  stress‐  or  oxygen‐induced  senescence  (Banito  and  Gil,  2010).  A different, i.e. higher concentration of Nanog‐TAT could eventually be important to overcome the above‐mentioned  limitations.  This  hypothesis  is  further  reinforced,  since  the  depletion  of several key molecules of the cell cycle in contrast was shown to greatly promote reprogramming efficiency (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; Marion et al., 2009; Utikal et al., 2009). Little is known about the karyotypic status of those cells though. The  second  experiment  seems  to  indicate  that  the  permanent  presence  of  Nanog  during  the complete process of reprogramming is not conducive to iPS cell generation. This assumption is further strengthened by the observation that the viral transduction of MEFs with OKSM plus an additional retroviral vector encoding for Nanog led to higher transformation within the culture dish  (Marc  Thier,  personal  communication). Maherali  and  colleagues  did  generate  human  iPS cells using  the classical  four reprogramming  factors OKSM as well as OKSM plus an additional viral  construct  encoding  for  Nanog.  They  do  not  state  any  difference  between  these  two approaches (Maherali et al., 2008). In line with this finding, another publication by Lowry at al., where  on  the  one  hand  OCT3/4,  SOX2,  C‐MYC  and  KLF4  as  well  as  on  the  other  hand  the beforehand mentioned  factors  together with  a  retrovirus  carrying  the  genetic  information  for NANOG were used  to  generate human  iPS  cells,  could not  show any difference between  these two experimental setups (Lowry et al., 2008). A combination of six reprogramming factors,  i.e. 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OCT3/4, SOX2, C‐MYC, KLF4, LIN28 and NANOG led to a ten‐fold increase in iPS cell generation (Liao et al., 2008) though. Moreover the appearance of those iPS cell colonies was accelerated. Since LIN28 was used in this experimental setup in addition to NANOG and OKSM it cannot be ruled out that the effect observed is due to LIN28 only, known to influence cell proliferation. Recently,  two  publications  defined  molecular  cornerstones  during  the  process  of reprogramming  (Brambrink  et  al.,  2008;  Stadtfeld  et  al.,  2008a).  It  was  shown  that  with  the decrease  of  the  representative  fibroblast‐specific  marker  Thy1,  the  sequential  increase  of pluripotency markers was  accompanied.  First,  AP  expression  could  be  detected  starting  from day 3 post  infection with OKSM. This event was  followed by  the expression of SSEA‐1 around day  6  and  finally  led  to  the  expression  of  Nanog  and  Oct3/4  starting  at  day  10  of  the reprogramming  process.  Additionally  telomerase  activity  as  well  as  the  reactivation  of  the  X chromosome  was  demonstrated.  The  observation  that  the  pluripotency  factors  Oct3/4  and Nanog became activated around day 10 post  infection,  led  to  the hypothesis  that Nanog most likely  has  an  influence  on  the  act  of  reprogramming  during  later  stages  of  the  process. Cultivation of MEFs ‐ retrovirally transduced with OKSM ‐ with Nanog‐TAT at three defined time points,  indicated  that  the  exogenous  Nanog  expression  was  of  great  benefit  for  the reprogramming efficiency when applied for 5 consecutive days starting at day 10. Application of Nanog‐TAT from day 6 and day 8 post infection did not show a substantial beneficial effect on the generation  of  iPS  cells.  It  was  now  interesting  to  exactly  determine  the  enhancement  of reprogramming efficiency. To this end, Nanog‐TAT was applied for 10 days on OKSM transduced MEFs starting from day 10 post infection. In the end, colonies that had re‐activated the Oct3/4 promoter  and  showed  iPS  cell morphology were  counted.  Compared  to  control  cells  infected only with  OKSM,  Nanog‐TAT  treated  cells  exhibited  an  increase  in  iPS  cell  generation  by  the factor of 3, an observation not completely surprising due to several data already published.  In 2006,  Silva  and  colleagues  could  show  that  an  elevated  level  of  Nanog  would  facilitate reprogramming  in  a  cell  fusion  paradigm  (Silva  et  al.,  2006).  In  a  follow‐up  publication  the authors  could  further  elucidate  the  role  of  Nanog  in  the  process  of  reprogramming,  an  event which Silva and colleagues termed the ‘establishment of the ground state of pluripotency’. They showed that Nanog mediates both, the acquisition of embryonic as well as induced pluripotency. Interestingly they found Nanog to be dispensable in the beginning of cellular reprogramming but essential  to partially reprogrammed cells  to transit  to the ground state of pluripotency. Nanog mRNA was  found to be up‐regulated  from day 7 onwards post  infection  in  the reprogramming process,  the  same  time  where  other  pluripotency  markers  became  up‐regulated  as  well. Especially the observation that Nanog‐deficient cells could be reprogrammed underlines its full dispensability in the initial steps of the reprogramming process (Silva et al., 2009). The process as  such  can  be  divided  into  several  stages.  The  first  step, mediated  by Oct3/4,  Sox2  and Klf4 seems to be the generation of dedifferentiated pre‐iPS cells. For the acquisition of the next step 
Discussion 
108 
cells have to overcome certain obstacles, as they appear to be trapped in this pre‐iPS cell stage (Okita  et  al.,  2007).  For  the  relief of  this  stage  the expression of Nanog  is  assumed  to play an important role. A possible function of Nanog within this process may be its ability to orchestrate transition to the ground state of pluripotency as it could facilitate the cooperative binding of the core  pluripotency  factors  to  their  related  ES  cell  targets.  A  high  throughput  screen  for  small molecules  able  to  substitute  viral  reprogramming  factors  led  to  the  emergence  of  RepSox, namely  a  replacement  molecule  for  Sox2  (Ichida  et  al.,  2009).  In  murine  replacement reprogramming approaches RepSox, an inhibitor of TGF‐β signaling, was able to give rise to iPS cells upon retroviral transduction with OKM only, and this is likely due to the fact that RepSox induces the expression of Nanog as it was shown by the authors. Furthermore the time window for the application of RepSox could be narrowed down to an optimal time point of application. Application  of  RepSox  11  days  post  retroviral  infection  with  the  reprogramming  factors  OKM seems to yield highest fold change in the generation of iPS cells. Unfortunately, the authors did not  show  the  fold  change  of  iPS  cell  generation  for  day  10  post  infection,  but  in  contrast  the treatment  with  RepSox  at  day  9  post  retroviral  infection  did  not  lead  to  an  enhanced reprogramming process. Day 10 post  infection  could therefore  likely be the optimal  time point for  the  application  of  RepSox,  i.e.  the  induction  of  Nanog.  This  would  be  in  line  with  the observations made  in  this work. RepSox was able  to  replace not only Sox2 but  c‐myc as well. Additionally,  retrovirally  transduced  Nanog  could  replace  Sox2  in  MEFs  infected  with  OKM (Ichida et al., 2009). Of course it would now be of interest to investigate whether Nanog‐TAT is able  to  beneficially  contribute  to  the  generation  of  iPS  cells  derived  from MEFs  infected with Oct3/4, Sox2 and Klf4 only. As both reprogramming factors, Oct3/4 and Sox2, are on hand in our workgroup  (Bosnali  and  Edenhofer,  2008)  in  the  form  of  transducible  proteins,  their  use together with Nanog‐TAT could lead to a reprogramming paradigm, where only one viral factor would  be  necessary.  This  factor  could  finally  be  removed  using  one  of  three  recombinases available in our workgroup (Anastassiadis et al., 2009; Patsch et al., 2010; Peitz et al., 2002). In a very recent study it was shown that Tbx3 was able to improve the germ‐line competency of iPS cells (Han et al., 2010). It was suggested that this finding is linked to the observation that Tbx3 appears  to  regulate  many  pluripotency‐associated  target  genes  as  judged  by  chromatin immunoprecipitation  sequence  analysis. Moreover,  Tbx3  shares  several  common downstream targets of Nanog for example. The authors propose that Tbx3 exhibits a role during initial phases of  the  reprogramming  process  as  well  as  during  later  stages.  Therefore  it  is  likely  that  the beneficial effects on germ‐line competency arise from the fact that Tbx3 and Nanog initiate the expression  of  shared  downstream  target  genes  thereby  conciliating  enhanced  germ‐line competency.  Taken  into  consideration  that  recently  Niwa  and  colleagues  suggested  a  parallel circuitry for LIF‐signaling, namely LIF not only exhibiting functionality via the Stat3 pathways, which leads to the activation of Klf4 and subsequently Sox2, but  instead LIF also being able to 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regulate  phosphoinositide  3(PI3)‐kinase  as well  as mitogen‐activated  protein  kinase  (MAPK), this  may  further  strengthen  the  above  mentioned  hypothesis.  As  on  the  one  hand  PI3K  was demonstrated to activate Tbx3 in the presence of LIF, MAPK signaling was shown to inhibit Tbx3 activity  upon  LIF  stimulation  on  the  other  hand.  Nanog,  being  downstream  of  Tbx3  then regulates the expression of Oct3/4 in concert with Sox2 (Niwa et al., 2009). It would therefore be conceivable that not Tbx3 but Nanog alone could be sufficient to impart enhanced germ‐line competency  to  iPS  cells.  To  elucidate  this  hypothesis  an  experimental  reprogramming  setup employing Nanog‐TAT transduction could be meaningful. Moreover it could be determined if it is eventually feasible to generate murine iPS cells in the absence of the cytokine LIF but in the presence  of  Nanog‐TAT.  LIF  signaling would  not  lead  to  the  inhibition  of  Tbx3  via  the MAPK pathway and exogenous Nanog‐TAT would introduce intrinsic Nanog activity in the absence of LIF.  
4.5 Outlook A transducible variant of Nanog, as analyzed  in  this work could be of great use under various aspects.  As Nanog‐TAT was  able  to  confer  juvenescent  properties  to  various  primary  somatic cell  lines  one  potential  application  could  be  found  in  tissue  replacement  therapy.  One major limitation therein is the cell expansion of primary cells in vitro (Sipe, 2002). The application of Nanog‐TAT would offer a non‐genetic approach to enhance cell proliferation whilst maintaining a stable karyotype. Another potential application could be the process of reprogramming via cell cycle modulation,  since  the  efficiencies  thereof  are  still  low.  The  depletion  of major  cell  cycle factors  like p53,  p21CIP/WAF  or  p16INK4a was  shown  to  greatly  facilitate  reprogramming but  the target  cells  were  likely  to  apply  an  aberrant  karyotype.  Nanog‐TAT,  potentially  able  to circumvent  this  limitation, was  not  able  to  overcome  the  cellular  background noise  occurring after introduction of the four classical retroviral reprogramming factors. There are several cell fates,  which  thereby  can  occur.  First  of  all,  cells  may  become  apoptotic.  Secondly  cells  can undergo transforming events and finally cells may acquire a senescent phenotype acquired due to RIS before they make their way towards partially reprogrammed cells  to  finally give rise to iPS cells (reviewed in Banito and Gil, 2010). Maybe the use of an enhanced Nanog fusion protein, exhibiting i) a higher applicable concentration in cell culture as well as ii) the additional usage of alternative  peptides  beneficial  for  the  process  of  protein  transduction,  cellular  stability  and activity, could exhibit functionality during initial stages of reprogramming and help overcoming RIS.  Interestingly,  Nanog‐TAT  could  enhance  reprogramming  efficiency when  applied  at  later stages  of  the  reprogramming  process.  As  the  ommitance  of  c‐myc  during  reprogramming  is highly  desirable,  due  to  potential  tumor  formation  of  the  target  cells,  it  decreases  the reprogramming  efficiency  though.  Thus,  Nanog‐TAT,  in  concert  with  certain  small  molecules 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shown  to  increase  reprogramming  efficiency  like  AZA,  TSA  or  VPA  (reviewed  in  Feng  et  al., 2009) could be used to substitute for c‐myc. As transducible variants of Oct3/4 and Sox2 are at hand  in  our  group  a  reprogramming  paradigm  applying  these  two  factors  together  with Nanog‐TAT would be imaginable. Only Klf4 would be introduced using viral vectors and could be excised  when  flanked  by  recognition  sites  for  site‐specific  recombinases.  It  was  shown  for human  ES  cells  that  NANOG  is  regulated  by  KLF4  and  PBX1  (Chan  et  al.,  2009),  since  the overexpression of KLF4 resulted in an up‐regulation of Nanog promoter activity. Maybe with the choice  of  a  cell  line  already  exhibiting  Klf4  expression,  Nanog‐TAT  could  replace  even  Klf4. Moreover,  it  would  be  of  great  interest  to  analyze  a  transducible  variant  of  human  Nanog, already  generated  in  our  workgroup,  for  its  functionality  in  the  reprogramming  process  of human cells or its beneficial effects on the maintenance of pluripotency. To further analyze the influence  of  Nanog‐TAT  on  the  process  of  reprogramming  one  could  think  of  several experiments.  Since  Nanog  was  shown  to  compensate  for  the  cytokine  LIF,  reprogramming paradigms of murine  fibroblasts with OKSM in  the presence of Nanog‐TAT and the absence of LIF  could  be  conducted.  To  gain  further  insight  into  molecular  changes  occurring  during application of Nanog‐TAT during reprogramming, feeder‐free reprogramming approaches using OKSM  transduced  MEFs  and  Nanog‐TAT  at  distinct  time  points  could  be  performed  with  a subsequent  analysis  of  genome‐wide  transcriptional  analysis.  In  order  to  further  verify  the beneficial effect of Nanog‐TAT on iPS cell generation, so‐called pre‐iPS cells could be cultivated with Nanog‐TAT  to  investigate whether  the  transducible  stemness  factor  is  able  to  shift  these cells into fully mature iPS cells. With the appearance of so‐called ‘naïve’ human ES and iPS cells (Buecker et al., 2010; Hanna et al., 2010), an experimental set‐up involving transducible Nanog combined with  the  cytokine  LIF,  Forskolin,  a  TGF‐beta  inhibitor,  a MEK  inhibitor  and  a  GSK3 inhibitor could be used to investigate whether it is possible to shift ‘primed’ pluripotent human cells towards their  ‘naïve’ pluripotent state, thereby allowing genetic modification in a feasible manner. 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5 Summary Pluripotency of embryonic stem (ES) cells is maintained through various extrinsic and intrinsic influences. In the center of intrinsic stemness signaling, a triad of transcription factors, namely Nanog, Oct3/4 and Sox2,  sustain ES  cell properties. Among  these, Nanog  is  a particular  factor since  it  mediates  acquisition  of  pluripotency,  however,  the  molecular  mechanism  underlying stemness  function  remains  unclear.  In  order  to  analyze  the  role  of  Nanog,  a  non‐genetic gain‐of‐function paradigm was applied by employing direct protein delivery of Nanog into cells (protein  transduction). The biological  activity of  cell‐permeant  recombinant Nanog protein,  in the following called Nanog‐TAT, was assessed using immunofluorescence techniques as well as EMSA  demonstrating  cellular  uptake  as  well  as  binding  to  a  specific  consensus  sequence.  A control  protein  lacking  the  homeodomain  of  Nanog  (ΔNanog‐TAT)  showed  no  binding  to  the specific  consensus  sequence.  Nanog  protein  transduction  specifically  results  in  an  enhanced pluripotent phenotype since the transducible stemness factor liberates murine ES cells from LIF dependence, a phenotype known from genetic overexpression of Nanog in murine ES cells. As it has been shown previously, upon incubation of NIH 3T3 cells with Nanog‐TAT, those cells lose contact  inhibition  and  primary  mouse  embryonic  fibroblasts  (MEFs)  exhibited  enhanced proliferation,  thereby  seeming  to  bypass  senescence.  Comprehensive  analysis  of  cell  cycle factors  revealed  that  these  phenotypic  characteristics  could  be  linked  to  an  influence  of Nanog‐TAT  on  the  cyclin  dependent  kinase  inhibitor  (CKI)  p27KIP1.  Nanog‐TAT  delivery diminished the expression of p27KIP1 in somatic cells. Western Blot analysis confirmed the mRNA expression analysis. Repression of CKI p27KIP1 subsequently led to the hyperphosphorylation of the  tumor  suppressor  retinoblastoma  protein  (pRb)  thus  shifting  the  protein  into  its  inactive state. These results indicate that MEFs are able to pass beyond the restriction point in cell cycle control  otherwise  guarded by pRb. A phenotype  similar  to Nanog‐TAT‐treated MEFs  could be observed upon cultivation of human dermal  fibroblasts with Nanog‐TAT as  those  cells  exhibit enhanced  proliferation  rates  and  additionally  do  not  show  senescence‐associated 
β‐Galactosidase  activity,  a  marker  associated  with  senescence.  Whole  genome  expression analysis  revealed  that  MP‐AF  cells  cultivated  with  Nanog‐TAT  show  partially  inverted modulation of gene expression compared to senescent human fibroblasts. At later stages during the process of  cellular  reprogramming, Nanog protein  transduction enhanced  the efficiency of induction of pluripotency analyzed by re‐activation of  the Oct3/4 promoter region 3‐fold. The thereby established  induced pluripotent  stem  (iPS)  cells,  generated by  retroviral  transduction with  Oct3/4,  Klf4,  Sox2  and  c‐myc  (OKSM)  and  the  application  of  Nanog‐TAT  from  day  10 onwards, did not differ  from iPS cells established by retroviral  transduction of OKSM alone as judged  by  the  expression  of  alkaline  phosphatase  (AP),  SSEA‐1  and  Oct3/4  and  their differentiation  potential  in  vitro.  Thus,  Nanog  protein  transduction  is  able  to  conditionally manipulate  the  stemness  status of  cells  and provides  an  experimental  basis  for  the molecular analysis of pluripotency maintenance and induction. 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